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Globally and in South Africa breast cancer is the most frequent malignancy amongst 
women. Most breast cancers are estrogen receptor (ER) positive and requires estrogen 
for growth and metastasis. Adverse side-effects associated with, and resistance to, the 
current standard of care (SOC) hormone therapies that target estrogen signalling, like 
tamoxifen, a selective estrogen modulator (SERM), and fulvestrant, a selective estrogen 
receptor down-regulator (SERD), have driven the recent development of using natural 
compounds or extracts as novel therapies, either alone or in combination with 
conventional chemotherapeutic agents, for the treatment and/or prevention of breast 
cancer. Previous work from our laboratory has suggested that a sequential methanol 
extract, SM6Met, prepared from the indigenous fynbos plant, Cyclopia subternata (honey 
bush), has several properties that may make it an effective chemopreventative and/or 
chemotherapeutic agent for breast cancer. The current study investigated the ability of 
SM6Met to prevent or treat breast cancer either as monotherapy or in combination with 
4-OH-Tam (the active metabolite of tamoxifen) by evaluating its effects on the processes 
required for the development and progression of breast cancer such as proliferation, 
migration, invasion and colony formation. Firstly, I validated previous findings, 
characterizing SM6Met as a selective estrogen receptor subtype modulator (SERSM) that 
behaves as an ERα antagonist and ERβ agonist, which is able to inhibit estrogen-induced 
breast cancer cell proliferation. Importantly, I show that although SM6Met as 
monotherapy could not compete, in terms of efficacy or potency, with current SOC 
therapies like 4-OH-Tam and fulvestrant, with regard to inhibiting breast cancer cell 
proliferation, SM6Met showed potential in targeting two pro-metastatic processes, 
invasion and colony formation, to an extent equal to, if not greater than the SOC therapies 
and thus has the potential to be developed into a phytoestrogenic nutraceutical that can 
be beneficial in the prevention and treatment of breast cancer and metastasis. Secondly, 
I show, for the first time, that the effects of SM6Met could be replicated and enhanced by 
combining an ERα selective antagonist (MPP) and an ERβ selective agonist 
(liquiritigenin), thus validating the concept that a treatment with these ideal ER subtype 
selective properties may be more beneficial for the treatment and prevention of breast 
cancer and metastasis than current SOC therapies. Thirdly, I show, for the first time, that 
the combination therapy of 4-OH-Tam and SM6Met produced a strong synergistic effect 
in terms of antagonizing breast cancer cell proliferation and that a 20 times lower dose of 
4-OH-Tam in combination with SM6Met is required to produce the same inhibitory effect 
on cell proliferation as 4-OH-Tam alone. Moreover, the best combination ratio (20:1) of 
SM6Met with 4-OH-Tam displayed greater anti-metastatic potential than the extract or the 
SOC therapies alone, suggesting that SM6Met together with 4-OH-Tam could be a viable 
drug combination for not only delaying resistance and ameliorating the negative side 
effects associated with current SOC therapies, like tamoxifen, but could also provide a 










Wêreldwyd en in Suid-Afrika is borskanker die mees algemene kanker onder vroue. 
Meeste borskankers is estrogeen reseptor (ER) positief en benodig estrogeen vir groei 
en metastase. Die verskeideneid newe-effekte wat geassosieer is met, asook weerstand 
teen, die huidige standaard gebruikte hormoon terapie wat estrogeen-sein teiken, soos 
tamoxifen, 'n selektiewe estrogeen reseptor modulator (SERM) en fulvestrant, 'n 
selektiewe estrogeen reseptor af-regulator (SERD), het die onlangse ontwikkeling van 
die gebruik van natuurlike verbindings of ekstrakte as nuwe terapieë gedryf, hetsy alleen 
of in kombinasie met konvensionele chemoterapeutiese middels, vir die behandeling 
en/of voorkoming van borskanker. Vorige werk uit ons laboratorium het getoon dat 'n 
opeenvolgende metanol ekstrak, SM6Met, wat vanaf die inheemse fynbosplant, Cyclopia 
subternata (heuningbos) voorberei is, verskeie eienskappe het wat dit 'n effektiewe 
chemovoorkomings en/of chemoterapeutiese middel vir borskanker kan maak. Die 
huidige studie het die potensiaal van SM6Met ondersoek om borskanker te voorkom of 
te behandel as enkelterapie of in kombinasie met 4-OH-Tam (die aktiewe metaboliet van 
tamoxifen) deur die effekte daarvan te evalueer op die prosesse wat nodig is vir die 
ontwikkeling en progressie van borskanker soos proliferasie, migrasie, indringing en 
kolonie vorming. Eerstens, bevestig ons vorige bevindinge, wat SM6Met kenmerk as 'n 
selektiewe estrogeen reseptor subtipe modulator (SERSM) wat optree as 'n ERα-
antagonis en ERβ-agonis, wat estrogeen-geïnduseerde borskanker-proliferasie kan 
inhibeer. Verder, wys ons dat, alhoewel SM6Met as monoterapie, met betrekking tot die 
inhibering van borskanker-proliferasie, nie in terme van effektiwiteit of sterkte kon 
meeding met huidige standaard gebruikte hormoon terapieë soos 4-OH-Tam en 
fulvestrant nie, wys SM6Met potensiaal om twee pro-metastatiese prosesse, indringing 
en kolonie vorming, te inhibeer tot 'n mate gelyk aan, indien nie groter as die standaard 
gebruikte hormoon terapieë nie, en sodoende het SM6Met die potensiaal om as 
fitoëstrogeniese neutraseutiese middel ontwikkel te word wat voordelig kan wees in die 
voorkoming en behandeling van borskanker en metastase. Tweedens wys ons, vir die 
eerste keer, dat die effekte van SM6Met gerekonstruktureer kan word deur 'n ERα 
selektiewe antagonis (MPP) en 'n ERβ selektiewe agonis (liquiritigenin) saam te 
kombineer, wat die konsep bevestig dat 'n behandeling met hierdie ideale ER subtipe 
selektiewe eienskappe meer voordelig kan wees vir die behandeling en voorkoming van 
borskanker en metastase as huidige standaard hormoon terapieë. In die derde plek wys 
ons, vir die eerste keer, dat die kombinasie terapie van 4-OH-Tam en SM6Met 'n sterk 
sinergistiese effek toon in terme van inhibisie van borskanker-proliferasie en dat 'n 20 
keer laer dosis 4-OH-Tam in kombinasie met SM6Met nodig is om dieselfde vlak van  
inhibisie as 4-OH-Tam alleen te produseer. Daarbenewens, het die beste kombinasie 
verhouding (20: 1) van SM6Met tot 4-OH-Tam groter anti-metastatiese potensiaal as die 
ekstrak alleen of die huidige standaard gebruikte hormoon terapieë alleen getoon, wat 
daarop dui dat SM6Met tesame met 4-OH-Tam 'n lewensvatbare 
geneesmiddelkombinasie kan wees, om nie net weerstand te vertraag en die negatiewe 
newe-effekte wat met huidige standaard gebruikte hormoon terapieë, soos tamoxifen, 
geassosieer word te verlaag nie, maar kan ook 'n nuwe, meer bekostigbare terapeutiese 
alternatief vir die behandeling of voorkoming van borskankermetastase voorsien. 
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In recent years, breast cancer has come to be the most common and deadly forms of cancer amongst 
women globally, and although statistics differ between populations, age and ethnic groups, women from 
developing countries such as South Africa present with an overall poorer prognosis regarding breast cancer 
survival than those from well-developed countries (1–7). It seems reasonable to postulate that the high cost 
of modern chemotherapeutic drugs have played a major role in the overall poorer prognosis. Apart from the 
high costs, endocrine resistance and negative side effects have also proved to be significant issues in 
breast cancer treatment (8). According to the national cancer registry, breast cancer incidence has 
increased by 72.5% amongst all women in South Africa from 2000 to 2014 (9). The high incidence of breast 
cancer, its contribution to cancer-related deaths and drawbacks associated with endocrine therapies have 
primarily driven the more recent development of novel therapies for breast cancer prevention and treatment 
that act through multiple mechanisms, in addition to new strategies like combined therapies, many of which 
notably include the use of more natural products, such as tea leaf extracts, in combination with conventional 
chemotherapeutic agents (8, 10, 11). Many such combined therapies have been shown to produce 
synergistic anti-cancer effects with tamoxifen as the conventional chemotherapeutic agent (10, 11).  
Tamoxifen was the first selective estrogen receptor modulator (SERMs) to be approved for breast cancer 
prevention and treatment and its major molecular target, the estrogen receptor (ER), is overexpressed in 
70% of breast tumours (12). The ER has been identified as a viable therapeutic target to overcome 
endocrine resistance, which suggests that the addition of another ER-targeted anti-cancer agent in 
combination with current standard of care (SOC) endocrine therapies, like tamoxifen, could prove effective 
for overcoming breast tumour resistance to tamoxifen (13). The ER consists of an alpha (α) and beta (β) 
subtype, where ERα subtype signalling has been associated with sustained breast cancer cell proliferation 
(and other cancer hallmarks) and ERβ subtype signalling has been linked to amelioration of ERα’s cancer 
promoting effects (14–22). Therefore, compounds that mediate their effects primarily via ERβ, like the 
natural phytoestrogenic compounds, genistein (soy) and biochanin A (red clover), are receiving greater 
interest for the development of novel, cost effective and affordable therapies for breast cancer prevention 
and treatment (23–26). 
Numerous studies have shown a strong correlation between the consumption of plant-based diets or plant 
extracts and the prevention and overall reduction of cancer, including breast cancer (27–33). Natural 
compounds and extracts elicit their anti-cancer effects by targeting multiple pathways involved in the 
process of breast carcinogenesis. Moreover, these natural compounds and extracts have been shown to 
not only ameliorate side-effects, such as nausea, fatigue, anaemia and mucositis, arising from currently 
used chemotherapy or other breast cancer treatments (34), but have also shown synergistic action and/or 
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enhancement of effectiveness when used in combination with other chemotherapeutic or endocrine therapy 
agents (35). These beneficial outcomes have shifted pharmacological interest from highly selective single 
targeted therapies to compounds or extracts that may inhibit multiple molecular targets in breast cancer. 
Moreover, the distinct physiological roles of the ER subtypes, ERα and ERβ, warrant further investigation 
into compounds or extracts that may act as ERα antagonists and ERβ agonists as a potential novel 
treatment strategy for breast cancer.  
The current study thus expands on previous studies to evaluate the potential of SM6Met, a sequential 
methanol extract of the indigenous fynbos plant, Cyclopia subternata or otherwise known as honey bush, 
as an alternative for breast cancer treatment and prevention in comparison to SOC endocrine therapies, 
such as tamoxifen. SM6Met was first identified in our laboratory as having an estrogenic potency 
comparable to many commercial phytoestrogenic nutraceuticals (20, 21, 36). More recent studies revealed 
that SM6Met selectively targets the ER subtypes, by acting as an ERα antagonist and ERβ agonist (20, 21, 
37, 38) and inhibits estrogen induced breast cancer cell proliferation in vitro (21). Furthermore, in vivo 
studies, showed that SM6Met delays ERα induced rat uterine growth (21) and reduces N-Methyl-N-
nitrosourea (MNU)-induced and LA7 cell-induced rat mammary tumours (39, 40).  
The main focus of the current study was to explore the physiological implications of the dual activity (multi-
targeting) of the selective estrogen receptor subtype modulator (SERSM), SM6Met, on the processes 
required for the development and progression of breast cancer such as proliferation, migration, invasion 
and colony formation, either as monotherapy or in combination with current SOC therapies, such as 
tamoxifen. In chapter 3 and 4, the following aims will be addressed: 
1. To investigate, with regard to their effects on human breast cancer cell proliferation, 
Objectives: 
a. To compare SM6Met to SOC therapies, like 4-OH-Tam (the active metabolite of tamoxifen) 
and fulvestrant 
b. To replicate the properties of SM6Met can by combining an ERα antagonist (MPP) with an 
ERβ agonist (liquiritigenin) 
c. To evaluate the synergistic potential of SM6Met in combination with 4-OH-Tam and how 
the combination of 4-OH-Tam with SM6Met compares to 4-OH-Tam alone  
 
2. To investigate, with regard to their effects on human breast cancer cell cycle regulation as well as 
metastatic potential, 
Objectives: 
a. To compare SM6Met to SOC therapies, like 4-OH-Tam  and fulvestrant 
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b. To replicate the properties of SM6Met can by combining an ERα antagonist (MPP) with an 
ERβ agonist (liquiritigenin) 
c. To evaluate the synergistic potential of SM6Met in combination with 4-OH-Tam and how 
the combination of 4-OH-Tam with SM6Met compares to 4-OH-Tam alone  
 
This dissertation consists of five chapters. The literature review in Chapter 2 will cover the process of 
carcinogenesis with the focus on breast cancer, the role of estrogen in breast cancer development, current 
treatments for breast cancer that target the ER, drawbacks of these therapies and alternative strategies to 
overcome breast cancer. Chapter 3 (addressing aim 1) and Chapter 4 (addressing aim 2), are written in 
manuscript format, where each chapter contains an introduction, methods, results and discussion section 
and therefore some repetition will inevitably occur. In the final chapter (Chapter 5), the results from the 
current study will be placed in a broader perspective and limitations and future work will be discussed.  
We hope this dissertation will highlight the potential of natural compounds with their beneficial multi-
targeting potential as alternatives for the treatment and prevention of breast cancer and provide insight into 
the advantages of targeting ERβ in combination with ERα for breast cancer treatment and prevention. 
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Cancer is the second leading cause of death in developing countries. Amongst women, breast cancer is 
the most commonly diagnosed malignancy amounting to 23% of all diagnosed cancer cases world-wide 
(1–5). In general, women from developing countries such as South Africa have been associated with a 
poorer prognosis in comparison to those from well-developed countries (6). It seems reasonable to 
postulate that the high cost of modern breast cancer therapies, both for treatment and prevention, have 
played a large role in this. Therefore, there is a need to better understand the cause of breast cancer 
development and progression to prevent breast cancer and/or develop breast cancer treatments that are 
not only highly effective, but highly tolerable, practical and affordable.   
For the purpose of this literature review, I will discuss the role of estrogen in breast cancer development 
and progression and elaborate on the mechanisms involved that are currently targeted for the prevention 
and treatment of breast cancer, discuss the drawbacks associated with these endocrine therapies and 
discuss alternative approaches involving natural compounds to overcome these drawbacks. Furthermore, 
I will discuss the potential of SM6Met, a Cyclopia subternata (Honeybush) extract, as alternative to current 
treatments, which is the overarching topic of this dissertation. 
2.1 Breast cancer development and progression with the focus on estrogen 
The process whereby a normal cell is transformed into a cancer cell is known as carcinogenesis, 
characterized by the dysregulation of the balance between the processes of proliferation and cell death 
(apoptosis). The process of carcinogenesis for multiple types of cancer, including breast cancer, is said to 
consist of three phases distinguished as: (1) initiation, (2) promotion and (3) progression (Fig. 2.1) (7–9).  




Figure 2.1: Three phases of carcinogenesis. Figure adapted from a study by Liu et al. (10). 
2.1.1 Initiation 
The irreversible process of initiation involves damage to the genomic DNA of a normal cell by various 
genetic, environmental and lifestyle factors such as UV radiation, tobacco smoke and genotoxins, which 
has either not been repaired or inadequately repaired, resulting in mutated cells that may undergo further 
division to form various clones of daughter cells that also carry the mutation and are susceptible to 
promotion (8, 11, 12). Furthermore, a defective DNA maintenance system that fails to detect DNA damage, 
repair damaged DNA and inactivate carcinogenic molecules that may inflict DNA damage, may also 
increase the probability of cancer initiation (13–17). 
With regard to breast cancer, there is a strong association between elevated circulating levels of the sex 
steroid hormone, estrogen, and breast cancer development and progression (18–20). Interestingly, the 
most widely accepted risk factors for breast cancer i.e. obesity (21, 22), early menarche (23, 24), late age 
at first full-term pregnancy (23, 25) and late-onset menopause (23, 25, 26) all contribute to excessive and 
cumulative exposure to estrogen. High levels of estrogen, both endogenous and exogenous, increases cell 
proliferation and decreases the time apportioned for DNA maintenance, thereby, subsequently increasing 
the probability of DNA damage and mutations. Moreover, catechol estrogens are metabolites of the 
endogenous estrogens, estrone (E1) and estradiol (E2), which can be oxidised to form reactive quinones 
that have been shown to inflict DNA damage, the basis of carcinogenesis (27–35).   
2.1.2 Promotion 
The promotion phase is characterized by increased clonal expansion of the already mutated cells. By 
driving alterations of gene expression the initiated cell acquires certain hallmark characteristics that favour 
the increase of cell growth (36, 37). These hallmark characteristics include the ability to stimulate own 
growth, the ability to resist anti-growth signals and the ability to evade programmed cell death (Fig. 2.2) 
(17, 36, 38).  




With regard to breast cancer, mutations in the gene that encodes for aromatase (a key enzyme involved in 
estrogen synthesis) may lead to overproduction of estrogen, which has been shown to induce breast tumour 
growth (39–43). Moreover, mutations in the estrogen receptor subtypes, ERα and ERβ, have been shown 
to promote breast cancer development (44, 45). Estrogen elicits its effects through these nuclear receptor 
transcription factors (46–49) and their structure and molecular function will further be discussed in section 
2.1.5. However, to clarify the implications of ER subtype mutations, it is important to know that previous 
studies have shown a positive correlation between ERα, mediator and driving component of cell 
proliferation, and the development of breast cancer (50), while, ERβ has been shown to oppose the 
proliferative actions of ERα  and may act as a tumour suppressor (51, 52). A mutation within the ERα 
subtype, the Tyr537Asn mutation, has been shown to enable ligand independent activation of ERα, thereby 
increasing proliferative signalling and contributing to hormone independent tumour growth (53). The gene 
that encodes for ERα has been shown to be amplified within proliferating breast cancers (54). Researchers 
hypothesize that the elevated receptor levels create cells that are hypersensitive to growth factors in order 
to sustain proliferative signalling (17). Furthermore, an ERβ gene mutation that reduces the expression of 
ERβ has been identified, which, taking into consideration the function of ERβ, may lead to a greater risk of 
breast cancer development (55). 
 
Numerous other mutations, although not discussed, have been shown to contribute to the promotion of 
breast cancer by not only contributing to the cell’s ability to sustain proliferative signalling (BRCA1 [82], 
CDK’s [38], Myc [38], cyclin D1 (56, 57), but also contributing to the cell’s ability to evade growth 
suppressors and apoptosis (PTEN [38], Akt [38], Bcl-2 [37,38], p35 [37,38]) (17, 58, 59). 
 
 
Figure 2.2: The six hallmarks of cancer. Figure taken from a study by Hanahan and Weinberg (16). 




The third and last phase of carcinogenesis, progression, is characterized by an increase in malignant 
potential through procurement of the remaining hallmark of cancer characteristics i.e. enabling replicative 
immortality, induction of angiogenesis and the activation of invasion and metastasis (Fig. 2.2) (8, 16).  
Normal cells do not have the capability to replicate indefinitely and are limited to a certain number of 
divisions before becoming non-proliferative (senescence) (17, 60). DNA sequences at the ends of 
chromosomes known as telomeres shorten with every cell division and activate senescence when they 
reach a certain length. Senescence is an irreversible process, which is always followed by apoptosis (17, 
61). Telomere length is, therefore, involved in the procurement of replicative immortality (17, 62) and cells 
may bypass senescence through manipulation of enzymes that increase telomere length. For example 
increased levels of telomerase, the enzyme responsible for adding telomeric repeats to telomeres, has 
been identified in cancer cells (63–65). Moreover, with regard to breast cancer, estrogen has been found 
to increase telomerase activity in the MCF-7 human breast cancer cell line via its cognate receptor, ERα, 
thus, implicating estrogen and its mechanism of action in the progression of breast cancer (66, 67). 
To support its immortal replicative ability acquired during cancer progression, the tumour cells kick-start a 
process called angiogenesis, which involves the formation of new blood vessels to continuously supply the 
tumour cells with adequate amounts of nutrients and oxygen as well as to remove metabolic waste and 
carbon dioxide (17, 68–70). Hypoxia, a state of oxygen deficiency, has been shown to play a pivotal role in 
the induction of angiogenesis (68). With regard to breast cancer, previous studies have shown that estrogen 
via ERα increases the production of nitric oxide (NO) and consequently hypoxia (68). Furthermore, 
increased levels of hypoxia-inducible factor 1 (HIF-1), a transcription factor known for its involvement in the 
initiation of angiogenesis, have been identified in breast cancer (68). Increased expression of ER and HIF-
1 has been shown to be interconnected (68), suggesting that estrogen via ERα plays a role in angiogenesis 
through induction of hypoxia or up-regulation of angiogenesis initiators. 
The final hallmark acquired during cancer progression is the ability of primary tumour cells to invade 
neighbouring tissue and spread (metastasize) to distant parts in the body (17, 71, 72). Metastasis is a 
complex multistep process that starts with local invasion (invasion of cells into adjacent tissue). Thereafter, 
the cells invade nearby lymphatic and blood vessels (intravasation), travel through the circulatory and 
lymphatic systems (transit), exit the system to invade the secondary site (extravasation) and form of a new 
colony of tumour cells also known as a secondary tumour (micrometastases and colonization) (17, 71, 73). 
However, if any of the steps are not accomplished the whole process may be inhibited (73). Therefore, all 
the above mentioned steps are potential therapeutic targets to curb metastasis, the leading cause of death 
amongst breast cancer patients (74–76).   
Stellenbosch University  https://scholar.sun.ac.za
15 
 
It is clear that estrogen and its cognate receptor plays a key role throughout the development and 
progression of breast cancer, making estrogen and the ER obvious therapeutic targets for both prevention 
and treatment of breast cancer. Before I discuss the treatments, I would like to further elaborate on estrogen 
synthesis and signalling.  
2.1.4 Estrogen synthesis and signalling 
Estrogen is most commonly known as the female sex hormone due to its role in the regulation of female 
reproductive activity as well as the development of secondary female sex characteristics. However, 
estrogen is also involved in the regulation of many other physiological systems i.e. reproduction, bone 
integrity, cardiovascular health, behaviour and cognition. Therefore it is not surprising that estrogen is 
involved in many diseases like cancer, cardiovascular disease and osteoporosis (77). Estrogens have been 
shown to play a protective role in diseases such as coronary heart disease, Alzheimer’s and osteoporosis, 
while being associated with poor prognosis in prostate, breast, ovarian and endometrial cancers (78). 
Estrone (E1), 17β-estradiol (E2) and estriol (E3) are the three major endogenous estrogens that naturally 
occur in a female’s body, however, E2 has been shown to be about 12 times more potent than E1 and about 
80 times more potent than E3 (79, 80). In pre-menopausal women, these estrogens are predominantly 
(±95%) produced in the ovaries in response to follicle stimulating hormone (FSH), while the rest is produced 
in peripheral tissues like the breast, liver, adrenal gland and adipose tissue from steroid precursors (81–
84). In post-menopausal women, however, estrogens are predominantly produced via peripheral 
conversion of steroid precursor molecules (73). In the classical pathway of estrogen steroidogenesis, 
androstenedione is synthesized from cholesterol through a series of intermediates via catalysed reactions 
in the theca cells of the ovaries, where-after androstenedione enters the granulosa cells were it is either 
converted through aromatase (CYP19A1) into E1 or via 17βHSD into testosterone, which in turn can be 
converted to E2, through the action of aromatase (85–87). Once synthesized and secreted, the estrogens 
are transported  via the blood stream bound to albumin and sex hormone binding globulin (SHBG) to their 
target tissues (e.g. vagina, bone, liver, breast and uterus (88–91)) were the free estrogen can ultimately 
elicit its biological effects (92–97). 
Although there are several other pathways, estrogen elicits its biological effects predominantly through the 
classical signalling pathway (Fig. 2.3), which involves E2 binding to the ER. Upon E2 binding to the inactive 
ERs, mostly located in the nucleus (95, 96, 98), the ER will undergo a conformational change resulting in 
hetero- or homo-dimerization depending on the co-expression of the ER subtypes. This in turn enables the 
ER-ligand complex to bind to the estrogen response element (ERE) present in the promoters of ER 
regulated genes leading to the direct or indirect (via co-factor proteins) recruitment of transcription 
machinery to up- or down-regulate the expression of these target genes (99). It is clear that the ERs are 
essential for estrogen signalling and the structure and function of the ERs will therefore be discussed further 
in more detail. 




Figure 2.3: The four signalling pathways through which estrogens produce a biological response. The classical 
pathway involves estrogen binding to its receptor (R), the ER, to form complexes that bind to the ERE which in turn up- 
or down-regulates estrogen responsive genes (1). The ligand independent pathway involves the activation of 
intracellular kinase pathways via growth factors (GF) or cyclic adenosine monophosphate (cAMP) which activates the 
ER through phosphorylation (2). The ERE-independent pathway involves other DNA-bound transcription factors (TFs) 
like Fos or Jun that tether the activated ER to genes with alternative response elements like activating protein 1 (AP-
1) (3). The non-genomic signalling pathway involves the stimulation of intracellular cascades or signalling pathways via 
activation of putative membrane-associated binding sites (4). Figure taken from Hall et al. (100).  
2.1.5 Estrogen receptors 
The ERs may be divided into two categories: the nuclear ER, which belongs to the steroid receptor family 
that forms part of the nuclear receptor family, and the membrane estrogen receptors (mERs). This study 
will, however, focus on the former. The nuclear receptor family represents the largest family of transcription 
factors that display structural homology (101–105). Up until the discovery of a second ER subtype (named 
ERβ) in 1996, it was thought that estrogens elicited their biological effects solely through one ER subtype 
(renamed ERα) (106, 107).  
2.1.5.1 ER subtype structure and homology 
The two ER subtypes are encoded by two different genes situated on different chromosomes. In humans, 
ERα is located on chromosome 6 and is encoded by the gene ESR1 (108), while ERβ is located on 
chromosome 14 and is encoded by the gene ESR2 (109). Although the human ERβ (hERβ) protein 
containing 530 amino acids (59.2 kDa) is shorter than the human ERα (hERα) protein containing 595 amino 
acids (66.2 kDa), the two ER subtypes share a significant degree of sequence homology (Fig. 2.4) 
especially in the DNA- and ligand-binding domains (110, 111). Both ER subtypes consist of five functional 
domains named A/B to F from the N-terminus to the C-terminus (Fig. 2.4), with the three major domains 
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being the C-domain or DNA binding domain (DBD), the E-domain or ligand binding domain (LBD) and the 
activation domains (AF), A/B and E domains (112).  
 
Figure 2.4: Basic domain structure and homology of ER subtypes, ERα and ERβ. Schematic representation of 
the homology of the functional domains of the human ER subtypes. The DNA binding domain has the highest homology, 
while the A/B domain containing AF-1 has the lowest homology. The numbers above the structures indicate the amino 
acid position, while the numbers at the bottom indicate the percentage sequence homology between the subtypes. 
Figure taken from Leitman et al. (113) 
 
The DBD is involved in DNA binding and is highly conserved between the two ER subtypes, therefore, both 
receptors recognize and bind to the same DNA response elements (EREs).  The DBD contains two zinc-
finger motifs that entail a motif situated at the C-terminal of the first zinc finger known as the proximal box 
(P-box) which is involved in DNA interaction and specificity and a second motif situated at the N-terminal 
of the second zinc finger known as the dimerization box (D-box) which is involved in receptor dimerization 
(98, 114–116).(116) The LBD is positioned close to the C-terminal end of the receptor and is involved in 
many processes beyond ligand recognition and binding, for example heat shock protein (HSP) release, 
dimerization, nuclear localization, co-regulator interaction and activation of transcription [65,127,130]. 
Because the LBD is less conserved (only 55% homology) than the DBD, E2 has a higher binding affinity 
towards ERα than ERβ (117), however, this does not apply to all ligands. Phytoestrogens, for instance, 
generally have a higher binding affinity for ERβ than ERα (118). Furthermore, the transcription activation-
function-2 (AF-2) site is located within the LBD, which in association with transcription activation-function-
1 (AF-1), located in the N-terminal domain, play important roles in co-activator recruitment, which is present 
in both ER suptypes (114, 119–121).  
2.1.5.2 ER subtype function and distribution 
In terms of physiological function, previous studies have characterized ERα, specifically in breast cancer 
cells, as mediator and driving component of cell proliferation, especially in the presence of estradiol (50) 
and have shown that more than 50% of all breast cancer cases can be ascribed to over expression of ERα 
(51, 89). Although, to date, ERβ is not as well characterized as ERα, it has been shown that ERβ has 
tumour suppressor characteristics in some cancer types, like breast cancer, including anti-proliferative 
effects (51, 52, 122). Although both ER subtypes are able to stimulate transcription of E2 target genes 
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through the classical pathway of binding to the ERE and stimulating co-regulator recruitment, ERα generally 
elicits a higher degree of transactivation than ERβ (115, 123–125). 
Both ER subtypes are widely expressed throughout the human body (Fig. 2.5) and in some tissues the ER 
subtypes are co-expressed, however, in some cases they are not expressed in the same cells within a 
particular tissue (126). Furthermore, the period of ER subtype expression may also differ. For example, 
during development of the uterus and pituitary gland only ERβ is expressed and once the tissue is mature 
only ERα is expressed (127). ERα is predominantly expressed in the endometrium, vagina, ovarian stromal 
cells, liver, breast, hypothalamus and pituitary (128), while ERβ is predominantly expressed in ovarian 
granulosa cells, kidney, prostate, epididymis, heart (129), lung, hypothalamus, and bladder (130). Although, 
both ER subtypes are found in breast tissue, ERα expression is up-regulated, while ERβ levels are down-
regulated during carcinogenesis. Thus, the ERα:ERβ ratio is higher in breast cancer tissue than in normal 
breast tissue (131, 132). It is clear that the ERs are important in estrogen signalling and play a role in breast 
cancer development and progression, therefore, in the next section I will discuss breast cancer therapies 











Figure 2.5: Estrogen receptor (ER) tissue distribution in the human body. This simplified diagram was taken from 
a study by Warner et al. (111). 
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2.2 Estrogen receptor targeted therapy for breast cancer treatment and prevention 
Breast cancer tumours that express steroid hormone receptors are known as hormone receptor positive 
(HR+) or hormone dependent breast cancer, which accounts for approximately 70% of breast cancers (133). 
However, the term HR+ breast cancer usually refers to the expression of the ER (ER-positive [ER+] breast 
cancer) as ER is the transcription factor that predominantly drives oncogenesis in HR+ breast cancer (134). 
Breast cancer is generally treated with surgery, followed by chemotherapy or radiation, however, ER+ breast 
cancers are more often treated with endocrine therapy agents, as neo-adjuvant (prior to surgery) or 
adjuvant (in addition to surgery) treatment. Current endocrine therapies include selective estrogen 
modulators (SERMs), selective estrogen receptor down-regulators (SERDs) and aromatase inhibitors (AIs) 
(135–137). Since this study will focus on hormone therapies that target the ERs and not the synthesis of 
E2, aromatase inhibitors, this will not be discussed as it is beyond the scope of this project.  
2.2.1 Selective estrogen receptor modulators (SERMs)  
SERMs were discovered during scientific studies to develop new contraceptives in the 1950s. It was then 
discovered that SERMs are structurally similar to endogenous estrogen, which allows them to interact with 
the ER, leading to the study of the effects of SERMs on hormone dependent breast cancer as a potential 
treatment option. However, unlike estrogens, SERMs may act like agonists or antagonists depending on 
the target tissue (124, 138–141), meaning that their effects are tissue specific. Most SERMs bind to the ER 
subtypes with equal affinity, however, the ER subtypes are not equally distributed throughout the human 
body and are not functionally equal, thereby influencing the agonist or antagonist properties within different 
target tissues. Other factors that influence the tissue selectivity of SERMs include cell type, ligand-
dependent conformational changes and co-factor recruitment (141–143).  
In general, the majority of SERMs elicit protective effects in the bone (ER agonist activity) and breast (ER 
antagonist activity), while the effects of SERMs on the uterus are known to vary. Due to their protective 
effects in the bone and breast, SERMs are most commonly used to treat breast cancer and post-
menopausal osteoporosis. However, due to the vast array of severe side-effects associated with SERM-
treatment, the search for the “ideal SERM” that would elicit strong anti-estrogenic effects to protect against 
endometrial- and breast cancer, while eliciting estrogenic effects in the bone to protect against osteoporosis 
(a known side-effect of currently used breast cancer treatments) is ongoing. SERMs may be classified 
according to their chemical structure as triphenylethylene, benzothiophene, or benzopyran compounds. 
Additionally the triphenylethylene SERMs, including tamoxifen and its derivatives, are also regarded as 
first-generation SERMs, while benzothiophene SERMs include compounds that are classified as second-
generation SERMs (like raloxifene) or third-generation SERMs, and benzopyran compounds are fourth 
generation SERMs (144). 
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Currently there are only two main classes of SERMs approved for clinical use namely the first-generation 
triphenylethylene derivatives, tamoxifen (145) and toremifene (146, 147), both used for treatment and 
prevention of breast cancer (148, 149); and the second-generation benzothiopene derivative, raloxifene, 
used for  treatment and prevention of osteoporosis (150) with the added benefit of reducing the risk of 
breast cancer development in post-menopausal women (151). The first generation SERM, tamoxifen, was 
discovered in 1967 and still remains the most commonly used hormone therapy for ER+ breast cancer 
treatment. Tamoxifen acts as an antagonist of ER in breast tissue thereby reducing breast cancer incidence 
and development, while acting as an ER agonist in the bone and endometrium (152–154), thereby 
protecting the bone, yet increasing endometrial cancer risk through increasing endometrial hyperplasia and 
cell growth. Tamoxifen is also associated with other severe side-effects such as increased risk of strokes, 
hot flushes and pulmonary embolism (140) that instigated efforts to develop further generations of SERMs. 
Toremifene (TOR), is structurally similar to tamoxifen (Fig. 2.6), with a single chloride in the side group 
being the only difference (155). TOR, like tamoxifen, is most commonly used for the treatment of breast 
cancer, however TORs are generally used for treatment of breast cancer in postmenopausal women as it 
has been found to interfere with contraception and may cause fetal harm (156). Due to the structural and 
functional similarities between TOR and tamoxifen, TOR has a similar side-effect profile to tamoxifen, 
therefore, it is not perceived as an improvement over tamoxifen (157, 158). The second generation SERM, 
raloxifene, is as effective as tamoxifen in reducing risk of breast cancer development, and although it is 
also associated with adverse side-effects like hot flushes and blood clots, raloxifene does not increase risk 
of endometrial cancer (159).  
 
Figure 2.6: Chemical structures of tamoxifen and toremifene. Figure taken from Shibutani et al. (10). 
Unfortunately, in addition to the adverse side-effects associated with tamoxifen and raloxifene, most of the 
patients treated with endocrine therapy eventually develop resistance, resulting in disease progression and 
mortality (160). Statistics show that about 30% of ER+ tumours show no response to tamoxifen (de novo 
resistance), while the majority of tumours that were initially responsive to tamoxifen treatment, develop 
resistance (acquired resistance) within two to five years (161).  
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The unwanted side-effects of SERMs together with the accumulating evidence of the anti-proliferative role 
of ERβ (52, 122) instigated the investigation and development of ER subtype selective SERMs, like the 
ERα selective antagonist known as methyl-piperidino-pyrazole (MPP) (162, 163) and the ERβ selective 
agonists including diarylpropionitrile (DPN), (163, 164), prinaberel (ERB-041) (165, 166), the plant extract 
MF101 (167), and liquiritigenin (168). However, it is speculated that the ideal subtype selective SERM or 
rather selective estrogen receptor subtype modulator (SERSM) would possess dual activity, by selectively 
antagonizing ERα (169), while transcriptionally activating ERβ (164, 167, 168, 170), stabilizing the protein 
levels of ERβ and down-regulating the protein levels of ERα, as well as demonstrating anti-inflammatory 
properties by inhibition of pro-inflammatory genes to ultimately decrease the risk of development of post-
menopausal osteoporosis (164, 171). 
2.2.3 Selective estrogen receptor down regulators (SERDs)  
The prospect of down-regulating ER protein levels to attenuate excessive estrogen signalling for therapeutic 
purposes lead to the development of selective estrogen receptor down-regulators (SERDs). SERDs elicit 
their function by competitively binding to the ER and inducing a structural change of the ER to a more 
hydrophobic state, which in turn stimulates proteosomal degradation (172, 173). However, the ideal SERD 
would function by selectively down-regulating only ERα protein levels, while up-regulating or stabilising ERβ 
protein levels, to ultimately decrease ERα-dependent breast cancer cell proliferation.  
The SERD, fulvestrant (ICI 182,780 or Faslodex) was discovered in the search for a pure ER antagonist 
and functions by downregulating the protein levels of ERα, while stabilizing the protein levels of ERβ (174). 
Notably, the majority of ER+ breast tumours that have become resistant to tamoxifen still remain responsive 
to treatment with fulvestrant, leading to its approval by the FDA as a second line treatment for tamoxifen 
resistant ER+ breast carcinomas (175),  thereby indicating that estrogen and the ERs continue to play an 
important role in regulation of tumour growth even in resistant tumours.  
Despite fulvestrant’s effectiveness as a second line therapy, its poor systemic exposure, lack of oral 
bioavailability and association with minor to moderate severity side-effects including, but not limited to, 
menses disturbances, headaches, nausea, weakness, diarrhoea, hot flushes and vomiting, eliminates 
fulvestrant as the ideal breast cancer treatment and has led to the development and investigation of newer 
generation SERDs like etacstil,  brilanestrant and elacestrant, which incorporate SERM activity and are 
known as SERM/SERD hybrids (SSHs). However, none of the SSH’s are currently available in the clinic, 
as elacestrant is currently undergoing clinical trials, while brilanestrant and etacstil were discontinued during 
clinical trials for non-scientific reasons (176–178). 
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• Overexpression of positive 
regulators (e.g. MYC, cyclin 
E1, cyclin D1) 
• Inhibition of negative 
regulators (e.g. p21 and p27) 
• Overexpression of anti-apoptotic 
molecules (e.g. BCL-XL) 
• Reduced expression of pro-apoptotic 
molecules (e.g. caspase 9) 
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regulation (e.g. NCoR 
• Co-activator over-
expression (e.g. AIB1) 
•  Increased expression of 
transcription factors 
(e.g. AP-1, SP-1, NFκB) 
2.3 Endocrine therapy resistance 
Endocrine therapy is perhaps the longest standing, well-tolerated and effective systemic therapy for both 
adjuvant and metastatic breast cancer treatment (179), with the most commonly used endocrine treatments 
being AIs, SERMs and SERDs. However, de novo and acquired resistance to these treatments poses a 
substantial clinical dilemma. Current investigations on possible mechanisms and cell signalling of endocrine 
resistance have brought forth important advances in understanding endocrine resistance. Although the 
mechanisms associated with resistance are very diverse and any alteration of the components involved in 
cell signalling pathways could give rise to resistance, the growing understanding of these mechanisms 
provides the foundation for strategy development to overcome resistance. 
Although several mechanism of endocrine resistance have been identified in breast cancer over recent 
years, this section will provide a brief overview of the principal mechanisms summarized in Fig. 2.7.  More 




















Figure 2.7: Summary of principal mechanisms of endocrine resistance. ER: estrogen receptor; AIB1: amplified in 
breast 1; NCoR: nuclear receptor corepressor; AP1: activator protein 1; SP-1: specificity protein 1; NFκB: nuclear factor-
κB; EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; HER2: human epidermal growth factor 
receptor 2; IGF1R: insulin growth factor 1 receptor; PI3Ks: phosphatidylinositol 3-kinases; MAPK: mitogen activated 
protein kinase; JNK: c-Jun N-terminal kinase; BCL-XL: B-cell lymphoma-extra-large; BCL2: B-cell lymphoma 2. Figure 
drawn by the author, Lorinda van Dyk. 
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2.3.1  ER expression 
To date, ER expression is the leading biomarker for the prediction of endocrine resistance and loss or 
down-regulation of ER expression (mainly ERα) is thought to be the principal mechanism of innate (de 
novo) resistance, whereas after treatment with endocrine therapy (acquired resistance), loss of ER 
expression occurs only in 17-28% of resistant breast cancer cases (185–188). Complete loss or down-
regulation of ER expression may occur through numerous mechanisms. However, it is thought that ER 
expression is primarily controlled by ER gene mutations (only 1% of resistant breast cancers) (189–192), 
post-transcriptional modifications of the ER (e.g. methylation, ubiquitination and phosphorylation) (160, 
193–195) and epigenetic modifications of the ER gene or ER associated gene expression that leads to 
phenotypical changes (196–200).  
2.3.2 ER transcriptional components  
The ER elicits its biological effects through association with co-regulatory proteins which together form a 
transcription initiation complex (201). Thus the effectiveness of endocrine therapies could be greatly 
influenced by changes in this complex of proteins responsible for ER transcriptional activity (202, 203). 
Firstly, the relative expression levels of co-regulatory proteins is believed to maintain the equilibrium 
between agonist and antagonist activity of SERMs and changes in the levels of expression of the co-
regulators could contribute to endocrine resistance by switching from antagonist to agonist activity and vice 
versa. Results from pre-clinical and clinical studies have suggested that tamoxifen resistance is associated 
with increased phosphorylation or over-expression of the ER co-activator, AIB1 (otherwise known as 
NCoA3 or SRC3) (204, 205), whereas experimentally tamoxifen-refractory tumours were found to down-
regulate the co-repressor NCoR (206). Secondly, endocrine resistance is also associated with increased 
activity of transcription factors (TFs) which are important for mediating ER signalling through the non-
classical pathway, for example through NFκB, SP-1 and AP-1 (207, 208).   
2.3.3 Signal transduction pathway regulation 
Cross-talk between different signalling pathways (e.g. cytokine, stress, cell survival (AKT/PI3K) and/or 
growth factor receptor (GFR) signalling pathways) and the ER signalling pathway have been associated 
with innate and acquired endocrine resistance. Growth factor receptor tyrosine kinases (RTKs) and their 
downstream signalling pathways may stimulate cancer growth together with ER signalling or by bypassing 
the ER signalling pathway. Moreover by modulating ER activity these alternative pathways can directly 
counter or overcome the inhibitory effects of endocrine therapies.  
Over-expression of RTKs such as epidermal growth factor receptor (EGFR), human epidermal growth factor 
receptor 2 (HER2) and insulin-like growth factor 1 receptor (IGF1R) has been shown to produce tamoxifen 
resistance in breast cancer cell lines (209–211). Furthermore, clinical evidence has shown that in 
tamoxifen-treated patients poorer outcomes are associated with EGFR and/or HER2 overexpression (212, 
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213). In some cases, epigenetic or genetic modification of signal transduction intermediates may cause 
RTK overexpression (211, 214). Growth factor RTK signalling can be upregulated through the nuclear as 
well as the non-nuclear activities of the ER, while both the genomic and non-genomic activities of the ER 
can simultaneously be modulated via numerous RTK pathways. This bidirectional crosstalk has been 
shown to result in endocrine resistance by activating the ER in the presence of anti-estrogens (215, 216).   
2.3.4 Cell cycle and apoptosis regulators  
Preclinical and clinical studies have shown a correlation between tumour sensitivity to endocrine therapies 
and cell cycle regulators (217). More specifically, overexpression of MYC, as well as cyclins D1 and E1, all 
positive cell cycle regulators, produces endocrine resistance via stimulation of cyclin-dependent kinases 
important for the G1 phase transition or by inhibiting the stability, activity or expression of negative cell cycle 
regulators, like p27 and p21, thereby promoting cell cycle progression (218, 219). Furthermore, anti-
estrogen mediated apoptosis (cell death) is regulated by apoptotic/survival molecules, thus reduced 
expression of pro-apoptotic molecules, like caspase 9 and BCL2-interacting killer, or overexpression of anti-
apoptotic molecules and proteins, like BCL-XL and Bcl-2, result in deregulation of apoptosis characterized 
in breast cancer and may also lead to endocrine resistance (220). 
2.4  Alternative approaches to overcome the drawbacks associated with 
endocrine therapy 
Earlier I discussed the drawbacks of endocrine therapies that specifically target the ER for breast cancer 
treatment and prevention, as well as the general mechanisms involved in the occurrence of endocrine 
resistance in breast cancer. Alternative approaches are, therefore, needed for the treatment of breast 
cancer to lower side-effects and prevent and/or delay endocrine resistance. The biological rationale behind 
the multi-targeted approach for breast cancer treatment and prevention is to target tumours by supressing 
or activating different signalling pathways or processes that are essential for the survival of the tumour, like, 
for example, inducing apoptosis, inhibiting tumour growth, and inhibiting inflammatory processes, to in turn 
lower side-effects and delay resistance to the individual drugs (139, 221, 222). In this section I will discuss 
multi-targeted approaches to breast cancer therapy for the reduction of side-effects associated with SOC 
endocrine therapies as well as for the prevention or deferment or endocrine resistance. Here I will focus on 
natural compounds and extracts with multi-targeted mechanisms of action and combination therapies, 
which include natural compounds.  
2.3.1 Natural compounds as therapeutics for breast cancer 
For many years natural compounds, otherwise known as phytochemicals, have formed the basis for new 
anti-cancer drug developments (223). It is evident that many natural compounds elicit anti-breast-cancer 
activity by acting on multiple signalling pathways (Table 1), thereby providing a multi-targeted approach to 
breast cancer treatment. Furthermore, natural compounds have been shown to have minimal toxicity and 
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lower side-effect profiles, in vitro and in vivo, compared to current synthetic drugs (224). Natural compounds 
are therefore a promising alternative to current endocrine therapies for breast cancer treatment. In this 
section, I will briefly highlight some molecular mechanisms whereby natural chemical compounds act 
against breast cancer. 
Epigenetic dysregulation, characterized by phenotypical modification of a cell without modification of DNA 
sequences, most commonly occurs during initiation and progression of carcinogenesis (225). Epigenetic 
modification mechanistically involves DNA methylation, acetylation, ubiquitination, phosphorylation and 
sumoylation of histones and non-coding RNA’s or miRNAs, which affect the expression of mammalian 
genes (226). With regard to breast cancer, epigenetic silencing of tumour suppressor genes and genomic 
instability during breast carcinogenesis has been linked to abnormal histone modifications and DNA hyper-
methylation (227, 228). Source phytochemicals have the ability to modulate epigenetic events and reverse 
breast cancer causing epigenetic changes. For example, genistein (Table 1) has been found to inhibit DNA 
methylation and increase tumour suppressor gene expression, specifically up-regulating p21 and p16 
expression, in addition to inhibiting DNMT1 expression, the main methyltransferase enzyme responsible 
for the maintenance of DNA methylation, and re-establishing ERα expression (229, 230). Furthermore, 
phytochemicals may reactivate tumour suppressor genes and induce cell cycle arrest and apoptosis 
through epigenetic alterations of specific key transcription factors, kinases and growth factor receptor 
mediated pathways (231, 232). For example, curcumin (Table 1) has been shown to inhibit class I histone 
deacetylases (HDACs), histone-modifying enzymes associated with silencing of key genes and 
transcription factors that regulate physiological functions like cell proliferation and apoptosis, and to 
upregulate the expression of some miRNAs to reduce the expression of Bcl-2 (233, 234). For more 
information on the functional roles of epigenetics in breast cancer or more detail on potential epigenetic 
targets for breast cancer treatment, the reader is referred to the reviews by Lustberg and Ramaswamy 
(235) and Basse and Arrock (236). 
Numerous phytochemicals have been shown to target E2 signalling through inhibition of aromatase, an 
enzyme that plays a key role in estrogen synthesis (237, 238). For example, resveratrol (Table 1) has been 
found to target estrogen signalling by reducing aromatase mRNA expression and by inhibiting 
transactivation CYP19 promoters (239). The reader is referred to a review by Chumsri et al. (240) for further 
reading on aromatase inhibition. 
Furthermore, phytochemicals have shown chemopreventative properties by targeting metabolic processes 
like the arachidonic acid (AA) pathway, which involves metabolic enzymes implicated in inflammation like 
lipoxygenases (LOXs), cyclooxygenases (COXs) and phospholipase A2s (PLA2s) (241–243). Specifically, 
high expression levels of COX-2 have been linked to increased density, invasiveness, metastasis and a 
poor prognosis in breast cancer (244, 245). Numerous phytochemicals like genistein (Table 1) have been 
shown to also inhibit the synthesis of metabolic products of the AA pathway like leukotrienes and 
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prostaglandins (243). For further insight into the AA pathway the reader is referred to a review by Borin et 
al. (246).   
Dysregulation of apoptosis, a form of programmed cell death, is a hallmark associated with tumour 
formation, which also plays a significant role in the development of endocrine resistance (247). Therefore, 
targeting pathways linked to the evasion of apoptosis are considered to be one of the most significant 
strategies for cancer treatment, including breast cancer, and to overcome resistance (248). Previous 
studies have found that phytochemicals, like genistein, epigallocatechin gallate (EGCG), 3,3-
diidolylmethane (DIM), curcumin, lycopene, resveratrol, silibin and sulforaphane induce apoptosis in pre-
malignant or malignant breast cells through regulation of the two main pathways associated with the 
activation of apoptosis, i.e. the intrinsic (mitochondrial-mediated) and extrinsic (death receptor-mediated) 
pathway (Table 1) (248). For example, resveratrol (Table 1) has been found to induce mitochondrial 
mediated apoptosis by stimulating the p53-dependent pathway and by activating the mitochondrial protein, 
Smac/DIABLO, thus, promoting caspase activation (caspase-9, and caspase-3) (249–252), while lycopene 
induces death-receptor mediated apoptosis by increasing the expression of the proapoptotic protein Bax. 
The very promising role of natural compounds in treatment and prevention of breast cancer warrants further 
investigation into potential novel phytochemicals. SM6Met is a sequential methanol extract prepared from 
the indigenous fynbos plant Cyclopia subternata (Fig. 2.8) by sequential extraction using dichloromethane, 
ethyl acetate, ethanol and methanol and HPLC analysis of the extract indicates the presence of xanthones, 
flavones, flavanones, dihydrochalcones, benzophenones and phenolic carboxylic acids (51,255). SM6Met 
has shown great promise for the prevention and treatment of breast cancer. Specifically, previous studies 
have shown that SM6Met displays phytoestrogenic and anti-mutagenic activity (194), has estrogen receptor 
subtype selective activity by acting as an ERα antagonist and ERβ agonist, inhibits E2 induced breast 
cancer cell proliferation, displays anti-inflammatory behaviour, and antagonizes E2-induced uterine growth 
(255). Furthermore, in vivo studies have shown that SM6Met acts as chemopreventative agent against LA7-










Figure 2.8: Cyclopia subternata shoots (left) and the iconic yellow flowers associated with the Cyclopia species 
(right). Photos taken from the South African Honeybush Tea Association (SAHTA) website (258). 
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Major Source Molecular mechanism of action  
Biochanin A Red clover 
 Targets estrogen synthesis by inhibiting aromatase expression (259). 
 Targets breast cancer cell viability, proliferation and invasion by inhibiting human epidermal 
growth factor receptor (HER-2) activation, Erk1/2, Akt, mTOR, MMP-9, MT-MMP1 and NF-κB 
(260). 
Curcumin Turmeric 
 Induces apoptosis by increasing the levels of p53, which in turn increases Bax expression 
leading to an elevated Bax/Bcl-2 ratio (261),  
 Inhibits breast cancer cell proliferation by downregulating cyclin D, MMP1 and NF-κB 
transcription (262). 
 Targets self-renewal in breast stem/progenitor cells through inhibition of the Wnt signaling 
pathway, a pathway dysregulated in many malignancies, including breast cancer (261). 
 Has epigenetic activity as it has been shown to inhibit class I histone deacetylases (HDACs) 
and upregulate the expression of some miRNAs to reduce the expression of Bcl-2, thereby, 
inhibiting carcinogenesis of breast cancer (233, 234). 
3,3-Diidolylmethane 
(DIM) 
Broccoli, cauliflower and 
cabbage 
 Down-regulates genes involved in maintenance of cell growth, cell cycle and apoptosis like 
survivin, Bcl-2 and cdc25A, while upregulating the cyclin-dependent kinase inhibitor, p21WAF1, 
resulting in DNA damage and cell cycle arrest (263).  
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 Targets the arachidonic acid pathway, by specifically inhibiting cyclooxygenase-2 (COX-2, an 
enzyme known to promote inflammation and carcinogenesis) expression  in MCF-7 breast 
cancer cells (263). 
 Targets estrogen synthesis by inhibiting aromatase expression (264). 
 Inhibits angiogenesis, by reducing the accumulation of hypoxia-induced factor (HIF)-1α and 
subsequently decreases expression of key hypoxia responsive factors, VEGF, furin, enolase-
1, glucose transporter-1, and phosphofructokinase in hypoxic tumour cell lines (265). 
Emodin Rhubarb and buckthorn 
 Inhibits HER-2/neu-overexpressing breast cancer cell proliferation by inhibiting HER-2/neu 




 Induces apoptosis by decreasing aryl hydrocarbon- (AhR-) regulated genes; blocking the ERβ-
specific inhibitor, PHTPP; down-regulating the expression of Bcl-2, while increasing Bax 
levels; increasing production of cytochrome c; increasing Apaf-1 expression; activating 
caspase-3 and poly(ADP-ribose) polymerase; altering the activity of EGFR; and increasing the 
expression of proapoptotic genes like p21 and p27, caspase-3, caspase-8, and caspase-9 and 
TP53 (267–276).  
 Targets the arachidonic acid pathway, by inhibiting COX-2 expression and activation of NF-κB 
(277, 278). 
 Modulates the expression of tumour suppressor genes through epigenetic processes involving 
DNA methylation and histone modifications, specifically decreases 5-methylcytosine, DNA 
methyltransferase (DNMT) activity, specifically, DNMT1, DNMT3a, and DNMT3b; decreases 
histone deacetylase activity; increases levels of acetylated lysine 9 and 14 on histone H3 (H3-
Lys 9 and 14) and acetylated lysine 5, 12, and 16 on histone H4; decreases the levels of 
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methylated H3-Lys 9; increases the expression of p16INK4a and Cip1/p21; and induces the 
expression of the epigenetically repressed TIMP-3 gene (275, 276, 279). 
Genistein Soy bean 
 Induces apoptosis by up-regulating Bax and p21WAF1 protein; down-regulating caspase-3; 
blocking the IGF-1R-PI3K/Akt pathway and reducing the Bcl-2/Bax ratio; and enhancing G2/M 
arrest through activation of the ATM/Chk2/Cdc25C/Cdc2 checkpoint pathway (280–283). 
 Inhibits cell proliferation and induces cell cycle arrest through up-regulation of ERβ (284). 
 Targets the arachidonic acid pathway, by inhibiting COX-2 expression, regulating PEG2 by 
acting as antagonist of AA; inhibiting sPLA2, NF-κB and ERK mediated phosphorylation of p65 
and activation of ERα and ERβ (284–288). 
 Has epigenetic activity as it inhibits DNA methylation and increases tumour suppressor gene 
expression, specifically up-regulation of p21 and p16 expression, inhibition of DNMT1 
expression and re-establishing ERα expression (229, 230). 
Lycopene 
Tomato, carrot, 
watermelon, papaya and 
cherry 
 Reduces cell proliferation and induces apoptosis through regulation of growth factor signalling 
pathways and activation of cell cycle arrest, by specifically inhibiting the phosphorylation of Akt 
as well as upregulating the proapoptotic Bax without affecting antiapoptotic Bcl-xL; suppressing 
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cyclin D1 and upregulating p21; sustaining ERK1/2 activation; increasing p53 expression (289, 
290). 
 Upregulates GSTP1 and demethylates GSTP1 promoter by epigenetic modification, a gene that 
is silenced in breast cancer by promoter hyper-methylation (291). 
Resveratrol Grapes 
 Induces apoptosis, by stimulating the p53-dependent pathway; suppressing the PI3K pathway; 
regulating Src tyrosine kinase and signal transducer and activator of transcription 3 (STAT-3) 
phosphorylation pathways; inhibiting Akt phosphorylation, while activating procaspase-9; and 
activating mitochondrial protein (Smac/DIABLO), caspase-9, and caspase-3 (249–252) 
 Targets the arachidonic acid pathway, by inhibiting ERβ, COX-2, NQO2, IKK, and GSTP1 (292, 
293). 
 Targets estrogen signalling by reducing aromatase mRNA expression and inhibiting 
transactivation of I.3 and II CYP19 promoters (239). 
 Elicits it anti-tumour effects through epigenetic pathways by inhibiting DNMT 3b expression and 
decreasing RASSF-1αmethylation; activating SIRT1 and acetyl transferase p300; decreasing  
DNMT1, DNMT3a, DNMT3b, HDAC1, and methyl CpG binding protein 2 (MeCP2) expression 
(294–297). 
Rosmeric acid Rosemary 
 Targets the arachidonic acid pathway, by inhibiting COX-2 expression, blocking AP-1 activation, 





 Induces apoptosis through multiple pathways like decreasing steroid sulfatase gene 
expression; activating caspase-3; suppressing NF-κB pathway, Bcl-2, and Bax; down-
regulating p65; and inhibiting IκB-α phosphorylation (300, 301). 
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 Targets estrogen signalling pathways, by specifically activating ER ubiquitination which in turn 
activates ER degradation, inhibiting pS2 and c-myc, estrogen responsive gene promoters, and 
inducing DNA damage by triggering the Nrf2 pathway (302, 303). 
Silibin Milk thistle 
 Induces apoptosis through down-regulation of Bcl-2 expression, while up-regulating Atg12-
Atg5 formation and increasing beclin-1 expression (304). 
 Targets the arachidonic acid pathway, by suppressing Wnt/LRP6 signaling; down-regulating 




 Inhibits cell proliferation by targeting estrogen signalling, specifically by acting as an ERα 
antagonist and ERβ agonist (255). 
Sulforaphane 
Broccoli, water crass, 
broccoli sprouts, 
cabbage and kale 
 Induces apoptosis through activation of poly(ADP-ribose) polymerase 1 and caspase family 
proteins; enhancing cyclin B1 expression; inhibition of tubulin polymerization; down-regulation 
of the NF-κB signaling pathway; reduction of Bcl-2 and phosphorylated Akt serine/threonine 
kinase expression (307–309). 
 Targets the arachidonic acid pathway, by inhibiting NF-κB and COX-2 expression, which is 
mediated by ERK1/2-IKK-α and NAK-IKK- β (310, 311). 
 Inhibits hTERT (human telomerase reverse transcriptase) through an epigenetic pathway 
involving DNA methylation and histone modification (309).  
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2.3.2 Combination therapy approach for breast cancer treatment and prevention 
The biological rationale behind combination therapy for breast cancer treatment and prevention is twofold. 
Firstly, combinations that target the same cellular pathway may result in increased target selectivity and 
synergistic effects. Synergistic combinations not only increase the efficacy of the therapeutic effect, but also 
reduce the dose needed to exert the same level of effect (increase in potency), thereby, potentially reducing 
toxicity (adverse side-effects) and delaying or reducing the risk of resistance development (312). Secondly, 
combinations of drugs with different molecular targets could delay the process through which cancer cells 
adapt and subsequently delay the occurrence of resistance (139). However, not all combinations work 
synergistically or enhance effectiveness, which could lower side-effects or delay endocrine resistance, and 
thus the development of optimum combinations relies on the understanding and identification of possible 
mechanisms and cell signalling events involved in the development of endocrine resistance that may be 
targeted (discussed in section 2.3). 
Natural compounds with their beneficial multi-targeting activity (Table 1), have been shown to not only 
ameliorate side-effects such as nausea, fatigue, anaemia and mucositis arising from currently used 
chemotherapy or other breast cancer treatments (313), but have also shown synergistic action and/or 
enhancement of effectiveness when used in combination with other chemotherapeutic or endocrine therapy 
agents (314). Some examples of combinations with positive or synergistic effects on breast cancer include: 
the combination of DIM with paclitaxel, a well-known tubulin-targeting chemotherapy agent for breast 
cancer treatment, that synergistically induces apoptosis (315), curcumin in combination with the PI3K 
inhibitor, LY290042, that synergistically induces apoptosis (316), and enhancement of chemosensitivity to 
paclitaxel by the addition of sulforaphane (317). Furthermore, in combination, EGCG increases the 
bioavailability of doxorubicin (317) or 5-fluorouracil (317), both medications used for breast cancer 
treatment that targets DNA production, as well as the SOC endocrine therapy agent, tamoxifen (317). 
Moreover, genistein in combination with doxorubicin displayed synergistic cytotoxic effects (317).  
2.5 Conclusion 
It is apparent from the literature review that multi-targeted therapies herald a new era for anti-cancer 
pharmaceuticals as an approach to not only enhance efficacy and subsequently lower side-effects, but to 
also delay the onset of resistance associated with current endocrine monotherapies. Natural compounds 
and extracts are of great significance in this field as they have not only been found to elicit their action 
through a number of pathways without initiating any kind of unusual toxic effect, but also to enhance the 
effects of conventional chemotherapeutic agents in a synergistic or additive manner. Therefore, more 
research is needed to optimize the activity of these natural compounds and extracts and to develop them 
into novel therapeutic agents, either as monotherapies or in combination with other conventional therapeutic 
agents, for the treatment and prevention of breast cancer. 
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The distinct physiological functions of the ER subtypes, where ERα promotes breast cancer cell 
proliferation, while ERβ opposes its activity (52, 122), suggest that a compound or extract with dual SERSM 
activity that acts as an ERβ agonist and an ERα antagonist would be highly beneficial for breast cancer 
prevention and treatment. Phytoestrogens are estrogen mimicking compounds derived from plants that 
have currently gained pharmacological interest as these compounds are found to be ER-subtype selective 
with a higher affinity for ERβ (318, 319). Visser et al. (255) showed that the phytoestrogenic extract, 
SM6Met, from the native South African plant, Cyclopia subternata, displays the above mentioned ideal 
SERSM properties as well as anti-mutagenic activity, suggesting that SM6Met is a superior candidate to 
prospectively be developed into a phytoestrogenic nutraceutical for prevention and treatment of estrogen 
induced breast cancer. 
Furthermore, the unknown potential of targeting the ERβ signalling pathway in combination with SOC 
endocrine therapies that mainly target ERα (137), warrants further investigation into such combination 
therapies for the prevention and treatment of breast cancer. In addition, such a combination could be 
beneficial for preventing or delaying resistance as the ER has been shown to still play an important role 
even after endocrine resistance has occurred (175),  SM6Met, containing a wide variety of polyphenols, 
could modulate the ER via multi-targeted interventions in comparison to conventional anti-breast cancer 
drugs, such as tamoxifen, and in combination could potentially show synergistic effects and help combat 
the existing challenges of breast cancer treatment including endocrine resistance and toxicity. 
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SM6Met, a Selective Estrogen Receptor Subtype Modulator 
(SERSM), synergizes with Tamoxifen, a standard of care treatment 
(SOC) breast cancer hormone treatment, in reducing breast cancer 
cell proliferation 
3.1 Introduction 
Reproduction, bone integrity, cardiovascular health, behaviour and cognition, amongst others, are all 
examples of physiological systems influenced by estrogens (1). Therefore, it is not surprising that estrogen 
is involved in various diseases including, amongst others, osteoporosis, cardiovascular disease and 
various cancer types, including breast cancer (1).  The aforementioned physiological systems are regulated 
by distinct cellular functions like cell growth, gene expression and apoptosis, which are activated in 
response to estrogen binding to the estrogen receptors (ERs) (2, 3). Estrogen signalling is mediated by 
estrogen binding to two main intracellular ER subtypes, ERα and ERβ (4, 5).  Both ER subtypes are widely 
expressed throughout the human body. ERα is predominantly expressed in the endometrium, vagina, 
ovarian stromal cells, liver, breast, hypothalamus and pituitary (6). ERβ, on the other hand, is predominantly 
expressed in ovarian granulosa cells, kidney, prostate, epididymis, heart, lung, hypothalamus, and bladder 
(7, 8). Previous studies have characterized ERα, especially in breast cancer cells, as mediator and driving 
component of cell proliferation in die presence of estradiol (9) and have shown that more than 50% of all 
breast cancer cases may be ascribed to over expression of ERα (10, 11). In contrast, ERβ has shown anti-
proliferative effects on breast cancer cells by opposing the actions of ERα (10, 12). Although to date ERβ 
is not as well characterized as ERα, it is has been shown that ERβ has tumour suppressor characteristics 
(13). It is clear that ER signalling is critical in the regulation of differentiation and proliferation of breast 
cancer cells, therefore, the ER may be targeted therapeutically to ultimately inhibit cancer growth (14–16). 
ERβ’s therapeutic potential and value for breast cancer prevention and treatment is, however, still under 
investigation and thus current breast cancer therapies target ERα only. Current standard of care (SOC) 
hormone therapies include selective estrogen modulators (SERMs), selective estrogen receptor down-
regulators (SERDs) and aromatase inhibitors (17–19).  
SERMs are a group of compounds with the ability to selectively act on the ER as an agonist or antagonist 
in a tissue selective manner. For example, the first generation SERM, tamoxifen, acts as an antagonist of 
ER in breast tissue, while acting as an ER agonist in the endometrium (20). The antagonistic effects of 
tamoxifen in the breast is what makes tamoxifen successful in preventing and treating breast cancer (21–
23). The tissue selective agonism/antagonism character of each SERM is influenced by their structure, 
differential cofactor recruitment, ER subtype tissue expression and ratio, and conformational changes of 
the ER upon ligand binding (21, 24). Therefore, each SERM has a different tissue selective 
agonism/antagonism profile, which results in distinctly different biological effects (25). The second 
generation SERM, raloxifene, for instance, acts as an ER agonist in the bone and liver tissue, while it acts 
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as an ER antagonist in the breast and uterus (26). Raloxifene is as effective as tamoxifen in reducing the 
risk of breast cancer development, however it failed as a breast cancer treatment showing no effect in pre-
menopausal women and is now most commonly used to treat osteoporosis (27, 28). Despite the 
advantages of both tamoxifen and raloxifene, they have been associated with adverse side effects like hot 
flushes and blood clots (29). However, in contrast to tamoxifen, raloxifene does not increase the risk of 
endometrial cancer (30). In addition to the side-effects caused by current SERMs, some breast cancer 
cases develop resistance to the SOC therapies like tamoxifen and raloxifene (31–33). Although, the 
mechanism of resistance is still not completely understood (34, 35), selective estrogen receptor 
downregulators (SERDs) like fulvestrant, are used as a second line of treatment when resistance occurs 
(32). SERDs, stimulate proteosomal degradation of the ER upon binding to the ligand binding domain (LBD) 
of the ER, thereby inhibiting ER signalling and estrogen binding (36, 37).  Fulvestrant is a pure anti-estrogen 
meaning it is an antagonist of both ER subtypes in all estrogen target tissues (38). Although fulvestrant, 
like tamoxifen, inhibits proliferation of breast cancer, it is associated with a wider range of adverse side-
effects such as hot flushes, muscle weakness, vasodilatation, asthenia, headache, back pain, nausea, 
vomiting, and diarrhoea (23, 30, 39) limiting its use by patients who find the side-effects too severe to 
continue therapy.  
The previously mentioned adverse side-effects related to SERMs (23, 30) and SERDs (39) plus the 
accumulating evidence of the anti-proliferative role of ERβ (12, 13) has resulted in the search for safer 
alternative SERMs with the ideal selective ER subtype modulator (SERSM) properties of acting as ERβ 
agonists and ERα antagonists (30). This has produced a shift in pharmacological interest from tissue 
selective treatments to developing ER subtype selective ligands for the treatment of breast cancer (14, 40). 
Resistance has not only triggered interest in the development of novel therapies, but also in the 
development of combined therapies with current SOC treatments, many of which notably include the use 
of more natural compounds for the treatment of breast cancer (41). Interestingly, a few studies on combined 
therapies using tamoxifen as the SOC treatment agent showed synergistic anti-cancer effects (42, 43). 
Therefore, this chapter will not only focus on validating the ER subtype selectivity of SM6Met, a Cyclopia 
subternata extract, but also investigates SM6Met as a possible alternative to current therapies either as a 
monotherapy or in combination with tamoxifen.    
3.2 Material and Methods 
3.2.1 Test panel  
17β-Estradiol (E2), (2)-4-hydroxytamoxifen (the active metabolite of tamoxifen, which will be referred to as 
4-OH-Tam in this study) and fulvestrant (Ful) were all obtained from Sigma-Aldrich®, South Africa (Sigma). 
Methyl-piperidino-pyrazole (MPP) and liquiritigenin (Liq) are products of Tocris bioscience, which were 
obtained from Whitehead Scientific Pty (Ltd), South Africa. The C. subternata extract, SM6Met, was 
previously prepared by a former laboratory member, J.A.K.  Visser (44). E2, 4-OH-Tam, Ful, MPP and Liq 
stock solutions were prepared in absolute ethanol (EtOH), while the C. subternata methanol extract, 
SM6Met, stock solutions were prepared in dimethylsulfoxide (DMSO), which was diluted with absolute 
ethanol to a final concentration of 25%.  
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3.2.2 Cell culture 
The African green monkey kidney fibroblast (COS-1) cells and Human Embryonic Kidney 293 (HEK 293) 
cells (both from ATCC, United states of America) were maintained in 175cm2 filter cap culture flasks (SPL 
Life Sciences) containing, high glucose (4.5g/L) Dulbecco’s modified eagle’s medium (DMEM) from Sigma, 
supplemented with 10% (v/v) fetal calf serum (FCS) from Merck, South Africa, 100 IU/ml penicillin and 100 
μl/ml streptomycin (1% Penstrep), 44mM sodium-bicarbonate and 1mM sodium-pyruvate (Sigma). The 
MCF-7BUS human breast cancer cells (45) (a kind gift from A. Soto, Tufts University, Boston, 
Massachusetts, United States of America) were maintained in 175cm2 filter cap culture flasks containing, 
high glucose (4.5 g/L) DMEM, supplemented with 5% (v/v) heat inactivated fetal calf serum (HI-FCS), 1% 
Penstrep, 44mM sodium-bicarbonate and 1mM sodium-pyruvate.  
3.2.3 Plasmids 
The expression plasmids for human ERα (pSG5-hERα (46)) and human ERβ (pSG5-hERβ (47)) were kind 
gifts from Prof. F. Gannon (European Molecular Biology Laboratory, Heidelberg, Germany). The ERE-
containing promoter reporter construct (3ERE-pS2-pGL3 (48)) was a kind gift from Dr. B. Belandia 
(Molecular Endocrinology Laboratory, Imperial Cancer Research Fund, London WC2A 3PX, United 
Kingdom), while the empty vector plasmid (pGL2-Basic) was obtained from Promega Corporation, 
Madison, Wisconsin, U.S.A. 
3.2.4 Western blot 
The HEK 293 and COS-1 cells were plated into sterile 10cm2 tissue culture dishes (Nest Biotechnology 
Co., Ltd.) at a density of 2 x 106 cells/dish. The cells were incubated for 24hrs to allow them to adhere and 
settle. On day two, the HEK293 and COS-1 cells were transiently transfected with either 150ng of pSG5-
hERα per 10cm plate or 150ng of pSG5-hERβ per 10cm plate using XtremeGENE HPTM transfection 
reagent from Sigma, in concurrence with the recommended instructions of the manufacturer. In brief, the 
XtremeGENE HP:DNA (1:3) complex was left to incubate for 30min at room temperature. After the 30min 
incubation, the transfection complex was added to the cells in a dropwise manner and left to incubate for 
24hrs. After the 24hr incubation, the cells were re-plated into 6 well plates (Nest Biotechnology Co., Ltd.) 
at a cell density of 2 x 105 cells/well. On day four, the cells were lysed in 250µl SDS reducing buffer (10% 
(w/v) SDS, 20% (v/v) glycerol, 0.05% bromophenol blue, 0.2M Tris-HCl (pH 6.8) and 10mM β-mercapto-
ethanol) and transferred into 1.5ml microcentrifuge tubes to be boiled for 10min at 96°C before being stored 
at -20°C. Thawed  lysates (15μl) were separated on a 10% SDS-PAGE gel using electrophoresis and 
transferred to a Hybond-ECL nitrocellulose membrane (Amersham Biosciences, South Africa), which was 
probed for ERα (1:500), ERβ (1:250) and GAPDH (1:500). After the addition of secondary HRP labelled 
anti-rabbit antibody for ERβ (1:500), and secondary HRP labelled anti-mouse antibody for ERα (1:200) and 
GAPDH (1:5000), the proteins were visualized using ECL Western blotting detection reagents (Pierce®, 
Thermo Fisher Scientific Inc., U.S.A) and the Thermo Scientific™  MyECL Imager. The ERα and the ERβ 
primary antibodies (ERα (E115), cat# ab32063 and ERβ (EPR3777), cat# ab92306) were purchased from 
Abcam®, while the GAPDH primary antibody (GAPDH (0411), cat# sc-47724) was purchased from Santa 
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Cruz Biotechnology, Inc., U.S.A. The secondary anti-rabbit antibody (cat# sc-2005) and the secondary anti-
mouse antibody (cat# sc-2030), were both purchased from Santa Cruz Biotechnology, Inc., U.S.A. 
3.2.5 Promoter-Reporter Analysis 
The HEK 293 and COS-1 cells were plated into sterile 10cm2 tissue culture dishes at a density of 2 x 106 
cells/dish. The cells were incubated for 24hrs to allow them to adhere and settle. After the 24hrs, the 
HEK293 and COS-1 cells were transiently transfected with 1500ng of the ERE-containing promoter reporter 
construct (3ERE-pS2-pGL3), 4500ng empty vector (pGL2-basic), together with either 150ng pSG5-hERα 
or 150ng pSG5-hERβ expression vectors using XtremeGENE HPTM transfection reagent, in concurrence 
with the recommended instructions of the manufacturer as described in section 3.2.4. On the third day, the 
cells were re-plated into sterile 24 well tissue culture plates (Lasec SA [Pty] Ltd) at a density of 5 x 104 
cells/well and allowed 24hrs to settle. Thereafter, the cells were induced with increasing concentrations of 
test compounds dissolved in EtOH or methanol extracts dissolved in DMSO alone (agonist mode) or in the 
presence of 10-11M E2 (antagonist mode), all of which were prepared in treatment medium (phenol red free 
DMEM supplemented with 10% fetal calf serum double stripped with dextran coated charcoal (DS-FCS) 
and 1% Penstrep so that the final concentration of EtOH did not surpass 0.1% (v/v) and DMSO did not 
surpass 0.025% (v/v). The cells were induced for 24hrs, before the cells were washed with phosphate 
buffered saline (PBS) and 50µl of lysis buffer (0.2% (v/v) Triton, 10% (v/v) glycerol, 2.8% (v/v) Tris-
phosphate-EDTA, and 1.44mM EDTA) was added to each well. The plates were shaken at 4°C for 15min 
before being frozen overnight at -20°C. Luciferase activity was determined using the luciferase assay kit 
from Promega Corporation, Anatech, South Africa in consensus with the manufacturer’s instructions. In 
short, the plates were thawed and placed on ice, after which 5μl of cell lysate from each sample was added 
to a well in a 96 well white polysterene plate (Sigma, South Africa) and allowed to react with 25µl of 
luciferase substrate, which was automatically added by the Veritas microplate luminometer (Promega 
Corporation, Anatech, South Africa). The results were measured in relative light units (RLU's).  A further 
5μl of cell lysate from each sample was added to a 96-well clear microwell plate and allowed to react with 
250µl of Bradford solution for 5min in the dark. Thereafter, the protein content was measured as 
absorbance values at 620nm. During analysis, the luciferase RLU's were normalized to protein content 
determined using the Bradford assay (49). Each assay included E2 as positive control and three negative 
solvent controls including (1) treatment medium, (2) 0.1% (v/v) EtOH in treatment medium and (3) 0.025% 
(v/v) DMSO in treatment medium. In agonist mode, the results were expressed as fold induction relative to 
the average results from the three negative solvent controls as there was no significant difference between 
them in terms of proliferation potential (Suppl. Figure S1), whereas in antagonist mode, the results were 
expressed as fold induction relative to the positive control, E2. 
3.2.7 MTT cell proliferation assay 
The MCF-7BUS cells were withdrawn from steroids for a week before plating by changing the growth 
medium to DMEM without phenol red supplemented with 5% fetal calf serum double stripped with dextran 
coated charcoal and heat inactivated (DS-HI-FCS) and 1% Penstrep. Subsequently, on day one the MCF-
7BUS cells were seeded into 96-well tissue culture plates (Nest Biotechnology Co., Ltd.) at a density of 
3000 cells/well and allowed 24hrs to settle. The next day the cells were induced with test compounds 
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dissolved in EtOH or methanol extracts dissolved in DMSO alone (agonist mode) or in the presence of     
10-11M E2 (antagonist mode), all of which were prepared in treatment medium (phenol red free DMEM 
supplemented with 5% DS-HI-FCS and 1% Penstrep) so that the final concentration of EtOH did not exceed 
0.1% (v/v) and DMSO did not exceed 0.025% (v/v). The cells were induced for a period of seven days, 
wherein there were two retreatments on days three and six. On day eight the colorimetric MTT (3-[4,5- 
dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide from Sigma-Aldrich®) assay was performed as 
adapted from Verhoog et al. (50) and Mfenyana et al. (51). In short, after the 7 day incubation period the 
medium was aspirated and changed to 150μl/well unsupplemented DMEM without phenol red. Thereafter, 
50μL of MTT solution at a concentration of 5mg/ml was added to each well and left to incubate for four 
hours at 37°C. After the four hour incubation step, the medium was removed and 200μL of solubilisation 
solution (isopropanol) was added to each well. The plate was then covered with foil, shaken at room 
temperature for 5min, and the absorbance read at 550nm on a BioTek® PowerWave 340 
spectrophotometer. Each assay included E2 as positive control and three negative solvent controls 
including (1) treatment medium, (2) 0.1% (v/v) EtOH in treatment medium and (3) 0.025% (v/v) DMSO in 
treatment medium. In agonist mode, the results were expressed as fold induction relative to the average 
results of the three negative solvent controls as there was no significant difference between them (Suppl. 
Figure S1), whereas in antagonist mode, the results were expressed as fold induction relative to the positive 
control, E2. 
3.2.8 Statistical analysis of data 
GraphPad Prism® version 5.03 for Windows was used for graphical presentation and statistical analysis. 
One-way ANOVA with Tukey’s multiple comparisons test as post-test was used as statistical analysis 
method, except for the analysis of two groups (data sets) for which a two tailed unpaired student’s t-test 
was used (as described in all figure legends). Significant statistical difference between groups are indicated 
with different letters and was calculated as a p-value with levels of significance indicated for each 
experiment.  
3.3 Results 
3.3.1 Validation of the ER subtype selectivity of the test panel 
To validate the previously demonstrated ERα antagonist and ERβ agonist properties of SM6Met (52), I 
tested its effects on ERα and ERβ mediated ERE-luciferase promoter reporter activation and compared it 
to the agonist/antagonist profiles of the rest of the test panel. This includes E2 , a proven agonist of both 
ER subtypes with a higher potency toward ERα than ERβ, as shown in both proliferation and ligand binding 
studies (52–55) as positive control; 4-OH-Tam a proven antagonist of both ER subtypes in breast tissue 
(12, 56, 57) and fulvestrant a pure antagonist of both ER subtypes in all estrogen target tissues (38, 58, 
59) as representatives of current SOC therapies for breast cancer treatment; MPP as representative of a 
proven ERα selective antagonist (60, 61) and liquiritigenin as representative of a proven ERβ selective 
agonist (62).  
 










Figure 3.1: Confirmation of successful transfection of the ER subtypes into the HEK293 and COS-1 cell lines. 
The western blot was performed using antibodies raised against ERα, ERβ and GAPDH (loading control). The MCF-
7BUS cell line, loaded into lane 1, is known to endogenously express both ER subtypes and was used as a positive 
control. Un-transfected HEK293 and COS-1 lysates, loaded in lane two and three, respectively, was used as negative 
controls and depicted as (-). The transiently transfected HEK293 and COS-1 lysates where loaded in lane four and 
five, respectively, and depicted as (+).  
 
Experimentally the HEK293 and COS-1 cells, two cell models that do not contain the ER subtypes of 
interest, were transiently transfected with ERα or ERβ (Figure) together with an ERE-containing promoter 
reporter construct to evaluate the ERα agonism and antagonism (Figure & Suppl. Figure S2-5) and ERβ 
agonism and antagonism (Figure & Suppl. Figure S2-5), respectively.  
 
3.3.1.1 The C. subternata extract, SM6Met, like the ERβ selective agonist, liquiritigenin, induced 
transactivation via ERβ 
To evaluate ERα and ERβ agonism, the two cell lines, transiently transfected with the respective ER 
subtypes, were treated with the test panel in a dose dependent manner for 24hrs (Figure, Figure & Suppl. 
Figure S2-5). E2 was the only ligand to show agonist activity via both ER subtypes (Figurea and e &  Figurea 
and e). This endogenous ligand not only displayed a significantly (P<0.05) 6.3-fold higher potency, but also 
a significantly (P<0.001) 1.6-fold (63.5%) higher efficacy, via ERα than via ERβ in the COS-1 cell line (Table 
2 and Table 3). However, in the HEK293 cell line, there was no statistical difference in the potency of E2 
when comparing the two ER subtypes, but a notable (P<0.001) 27-fold (2582.6%) higher efficacy through 
ERβ than via ERα (Table 2 and Table 3).  
Out of the two SOC treatments, only 4-OH-Tam showed an effect in agonist mode, albeit an unexpected 
inverse agonist effect through ERα only in the HEK293 cell line (Suppl. Figure S2B). Although 4-OH-Tam 
has been shown to be an antagonist of ER in breast tissue (21), no literature was found to corroborate this 
effect in kidney cell lines or tissue via the ER.  
As expected, MPP on its own showed no agonist effect via either ER subtype in either cell line (Suppl. 
Figure S2D and J and Figure S4D and J). SM6Met, like liquiritigenin, displayed agonist effects via ERβ 
with no transactivation via ERα (Figurea & e), thereby, validating liquiritigenin as an ERβ selective agonist, 
whilst confirming that SM6Met acts as an ERβ agonist, albeit significantly less potent than liquiritigenin in 
both cell lines (Figurec & g and Table 2).  
The compounds that displayed ERβ agonist properties may be listed in order of decreasing potency as E2 
≈ liquiritigenin > SM6Met in both cell lines (Table 42) and in order of decreasing efficacy (% induction) as 
E2 > liquiritigenin = SM6Met in the HEK293 cell line and E2 ≈ liquiritigenin > SM6Met in the COS-1 cell line 
(Suppl. Figure S7a & b). 
MCF-7BUS HEK 293  
(+) 
ERα : 66kDa 
ERβ : 56kDa 
GAPDH : 37kDa 






Stellenbosch University  https://scholar.sun.ac.za
63 
 
3.3.1.2 The C. subternata extract, SM6Met, like the ERα selective antagonist, MPP, inhibited E2-induced 
transactivation via ERα 
To evaluate ERα and ERβ antagonism, the two cell lines, transiently transfected with the respective ER 
subtypes, where treated with the test panel in the presence of 10-11M E2 in a dose dependent manner for 
24hrs (Figure, Figure and Suppl. Fig. S2-5). The SOC treatments, fulvestrant and 4-OH-Tam, both acted 
as antagonists of E2-induced transactivation of ERα and ERβ in both cell lines (Figureb & f and Figureb & 
f). Fulvestrant displayed a significantly (P<0.001) 327-fold higher potency via ERβ than via ERα in the 
COS-1 cell line (Figureh and Figureh), with no statistical difference in efficacy. Similarly, in the HEK293 cell 
line, fulvestrant showed a significantly (P<0.01) 15.5-fold higher potency via ERβ than via ERα (Figured, 
Figured and Table 1 & 2), also with no statistical difference in efficacy. The results showed that         4-OH-
Tam elicits its antagonistic effects via both ER subtypes, with no statistical difference in potencies towards 
ERα and ERβ as well as no statistical difference in efficacies. 
Similarly to MPP, SM6Met displayed no antagonistic effects through ERβ (Figureb & f), but displayed 
significant inhibition of E2-induced ERE containing-promoter reporter activity via ERα (Figureb & f), thereby 
validating MPP as a selective ERα antagonist and confirming that SM6Met elicits its antagonistic effects 
via ERα with approximately the same potency and efficacy as MPP (Suppl. Fig. S6 and Figured & h).  
The test compounds that antagonized E2-induced transactivation via ERα in the HEK293 cell line may be 
listed in order of decreasing potency as 4-OH-Tam ≈ Ful > SM6Met ≈ MPP (Table 1 and Fig. 3.2d), whereas 
for the COS-1 cell line may be listed in order of decreasing potency as 4-OH-Tam > Ful ≈ MPP > SM6Met 
(Table 1 and Fig. 3.2h). The efficacies of the antagonists are not statistically different for either cell line, 
except in the COS-1 cell line where fulvestrant is significantly different from MPP (Suppl. Figure S6). In 
summary, when comparing the behaviour of SM6Met with the behaviour of the known agonist and 
antagonist test compounds, it is clear that SM6Met acts as an ERα antagonist and ERβ agonist, confirming 
previous work (52). 
3.3.1.3 Overall the HEK293 cell line appears to be a more sensitive testing model for ERβ agonism than 
the COS-1 cell line 
In agonist mode, E2 displayed a significantly (P<0.01) 10.8-fold higher potency via ERβ in the HEK293 cell 
line in comparison to via ERβ in the COS-1 cell line, whereas there was no statistical difference in potency 
via ERα between the two cell lines. This endogenous ligand was 4.5-fold more effective (P<0.001) via ERα 
in the COS-1 cell line, whereas for ERβ, E2 was 9.8-fold more effective (P<0.001) in the HEK293 cell line. 
SM6Met and liquiritigenin both displayed higher potencies via ERβ in the HEK293 cell line than via ERβ in 
the COS-1 cell line, while displaying the opposite in terms of efficacy. In summary, all the compounds that 
showed agonist effects via ERβ (E2, liquiritigenin and SM6Met) displayed higher potencies in the HEK293 
cell line, while higher efficacies were observed in the COS-1 cell line for liquiritigenin and SM6Met only. 
In antagonist mode, fulvestrant displayed a significantly (P<0.01) 38-fold higher potency via ERβ in the 
COS-1 cell line when compared to via ERβ in the HEK293 cells. In addition fulvestrant and MPP displayed 
a significantly (P<0.01) 1.8-fold and 3.3-fold higher potency towards ERα in the COS-1 cell line when 
compared to ERα in the HEK293 cell line, respectively. Furthermore, 4-OH-Tam displayed a significantly 
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higher potency via both ERα (P<0.05) and ERβ (P<0.001) in the COS-1 cell line when compared to the 
HEK293 cell line. In contrast, SM6Met displayed a significantly (P<0.05) 11.3-fold higher potency towards 
ERα in the HEK293 cell line in comparison to the COS-1 cell line. In summary, when comparing between 
the two cell lines, no significant difference was found in efficacy via ERα or ERβ for any of the antagonist 
compounds (fulvestrant, 4-OH-Tam, MPP and SM6Met). With regard to potency, three out of the four ERα 
antagonists (4-OH-Tam, fulvestrant and MPP) were more potent in COS-1 cells, while both ERβ 
antagonists (4-OH-Tam and fulvestrant) were more potent in the COS-1 cell line (Figuree and Figuree).  
To conclude, we were able to validate and quantify the ER subtype agonist and/or antagonist profiles of 
the commercially available and well-established test compounds, 4-OH-Tam, fulvestrant, MPP and 
liquiritigenin, in two cell models, allowing us to confirm and compare the ERα antagonist and ERβ agonist 
properties of SM6Met. SM6Met proved to be a weaker antagonist of ERα than the SOC therapies (4-OH-
Tam and fulvestrant) as well as a weaker ERβ agonist than the commercially available ERβ agonist, 
liquiritigenin. Interestingly, with regard to the two cell models, all the antagonists for both ER subtypes 
(except SM6Met) displayed a higher potency in the COS-1 cell line, while all the agonists for both ER 
subtypes displayed a higher potency in the HEK293 cell line. With regard to the two cell models, the 
HEK293 cell line proved to be a more sensitive testing model for ERβ agonism than the COS-1 cell line, 
while the COS-1 cell line proved to be a more sensitive testing model for antagonism of both ER subtypes. 
3.3.2 Evaluation of the effect of the test panel on E2-induced breast cancer proliferation  
As described previously ER subtype-selective action could be of great biomedical importance in developing 
an optimal therapy for breast cancer prevention and/or treatment. Having validated the ER subtype 
selective properties of SM6Met, I wanted to evaluate the effects of SM6Met not only in a more integrated 
model where both ER subtypes are co-expressed (Figure), but also on a more physiologically relevant 
model, namely breast cancer cell proliferation. 
3.3.2.1 Fulvestrant and MPP act as inverse agonists in breast cancer cell proliferation 
Agonism (Figurea-c and Suppl. Fig. S8) of cell proliferation was determined by using the colorimetric MTT 
assay after treating the MCF-7BUS cells with the test panel alone in a dose-dependent manner. E2, as 
expected, induced cell proliferation in a dose dependent manner with significant induction at a wide range 
of concentrations from 2.7 x 10-6µg/ml to 0.27µg/ml (10-11M to 10-5M), with a 2 ± 0.03-fold efficacy and a 
potency of 7.6 x 10-7 ± 0.19µg/ml (Table 4). In contrast, fulvestrant and MPP both displayed true inverse 
agonism as they significantly repressed cell proliferation on their own as no exogenous estrogen was 
present because of the use of phenol red free medium and DS-FCS (Figure S8 C & D). MPP revealed a 
significantly (P<0.05) higher efficacy in inhibiting cell proliferation on its own compared to fulvestrant 
(Figurea & e and Table 4), however, fulvestrant on its own displayed a much higher (P<0.001) potency 









































Figure 3.2: Evaluation of the ERα subtype selective agonism and antagonism of the test panel by measuring 
ERα induced ERE-containing promotor reporter luciferase activity in the HEK293 and COS-1 cells. HEK293 and 
COS-1 cells were plated into sterile 10cm2 tissue culture dishes at a density of 2 x 106 cells/dish and transiently 
transfected with pSG5-hERα together with an ERE-containing promoter reporter construct 24hrs after plating. To test 
agonism (a,c,e & g) the cells were treated with E2, 4-OH-Tam, fulvestrant, MPP, liquiritigenin and SM6Met in a dose 
dependant (a & e) manner 24hrs after transfection, whereas antagonism (b,d,f & h) was tested by treating the cells 
with 4-OH-Tam, fulvestrant, MPP, liquiritigenin and SM6Met in a dose dependant manner (b & f) in the presence of 10-
11M E2 (represented by the red dotted line). Subsequent to the 24hr induction with the test panel, the cells were lysed 
using passive lysis buffer. Luciferase activity was measured and normalised to protein content, which was determined 
using a Bradford assay. Statistical analysis of the Log IC50 values (d & h) was performed using One-way ANOVA with 
Tukey’s multiple comparisons test as post-tests, where different letters indicate statistical significance (P<0.05). The 





























































































































































































































































Figure 3.3: Evaluation of the ERβ subtype selective agonism and antagonism of the test panel by measuring 
the induced ERE-containing promoter reporter luciferase activity in the HEK293 and COS-1 cells. HEK293 and 
COS-1 cells were plated into sterile 10cm2 tissue culture dishes at a density of 2 x 106 cells/dish and transiently 
transfected with pSG5-hERβ together with an ERE-containing promoter reporter construct, 24hrs after plating. To test 
agonism (a,c,e & g) the cells were treated for with E2, 4-OH-Tam, fulvestrant, MPP, liquiritigenin and SM6Met in a dose 
dependant (a & e) manner 24hrs after transfection, whereas antagonism (b,d,f & h) was tested by treating the cells 
with 4-OH-Tam, fulvestrant, MPP, liquiritigenin and SM6Met in a dose dependant manner (b & f) in the presence of 10-
11M E2 (represented by the red dotted line). Subsequent to the 24hr induction with the test panel, the cells were lysed 
using passive lysis buffer. Luciferase activity was measured and normalised to protein content which was determined 
using a Bradford assay. Statistical analysis of the Log EC50 values (c & g) was performed using One-way ANOVA with 
Tukey’s multiple comparisons test as post-tests, where different letters indicate statistical significance (P<0.05). 
Statistical analysis of the Log IC50 values (d & h) was performed using a two tailed unpaired student’s test, where 
different letters indicate statistical significance (P<0.05). The average ± SEM is of two independent biological 
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Table 2: Summary of ERα agonism and antagonism of the test panel in the HEK 293 and COS-1 cell lines (data from Fig. 3.2 & Suppl. Fig. S2-6) 
Compounds 
Agonist modea Antagonist modeb 
Bio-characterf 
HEK 293 cell line COS-1 cell line HEK 293 cell line COS-1 cell line 
Efficacyc  
± SEM  
EC50g ± SEM 
(µg/ml) 
Efficacyc 
± SEM  
EC50g ± SEM 
(µg/ml) 
Efficacyd 
± SEM  
IC50h ± SEM 
(µg/ml) 
Efficacy
d ± SEM  











8.9 x 10-5 
±0.10 













9.1 x 10-6 $ $ 
±0.17 
Inverse Agonist (HEK 293) 
Antagonist 
Fulvestrant (Ful) - - - - 
79.9% 
±0.04 









- - - - 
58.3% $ 
±0.06 




1.3 x 10-2 
±0.49 
Partial Antagonist (HEK293) 
Antagonist (COS-1) 
Liquiritigenin (Liq) - - - - - - - - No effect 
SM6Met - - - - 
62.1% $ 
±0.04 




1.8 x 10-1 $ $ 
±0.19 
Partial Antagonist (HEK293) 
Antagonist (COS-1) 
(-) = No effect. 
aTested in the absence of E2.  
bTested in the presence of 10-11 M E2. 
cEfficacy in agonist mode is shown as % activation of ERα mediated ERE-promoter reporter activity, relative to solvent, with E2 set as 100%. Fold induction of E2 indicated in brackets. 
dEfficacy in antagonist mode is shown as % inhibition of E2-induced ERα mediated ERE-promoter reporter activation. 
eAll antagonists were compared to the full antagonist, fulvestrant ($, represents P < 0.05 and $ $, represents P < 0.01).  
fThe defining characteristic of the test compound as indicated by the results of the promoter reporter assay. Indicated as partial if the efficacy is significantly less than the full 
antagonist, fulvestrant. 
gConcentration of test compound that produces half-maximal ERE-promoter reporter activity. 
hConcentration of an inhibitor were the ERE-promoter reporter activation of an agonist is reduced to half. 
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Table 3: Summary of ERβ agonism and antagonism of test panel in the HEK 293 and COS-1 cell lines (data from Fig. 3.3 & Suppl. Fig. S2-5 & S7) 
Compounds 
Agonist modea Antagonist modeb 
Bio-characterg 
HEK 293 cell line COS-1 cell line HEK 293 cell line COS-1 cell line 
Efficacyc  
± SEM  
EC50h ± SEM 
(µg/ml) 
Efficacyc 
± SEM  




IC50i ± SEM 
(µg/ml) 
Efficacyd 
± SEM  




(61.7 fold)  
±2.3 





5.6 x 10-4 
±0.15 
- - - - Agonist 
4OH-Tam - - - - 
90.2% 
±0.08 




2.4 x 10-5 $ 
±0.13 
Antagonist (HEK293) 
Partial Antagonist (COS-1) 
Fulvestrant (Ful) - - - - 
76.9% 
±0.03 









- - - - - - - - No effect 
Liquiritigenin 
(Liq) 
4.7% *** e 
±0.14 




2.6 x 10-3 
±0.23 
- - - - 
Agonist (COS-1) 








2.7 x 10-1 *** 
±0.19 
- - - - Partial Agonist 
(-) = No effect. 
aTested in the absence of E2.  
bTested in the presence of 10-11 M E2. 
cEfficacy in agonist mode is shown as % activation of ERα mediated ERE-promoter reporter activity, relative to solvent, with E2 set as 100%. Fold induction of E2 indicated in brackets. 
dEfficacy in antagonist mode is shown as % inhibition of E2-induced ERα mediated ERE-promoter reporter activation. 
eAll agonists were compared to the full agonist, E2 (* represents P < 0.05 and *** represents P < 0.001). 
fAll antagonists were compared to the full antagonist, fulvestrant ($ represents P < 0.05 and $ $ represents P < 0.01). 
gThe defining characteristic of the test compound as indicated by the results of the promoter reporter assay. Indicated as partial if the efficacy is significantly less than the full agonist, 
E2 or the full antagonist, fulvestrant. 
hConcentration of test compound that produces half-maximal ERE-promoter reporter activity. 
iConcentration of an inhibitor were the ERE-promoter reporter activation of an agonist is reduced to half.
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Interestingly, these inverse agonists inhibited cell proliferation with a similar, not statistically different, 
efficacy when they were tested in the presence of E2 (antagonist mode). Fulvestrant was, however, 2.1 
times more potent on its own than in the presence of E2, while MPP proved to be a significantly (P<0.001) 
11.9 times more potent in the presence of E2 than on its own. In summary, fulvestrant proved to be more 
potent in reducing breast cancer cell proliferation than MPP, in both agonist and antagonist mode.  
 
3.3.2.2 The C. subternata extract, SM6Met, weakly antagonized E2-induced breast cancer cell proliferation 
Antagonism (Figureb) of E2-induced cell proliferation was determined by treating the MCF-7BUS cells with 
the test panel in a dose-dependent manner in the presence of 10-11M E2. The entire test panel, except 
liquiritigenin, was able to significantly inhibit E2-induced cell proliferation (Figureb) with MPP being the most 
effective (90% ± 0.02 inhibition) and SM6Met being the least effective (19% ± 0.01 inhibition). In comparison 
to MPP (the most effective antagonist), inhibition of cell proliferation by fulvestrant was a significantly 
(P<0.05) 11% lower than that of MPP, whereas inhibition by 4-OH-Tam was even lower than fulvestrant by 
a significant (P<0.001) 16%. Although, MPP proved to be the most effective antagonist, it also displayed 
the lowest potency, whereas the extract with the lowest efficacy, SM6Met, proved to be a significantly 
(P<0.01) 11.7 times more potent than MPP. Fulvestrant proved to be the most potent inhibitor of E2-induced 
breast cancer cell proliferation since it displayed a potency 28 times (P<0.01) higher than 4-OH-Tam, 209 
times (P<0.001) higher than SM6Met, and 2455 times (P<0.001) higher than MPP. In short, the compounds 
and extract that antagonized E2-induced cell proliferation may be ranked in order of decreasing potency as 
fulvestrant > 4-OH-Tam > SM6Met > MPP or in order of decreasing efficacy as MPP > Ful > 4-OH-Tam > 
SM6Met. 
3.3.2.3 Proof of concept that a combination of an ERα antagonist and ERβ agonist is more effective than 
an ERα antagonist or ERβ agonist on its own in preventing breast cancer cell proliferation. 
SM6Met is a selective estrogen receptor subtype modulator (SERSM) in that it selectively antagonizes ERα 
(Figureb & f), while selectively activating ERβ (Figurea & e), attributes thought to be advantageous in 
preventing breast cancer cell proliferation (14, 63–67). However, the limitations of natural extracts like 
SM6Met include, amongst others, lower activity in comparison to purified or synthetic compounds as 
demonstrated by the low efficacy and potency by which SM6Met inhibited E2 induced ERE-containing 
promoter reporter activity (Figure) and breast cancer proliferation (Figure). Therefore, we combined MPP 
(an ERα selective antagonist) with liquiritigenin (an ERβ selective agonist) in order to mimic the ER subtype 
selective characteristics of SM6Met. Thus, in a proof of concept study to demonstrate the advantages of a 
combined therapy consisting of an ERα antagonist and ERβ agonist in inhibiting breast cancer cell 
proliferation, a constant concentration of MPP (10-6M) was combined with increasing concentrations of 
liquiritigenin (10-11M to 10-7M), in the presence of 10-11M E2 (Figure). The IC50 concentration of MPP (2.7 x 
10-1µg/ml or 10-6M) as determined from the dose response curves in Figure S8 displayed a significant 
(P<0.001) 72% inhibition of E2-induced cell proliferation, while liquiritigenin with a ±40% average inhibition 
of E2-induced cell proliferation at all the concentrations tested, showed no statistically significant increase 
in inhibition when the concentration of liquiritigenin was increased. However, when the 10-6M of MPP was 
combined with liquiritigenin, the percentage inhibition of E2-induced breast cancer cell proliferation 
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increased in relation to the increase in concentration of liquiritigenin, with significant inhibition compared to 
10-6M MPP alone at combinations with 10-8M and 10-7M liquiritigenin (P<0.05 and P<0.001, respectively). 






























































































































































































Figure 3.4: Evaluation of the effects of the test panel on E2-induced breast cancer cell proliferation by means 
of dose response curves in human MCF-7BUS breast cancer cells, a cell line which endogenously expresses 
ERα and ERβ. The MCF-7BUS cell were withdrawn from steroids for a week before plating, by changing the growth 
medium to DMEM without phenol red supplemented with 5% DS-HI-FCS and 1% Penstrep. Thereafter, MCF-7BUS 
cells were treated with a 4-OH-Tam, fulvestrant, MPP, liquiritigenin and SM6Met in the absence (a, c & e) - agonist 
mode) and in the presence of 10-11M E2 (b, d & e - antagonist mode) in a dose dependent manner (a & b) for a period 
of seven days, wherein there were two retreatments. Thereafter, MTT solution was added to the cells and after a 4hr 
incubation the medium was removed and the formazan crystals that formed through metabolism were dissolved in 
isopropanol. Statistical analysis was performed using One-way ANOVA with Tukey’s multiple comparisons test as post-
tests, where different letters indicate statistical significance (P<0.05). The average ±SEM is of three independent 
biological experiments done in triplicate. E2 value is represented by the red dotted line (b). 
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Table 4: Summary of efficacy and potency of proliferation of the test panel evaluated in agonist and antagonist 
mode in the human MCF-7BUS breast cancer cell line (data from Figure) 
Compounds 









IC50k ± SEM (µg/ml) 
Estradiol (E2) 
100% 
(2.0 fold)             
±0.03 
7.6 x 10-7 
(±0.19) 











-77%     
±0.02 











-92%     
±0.09 




2.7 x 10-1  
$ $ $
 






- - - - 
No dose 
response 
SM6Met - - 
19% 
±0.01 
2.3 x 10-2  




(-) = No effect. 
aTested in the absence of E2.  
bTested in the presence of 10-11 M E2. 
cEfficacy in agonist mode is shown as % proliferation, relative to solvent, with E2 set as 100%. Fold induction of E2 
indicated in brackets. 
dEfficacy in antagonist mode is shown as % inhibition of E2-induced proliferation.  
eStatistically different from E2 (* represents P < 0.05, ** represents P < 0.01 and *** represents P < 0.001). 
fStatistically different from fulvestrant ($
 
, represents P < 0.05, $ $ represents P < 0.01 and $ $ $  represents P < 0.001). 
gStatistically different from 4-OH-Tam ( , represents P < 0.05,   represents P < 0.01 and   represents P < 0.001). 
hStatistically different from MPP (#, represents P < 0.05, # # represents P < 0.01 and # # # represents P < 0.001). 
iThe defining characteristic of the test compound as indicated by the results of the proliferation assay. 
jConcentration of test panel that produces half-maximal proliferation. 
kConcentration of test panel were the proliferative effect of the agonist, 10-11M E2, is reduced to half. 
 
The most effective combination (10-7M liquiritigenin together with 10-6M MPP) displayed 96.5% inhibition 
of E2-induced breast cancer cell proliferation, which is 24.5% higher than that obtained with 10-6M MPP on 
its own. In addition, it is also 6.5% higher than the efficacy of MPP, 33.5% higher than the efficacy of the 
SERM, 4-OH-Tam, and 17.5% higher than the SERD, fulvestrant, as determined from the dose response 
curves (summarized in Table 4). In conclusion, it is clear that a mixture displaying both ERα antagonist and 
ERβ agonist properties is not only more effective at reducing E2-induced breast cancer cell proliferation 
than ER subtype selective compounds on their own, but also more effective than some SERMs and SERDs 
on their own. Therefore, extracts like SM6Met that contain compounds that selectively modulate the ER 
subtypes show promise for the development of anti-cancer agents.  
 
















































































Figure 3.5: Checkerboard analysis of the effect of MPP (ERα antagonist) combined with liquiritigenin (ERβ 
agonist) on breast cancer cell proliferation. MCF7BUS cells were seeded into 96 well plates at 3000 cells/well on 
day one, then treated with increasing concentrations of liquiritigenin combined with a constant concentration of MPP, 
in the presence of 10-11M E2, on day three and retreated on day six. Thereafter, MTT solution was added to the cells 
and incubated for a 4hr period. The formazan crystals formed through metabolism indicates the number of viable cells. 
Statistical analysis was performed using One-way ANOVA analysis of variance with Tukey’s multiple comparisons test 
as post-test, where different letters indicate statistical significance (P<0.05).  Average ± SEM is of two independent 
biological experiments done in quadruplicate. 
3.3.3 Evaluation of SM6Met and 4-OH-Tamoxifen as combined therapy to inhibit breast cancer 
cell proliferation 
Drug combination studies to achieve enhanced effects is not only popular in cancer research, but also in 
antibiotic, anti-microbial, immune disease (i.e. AIDS) and viral infection studies (68, 69). Combination 
studies aim to reduce the amount of the drugs needed to elicit the desired response, thereby, possibly 
reducing the adverse effects (41). This multi-drug concept is used in cancer therapy to target tumours by 
suppressing or activating different signalling pathways or processes that are essential for the survival of 
the tumour, like, for example, inducing apoptosis, inhibiting tumour growth, and inhibiting inflammatory 
processes, and thus in turn delaying resistance to the individual drugs (70–72). To validate improved 
effectiveness of a drug combination is relatively simple with the checkerboard assay (Fig. 3.6) as the most 
commonly used method, however enhanced effectiveness does not necessarily mean that the drug 
combination is synergistic (73). In contrast to the checkerboard assay that only measures enhanced or 
reduced efficacy, methods to determine synergism measure the degree of enhancement or reduction by 
the change in potency, also referred to as the interaction index (𝛾), which will be described later on.  
 
3.3.3.1 SM6Met in combination with 4-OH-Tam displayed significantly higher inhibition of E2-induced breast 
cancer cell proliferation than each compound on their own 
Investigating enhanced effectiveness of combining SM6Met with 4-OH-Tam at inhibiting E2-induced breast 
cancer cell proliferation was the first step in determining the possible synergistic properties of SM6Met. 
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This was done by treating the MCF-7BUS cells with SM6Met and 4-OH-Tam in a checkerboard fashion in 























Figure 3.6: Diagram depicting the experimental layout for the treatment step of the checkerboard assay, 
thereby showing how 4-OH-Tam and SM6Met were combined. Increasing concentrations of SM6Met along the 
horizontal in row one combined with the constant concentration of 4-OH-Tam in row two and increasing concentrations 
of 4-OH-Tam along the horizontal in row four combined with the constant concentration of SM6Met in row three. Each 
block represents 4 wells of a 96 well tissue culture plate. 
 
In FigureA, 10-9M 4-OH-Tam displayed a 44% (P<0.001) inhibition of E2-induced cell proliferation, while 
SM6Met could only inhibit (22%, P<0.05) E2-induced cell proliferation at the highest concentration used 
(0.98µg/ml) for this assay. However, when 4-OH-Tam was combined with SM6Met, the % inhibition of E2-
induced cell proliferation increased in relation to the increase in concentration of SM6Met, with significant 
inhibition compared to 10-9M 4-OH-Tam alone at combinations with 0.0098µg/ml, 0.098µg/ml and 
0.98µg/ml SM6Met. The most effective combination (0.98µg/ml SM6Met together with 10-9M 4-OH-Tam) 
displayed 77% inhibition of E2-induced cell proliferation, which is 33% higher than the efficacy of 10-9M 4-
OH-Tam alone (44% inhibition) and 55% higher than the efficacy of 0.98µg/ml SM6Met alone (22% 
inhibition). In FigureB, a constant concentration of SM6Met (0.0098µg/ml) was combined with increasing 
concentrations of 4-OH-Tam. SM6Met at 0.0098µg/ml could not significantly inhibit E2-induced cell 
proliferation on its own, while 4-OH-Tam significantly reduced E2-induced cell proliferation in a dose 
dependent manner with significant inhibition at concentrations of 10-9M (44%, P<0.001), 10-8M (50%, 
P<0.001) and 10-7M (50%, P<0.001). However, when the 0.0098µg/ml SM6Met was combined with 4-OH-
Tam, the % inhibition of E2-induced cell proliferation increased in relation to the increase in concentration 
of 4-OH-Tam. The most effective combination (10-8M 4-OH-Tam together with 0.0098µg/ml SM6Met) 
displayed 73% inhibition of E2-induced cell proliferation, which is 23% higher than the efficacy of 10-8M       
4-OH-Tam alone (50% inhibition) and 64% higher than the efficacy of 0.0098µg/ml SM6Met alone (9% 
inhibition). In conclusion, SM6Met in combination with 4-OH-Tam shows promise as a combinatorial 
therapy that may be used to lower the side-effects or curb resistance, as lower dosages are needed to elicit 
the same effect as either 4-OH-Tam or SM6Met alone (monotherapy). 
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Figure 3.7: Checkerboard analysis of the effect of 4-OH-Tam (a SOC therapy) combined with SM6Met (a 
SERSM) on breast cancer cell proliferation. (A) MCF7BUS cells were induced with increasing concentrations of 
SM6Met combined with a constant concentration of 4-OH-Tam (IC50 concentration as determined in Figure S8) in the 
presence of 10-11M E2 on day three and retreated on day six. On day seven the cells were incubated for 4hrs in MTT 
solution in order for the live cells to metabolize and form formazan crystals, where the number of crystals formed 
indicates the number of viable cells. Thereafter, the crystals were dissolved in isopropanol and the absorbance 
quantified. Statistical analysis was performed using one-way ANOVA analysis of variance with Tukey’s multiple 
comparisons test as post-test, where different letters indicate statistical significance (P<0.05).  Average ± SEM is of 
two independent biological experiments done in quadruplicate. (B) MCF7BUS cells were treated with increasing 
concentrations of 4-OH-Tam combined with a constant concentration of SM6Met (IC50 concentration as determined in 
Figure S8) in the presence of 10-11M E2 on day three and retreated on day six. On day seven the cells were incubated 
for 4hrs in MTT solution in order for the live cells to metabolize and form formazan crystals, where the number of 
crystals formed indicates the number of viable cells. Thereafter, the crystals were dissolved in isopropanol and the 
absorbance quantified. Statistical analysis was performed using One-way ANOVA with Tukey’s multiple comparisons 
test as post-test, where different letters indicate statistical significance (P<0.05).  Average ± SEM is of two independent 
biological experiments done in quadruplicate. 
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3.3.3.2 SM6Met and 4-OH-Tam, administered together in certain fixed ratio combinations were synergistic 
in reducing E2-induced breast cancer cell proliferation 
Having shown that the combination of SM6Met with 4-OH-Tam enhances the reduction of E2-induced 
breast cancer cell proliferation in comparison to the individual treatments with SM6Met and 4-OH-Tam 
alone, the interaction index as described by Tallarida et al. (74, 75) was used in order to determine whether 
this combination is synergistic, additive or antagonistic. In short, the interaction index (𝛾) is obtained via 
the fixed ratio isobolar method in which the effect level (50%, 75% or 90% inhibition of breast cancer cell 
proliferation) is determined for each individual drug (monotherapy) and for each combination ratio using 
dose response curves.  
3.3.3.2.1 In combination, SM6Met increases the potency and efficacy of 4-OH-Tam to reduce E2-induced 
breast cancer cell proliferation 
The analysis of synergism starts with the determination of the potency of each drug (SM6Met and 4-OH-
Tam) in the presence of 10-11M E2 from dose-response curves (Figure). However, to save time we used 
fixed ratio combination mixtures previously made up by another student in our lab who showed potency 
values of 4-OH-Tam (3.128 x 10-7 µg/ml) and SM6Met (8.841 x 10-3 µg/ml) in the presence of 10-11M E2, 
similar to mine. These mixtures were created using the IC50 concentration of SM6Met in relation to the IC50 
concentration of 4-OH-Tam and diluted serially as depicted in Figure  (2-fold dilution with several 


















Figure 3.8: Diagram depicting the principle behind the fixed ratio mixtures made by another student in the lab 
using their IC50 concentrations of 4-OH-Tam (3.128 x 10-7 µg/ml) and SM6Met (8.841 x 10-3 µg/ml) determined 
using proliferation dose response assays. These concentrations serve as the starting point after which 2-fold 
serial dilutions of the mixtures were made and used to treat the MCF-7BUS cell line in order to create dose 
response curves required for the analysis of synergism. 
 
 
x 2 x 2 x 2 ÷ 2 ÷ 2 ÷ 2 
SM6Met 
(8.841 x 10-3 µg/ml) 
4-OH-Tam  
(3.128 x 10-7 µg/ml) 
+ 
Starting point of 1:1 ratio 
x 2 x 2 x 2 ÷ 2 ÷ 2 ÷ 2 
+ 
Starting point of 5:1 ratio 
x 2 x 2 x 2 ÷ 2 ÷ 2 ÷ 2 
+ 
Starting point of 1:5 ratio 
18 19 20 21 17 16 15 
SM6Met 
(8.841 x 10-3 µg/ml) 
4-OH-Tam  
5 x (3.128 x 10-7 µg/ml) 
SM6Met 
5 x (8.841 x 10-3 µg/ml) 
4-OH-Tam  
(3.128 x 10-7 µg/ml) 
18 18 
Variable x 
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The chosen fixed ratios included a 1:1, 1:5, 5:1, 1:10, 10:1, 1:20, 20:1, 1:50 and 50:1 ratio and the MCF-
7BUS cells were treated with a 2-fold dilution series of each ratio, all in the presence of 10-11M E2. Each 
dilution was assigned a number (variable x) in order to keep track of the concentrations of each compound 
and/or extract (SM6Met and 4-OH-Tam) in each vial, subsequently the concentration of each compound 
can be calculated at any point of the dose-response curve of any fixed ratio combination. 
The resulting dose-response curves in FigureA of 4-OH-Tam shift to the left, in the presence of increasing 
SM6Met concentrations, indicating an increase in potency. The shift seems to be proportional to the amount 
of SM6Met added, as increasing the amount of SM6Met in the ratio resulted in an increase in the shift and 
an increase in potency (FigureC), with the exception of the ratio combination of 50:1. Interestingly, in 
FigureB the curve of SM6Met shifts to the right (decreasing potency) when combined with 4-OH-Tam at a 
ratio of 1:1 and 1:5.  However, when 4-OH-Tam is increased more than five times in relation to SM6Met 
(1:10, 1:20 and 1:50), the curves shift back in the direction of the monotherapy curve of SM6Met.  
There was no statistical difference between the efficacy of 4-OH-Tam alone and the efficacy of 4-OH-Tam 
in a 1:1 ratio combination with SM6Met (FigureA).  However, the combinations with higher SM6Met ratios 
in relation to 4-OH-Tam, like the 5:1, 20:1 and 50:1 ratios, displayed significantly (P<0.001) higher efficacies 
than the 1:1 ratio combination. As there was no significant difference between the efficacies of the 1:5, 
1:10, 1:20 and 1:50 ratios of SM6Met:4-OH-Tam it suggests that increasing the concentration of SM6Met 
in the combination with 4-OH-Tam, will only improve the efficacy to a certain extent. On the other hand, the 
addition of 4-OH-Tam to SM6Met in a 1:1 ratio significantly increased the efficacy (P<0.001) in comparison 
to the efficacy of SM6Met alone (FigureB). The combinations with higher 4-OH-Tam ratios in relation to 
SM6Met were also significantly more efficacious than the efficacy of SM6Met alone. Increase in efficacy 
seems to be directly correlated to the increase in concentration of 4-OH-Tam in relation to SM6Met, with 
significant increases in efficacy for the combination ratios of 1:20 and 1:50, but not 1:5 and 1:10, in 
comparison to the efficacy of the 1:1 combination ratio (FigureB). 
In summary, adding SM6Met in combination with 4-OH-Tam enhanced the potency whereby 4-OH-Tam 
inhibited breast cancer cell proliferation, thereby indicating a possible synergistic effect. The 20:1 
combination ratio is considered the best combination ratio of SM6Met:4-OH-Tam, as it had the highest 
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Figure 3.9: Dose response curves illustrating the effect of the combination treatment of SM6Met with 4-OH-
Tam in different IC50:IC50 ratios. MCF-7BUS cells were treated with combinations with a higher ratio towards SM6Met 
(A) and combinations with a higher ratio towards 4-OH-Tam (B) using a 2-fold dilution series of each combination ratio 
in the presence of 10-11M E2 for a period of seven days wherein there were two retreatments. Thereafter, MTT solution 
was added to the cells and after a 4hr incubation the medium was removed and the formazan crystals that formed 
through metabolism was dissolved in isopropanol. The number of viable cells were measured as absorbance to 
generate dose response curves using non-linear regression fitting to determine the potency and efficacy values of each 
combination. Statistical analysis was performed using One-way ANOVA with Tukey’s multiple comparisons test as 
post-test, where different letters indicate statistical significance (P<0.05). Average ± SEM is of three independent 
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Table 5: Summary of the concentrations (µg/ml) of SM6Met and 4-OH-Tam for each combination ratio, as 
determined by non-linear regression analysis, at effective levels of 50%, 75% and 90% in Figure   
Ratio of  
SM6Met:4-OH-Tam 
Concentration in µg/ml at 
the ED50 ±SEM 
Concentration in µg/ml at 
the ED75 ±SEM 
Concentration in µg/ml at 













1.66 x 10-3 
± 0.23 
- 
9.95 x 10-4 
± 0.61 
- 






5.32 x 10-7 
± 0.12 
- 
2.66 x 10-7 
± 0.34 
- 




7.51 x 10-3 
± 0.12 
2.66 x 10-7 
± 0.12 
3.54 x 10-3 
± 0.33 
1.25 x 10-7 
± 0.33 
1.55 x 10-3 
± 0.50 






6.01 x 10-5 
± 0.14 
9.05 x 10-1 
± 0.28 
3.20 x 10-5 
± 0.28 
4.81 x 10-1± 
0.44 




4.14 x 10-4 
± 0.11 
1.47 x 10-8 
± 0.11 
1.24 x 10-4 
± 0.21 
4.40 x 10-9 
± 0.21 
2.94 x 10-5 
± 0.35 




9.62 x 10-1 
± 0.11 
3.40 x 10-5 
± 0.11 
4.53 x 10-1 
± 0.24 
1.60 x 10-5 
± 0.24 
1.98 x 10-1 
± 0.38 




2.21 x 10-4 
± 0.09 
7.82 x 10-9 
± 0.09 
7.60 x 10-5 
± 0.29 
2.69 x 10-9 
± 0.29 
2.59 x 10-5 
± 0.44 




2.55 x 10-1 
± 0.11 
9.01 x 10-6 
± 0.11 
8.49 x 10-2 
± 0.27 
3.00 x 10-6 
± 0.27 
3.01 x 10-2 
± 0.42 




1.31 x 10-4 
± 0.08 
4.64 x 10-9 
± 0.08 
4.83 x 10-5 
± 0.30 
1.71 x 10-9 
± 0.30 
1.55 x 10-5 
± 0.46 




1.20 x 10-1 
± 0.13 
4.25 x 10-6 
± 0.13 
6.01 x 10-2 
± 0.27 
2.13 x 10-6 
± 0.27 
3.01 x 10-2 
± 0.42 




2.76 x 10-4 
± 0.10 
9.78 x 10-9 
± 0.10 
9.67 x 10-5 
± 0.35 
3.42 x 10-9 
± 0.35 
2.24 x1 0-5 
± 0.58 




aVariable representing the concentration of SM6Met used in the specified combination ratio that elicits the 
50%, 75% or 90% inhibitory effect calculated from the dose response curve depicted in Figure. 
bVariable representing the concentration of 4-OH-Tam used in the specified combination ratio that elicits the 
half maximal 50%, 75% or 90% inhibitory effect calculated from the dose response curve depicted in Figure. 
cEfficacy shown as % inhibition of E2-induced proliferation. 
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3.3.3.2.2 The combinatorial effects of SM6Met with 4-OH-Tam on breast cancer cell proliferation is 
synergistic 












where the interaction index (𝛾) is equal to the sum of the concentration of SM6Met [a] and 4-OH-Tam [b] 
at the IC50, IC70 or IC90 point of the selected combination ratio, divided by the IC50, IC75 or IC90 concentration 
of (A) SM6Met alone (1:0) and (B) 4-OH-Tam alone (0:1), (Table 4). If the combination is synergistic, the 
index will be less than one (𝛾 < 1), if additive it will be equal to one (𝛾 = 1), while if it is antagonistic the 
index will be greater than one (𝛾 > 1) (76). In layman’s terms, antagonism signifies drugs acting against 
each other, synergism signifies drugs working together and additivity is the summation of the individual 
drug effects also referred to as the zero-interactive state (77). 
 
Table 6: Summary of the interaction index for each combination ratio, at effective levels 50%, 75% and 90% 
Ratio of 
SM6Met:4-OH-Tam 
Interaction Index at 
50% effect level 
(𝜸50) 
Interaction Index at 
75% effect level 
(𝜸75) 
Interaction Index at 
90% effect level 
(𝜸90) 
1:50 80.28 68.41 69.04 
1:20 170.55 96.60 69.04 
1:10 643.43 515.43 454.47 
1:5 1137.07 1029.85 1103.81 
1:1 5.02 4.03 3.56 
5:1 0.28 0.14 0.07 
10:1 0.15 0.09 0.06 
20:1 0.09 0.05 0.04 
50:1 0.18 0.11 0.05 
 
The interaction index values calculated and summarized in Table 6 was used to create an interaction index 
plot, a convenient and simple graphic representation of the interaction index (Figure). The combinations 
with a higher ratio towards SM6Met (5:1, 10:1, 20:1 and 50:1) showed an interaction index less than one 
at all three selected effect levels, whereas the 1:1 combination of SM6Met with 4-OH-Tam and all of 
combinations with higher ratios towards 4-OH-Tam (1:5, 1:10, 1:20 and 1:50) displayed an interaction index 
greater than one at all three selected effect levels, thereby indicating that increasing the concentration of 
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SM6Met in the combination synergizes the effect of 4-OH-Tam, while increasing the concentration of 4-
OH-Tam in the combination antagonizes the effect of SM6Met.  
 
 






















































Figure 3.10: Interaction index plot for the SM6Met:4-OH-Tam ratio combinations at 50%, 75% and 90% 
inhibition of breast cancer cell proliferation. The dose of SM6Met in combination (a) divided by the dose of SM6Met 
alone (A) plus the dose of 4-OH-Tam in combination (b) divided by the dose of 4-OH-Tam alone (B) at the selected 
effect level equals the interaction index (𝜸). If the combination is synergistic, the index will be less than one (𝜸 < 𝟏), if 
additive it will be equal to one (𝜸 = 𝟏), while if it is antagonistic the index will be greater than one (𝜸 > 𝟏). 
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The combinations may be listed in the order of increasing synergism as follows: 5:1 < 50:1 < 10:1 < 20:1 
at 50% and 75% inhibition and 5:1 < 10:1 < 50:1 < 20:1 at 90% inhibition. The combinations may be listed 
in the order of increasing antagonism as follows: 1:1 < 1:50 < 1:20 < 1:10 < 1:5 at 50% and 75% inhibition; 
and 1:1 < 1:50 = 1:20 < 1:10 < 1:5 at 90% inhibition (Figure and Table 6). In summary, the combination 
ratio of SM6Met:4-OH-Tam of 20:1 displayed the lowest interaction index at all the effect levels thereby 
making it the combination ratio with the highest degree of synergism. 
3.4 Discussion 
 
The adverse side-effects together with the high instances of resistance encountered with the use of SOC 
hormone therapy for breast cancer treatment such as SERMs, like tamoxifen, and SERDs, like fulvestrant 
(78), have led to the search for healthier, more natural compounds for breast cancer prevention and 
treatment as well as for new strategies, like multi-targeted therapy also known as combination therapy. 
Many of these strategies involve combining natural products, like tea extracts, with conventional hormone 
therapies (41–43).  
3.4.1 Evaluation of the ER subtype selectivity of the test panel 
In this study we validated the subtype selectivity of SM6Met in two cell models, that don’t express 
endogenous ER, by comparing it to known ER subtype agonists and antagonists including the natural 
ligand, E2 (summarized in Table 2 and Table 3). Transfection of the ER subtypes into the two cell models, 
the HEK293 and the COS-1 cell line, allowed for evaluation of agonism and antagonism of the ER subtypes 
separately using the classical ERE transactivation model.  
E2, in correspondence with previous studies, acted as a full agonist of both receptor subtypes with a higher 
potency via ERα than via ERβ in both HEK293 and COS-1 cell lines (50, 52, 79, 80). In contrast, Barkhem 
et al. (81), showed that E2 displayed a higher potency via ERβ than via ERα in the HEK293 cell line. 
 As expected the two SOC treatments, fulvestrant and 4-OH-Tam, both acted as antagonists of E2-induced 
transactivation of ERα and ERβ in both cell lines. However, the inverse agonism of 4-OH-Tam via ERα in 
the HEK293 cell line was an unexpected result, as a conscious effort was made to limit or remove any 
basal steroid levels by performing the assay in phenol red free medium with DS-FCS. To our knowledge 
this inverse agonist effect has not been described in previous studies and this phenomenon may be 
ascribed to the use of different experimental conditions, cell lines, plasmids, response elements and 
estrogen receptor concentrations than that used by other studies found in literature or to the presence or 
absence of certain co-regulators in different cell lines.  
MPP antagonized the effect of E2 via ERα in the HEK293 cell line with the same potency as MPP 
antagonized E2-induced ERE-promoter reporter activity via ERα in the study of Zhou et al. (82), using HEC-
1 cells. As expected liquiritigenin showed agonist effects via ERβ, however, the potency with which it 
activated the ERE-luciferase activity via ERβ differed from the study done by Mersereau et al. (66). In the 
current study, the potency of liquiritigenin via ERβ in the HEK293 cells was significantly (P<0.001) 136.8-
fold higher than via ERβ in the COS-1 cell line, moreover it was 492.1-fold higher than the potency (36.5 
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nM) for liquiritigenin via ERβ found by Mersereau et al. (66), in transiently transfected human osteosarcoma 
U2OS cells. Although liquiritigenin did not display any agonist effects via ERα in either of the two cell lines, 
some studies have shown liquiritigenin to be a partial ERα agonist at high concentrations equivalent to 
what was used in the current study (Suppl. Fig. S4) (83).  
 
In correspondence to a study done by Visser et al. (52), SM6Met displayed agonist effects via ERβ and 
antagonistic effects via ERα, however, in contrast to the study by Visser et al., dose response curves were 
established and potency and efficacy values could be determined in the current study. 
In summary, from the ERE-containing promoter reporter studies we were able to validate the 
agonist/antagonist profiles of all the test compounds, as well as the extract, SM6Met. With the knowledge 
that ERα is associated with increased breast cancer cell proliferation, while ERβ has been associated with 
tumour suppressor characteristics by inhibiting the effects of ERα (10, 12, 84, 85), the subtype selective 
properties of SM6Met may be of physiological importance as it could possibly enhance the prevention of 
excessive cell growth associated with cancer development (86).  
3.4.2 Evaluation of the effect of the test panel on E2-induced breast cancer proliferation 
A cascade of events that elicits an estrogenic or anti-estrogenic response, is initiated by a ligand binding 
to the ER subtypes. Therefore, transactivation of an ERE-containing promoter reporter element as well as 
induction or repression of cell proliferation are both endpoints used to identify and evaluate the estrogenic 
or anti-estrogenic potential of a compound or extract (50). We, therefore, set out to determine the effects 
SM6Met on a more physiologically relevant model (MCF-7BUS cell line), where the ER subtypes are co-
expressed (Figure) in order to evaluate the effect of SM6Met on breast cancer cell proliferation and 
compare its effects to the SOC therapies as well as to the commercially available ER subtype selective 
ligands.  
E2 was the only compound from the test panel that induced breast cancer cell proliferation, with a potency 
(7.6 x 10-7µg/ml)  more or less similar to the potency (2.79 x 10-7µg/ml) determined by Verhoog et al. (87), 
both about 10-fold more potent than the potency (2.59 x 10-6µg/ml) determined by Visser et al. (52). The 
proliferative results suggest that E2 is ER dependant as it was antagonized by the ER down-regulator, 
fulvestrant in the current study. 
It was not surprising that the SOC treatment, 4-OH-Tam, which inhibited E2 induced ERE-luc transactivation 
via ERα and ERβ, was able to inhibit E2 induced breast cancer cell proliferation, yet, fulvestrant was able 
to do so at a higher efficacy and potency than 4-OH-Tam (Figure and Table 4). The potency with which 4-
OH-Tam (3.1 x 10-3µg/ml) inhibited the E2 induced proliferation of the MCF7-BUS cells in the current study 
was found to be about 1626-fold higher than the potency (13.13µM or 5.04µg/ml ) of 4-OH-Tam determined 
by Roberts et al. (88), using MCF-7 and T47D breast cancer cells. The potency of fulvestrant (1.1 x               
10-4µg/ml) in the current study was also found to be about 49-fold higher than the potency (9nM or 5.46 x 
10-3µg/ml) determined by Joseph et al. (89).  
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Interestingly, MPP, as well as fulvestrant, reduced breast cancer cell proliferation in the absence and 
presence of E2 and although no literature was found to support the aforementioned result for MPP, a study 
by Joseph et al. (89) demonstrated the same inverse agonist effect of fulvestrant on breast cancer cell 
proliferation. In the presence of E2, liquiritigenin was able to inhibit E2 induced breast cancer cell 
proliferation at certain concentrations (2.6 x 10-9µg/ml to 3.9 x 10-5µg/ml), however, the potency and efficacy 
of liquiritigenin could not be determined as a dose-response curve could not be established (Suppl. Fig. 
S8E). With regard to transactivation, both SM6Met and liquiritigenin displayed agonism via ERβ, however, 
unlike SM6Met, liquiritigenin had no effect on transactivation via ERα, thereby, suggesting that agonism 
through ERβ alone is not enough to inhibit breast cancer cell proliferation to a degree that is comparable 
to current SOC therapies. 
 
In contrast to the study done by Visser et al. (52) showing inhibition of E2 induced breast cancer cell 
proliferation only at certain concentrations (0.98, 9.8 and 98000µg/ml), in the current study SM6Met was 
able to inhibit E2 induced breast cancer cell proliferation in a dose dependant manner allowing for the 
determination of the potency and efficacy of SM6Met. However, SM6Met was not as effective or potent as 
either 4-OH-Tam or fulvestrant. SM6Met as a monotherapy was therefore not able to compete with the 
efficacy or potency of current SOC therapies (fulvestrant and 4-OH-Tam). Although SM6Met was the least 
effective of all the antagonists of E2 induced breast cancer cell proliferation, it proved to be more potent 
than the ERα selective antagonist, MPP. This suggests that a compound or extract that combines ERα 
antagonist and ERβ agonist properties may be more beneficial for breast cancer treatment or prevention 
than a compound that selectively antagonizes only ERα (MPP) or a compound that acts as a selective ERβ 
agonist (Liq).  
3.4.3 Proof of concept that a combination of an ERα antagonist and ERβ agonist is more 
effective in preventing E2 induced breast cancer cell proliferation than an ERα antagonist or ERβ 
agonist on their own 
Nutraceuticals are generally less potent than synthetic drugs as synthetic drugs are the pure, highly 
concentrated active ingredient of an extract or natural compound that has been chemically replicated and 
mass produced. A recent study showed that the desirable estrogenic effects of SM6Met could not be 
retained or significantly enhanced by fractionation (90). In addition, another limitation of natural compounds 
and extracts include differences in composition of batches harvested due to variables in the environment 
(91–93). Therefore, the checkerboard assay was used to combine an ERα selective antagonist (MPP) with 
an ERβ selective agonist (liquiritigenin) to mimic the SERSM characteristics of SM6Met and to validate the 
principle that a compound with the subtype selective properties of SM6Met would be more advantageous 
in inhibiting E2 induced breast cancer cell growth than generally used SERMs, like tamoxifen, or an ERα 
selective antagonist (MPP) or an ERβ selective agonist (liquiritigenin) on their own.  
With regard to inhibition of E2 induced breast cancer cell proliferation, combining the ERα antagonist, MPP, 
with the ERβ agonist, liquiritigenin, resulted in a higher reduction of E2 induced breast cancer proliferation 
in comparison to the ER selective ligands alone. The most effective combination (10-7M liquiritigenin 
together with 10-6M MPP) was not only more effective than 10-6M MPP alone and 10-7M liquiritigenin alone, 
but was also more effective than the SOC therapies, 4-OH-Tam and fulvestrant on their own (Table 4), 
Stellenbosch University  https://scholar.sun.ac.za
84 
 
thereby suggesting that the ideal ER subtype selective properties of SM6Met can be replicated and a purer, 
highly concentrated synthetic drug or nutraceutical with the same SERSM characteristics could possibly 
be synthesized. To our knowledge the combination of a selective ERα antagonist, like MPP, with a selective 
ERβ agonist, like liquiritigenin, has not previously been investigated and results pertaining to the effects of 
this combination are novel. 
3.4.4 Evaluation of SM6Met and 4-OH-Tamoxifen as combined therapy to inhibit breast cancer 
cell proliferation 
Drug combination studies are becoming increasingly more popular in the field of cancer research in an 
attempt to lower side-effects related to current therapies and to lower the risk of resistance by lowering the 
doses of drugs needed to elicit the desired effects (73, 94). After validating the beneficial effects of ER 
subtype selective treatment in lowering breast cancer growth, I wanted to evaluate the potential of SM6Met 
to be used in combination with other SOC treatments as a multi-targeted approach to lowering breast 
cancer growth.  
 
The checkerboard assay showed that the degree to which E2 induced breast cancer cell proliferation was 
inhibited was increased by combining SM6Met with 4-OH-Tam, however enhanced effectiveness does not 
necessarily mean that the drug combination is synergistic (73). Therefore, the synergistic potential of 
SM6Met in combination with 4-OH-Tam was evaluated using the fixed ratio isobolar method as described 
by Tallarida et al. (74, 75). This study, demonstrated for the first time that the C. subternata extract, 
SM6Met, synergistically promoted tamoxifen-induced antagonism of E2 induced breast cancer 
proliferation.  
The results showed that increasing the concentration of SM6Met in the combination ratio of SM6Met:4-OH-
Tam resulted in an increase in potency up to a point where the endogenous ERs possibly became saturated 
(ratio of 50:1) and the potency could not increase further (FigureC). Increasing the concentration of 4-OH-
Tam in the combination ratio of SM6Met:4-OH-Tam resulted in a decrease in potency at the ratio of 1:1 
and 1:5, however, when 4-OH-Tam is increased more than five times in relation to SM6Met (1:10, 1:20 and 
1:50), the potency increases slightly, but never reaching the same potency as that of the combination ratio 
1:1. This strange biphasic trend in potency changes could be due to the high concentration of 4-OH-Tam 
present in the ratios 1:10, 1:20 and 1:50, which could possibly completely outcompete SM6Met, thereby 
shifting the response to resemble the effects of 4-OH-Tam as monotherapy. 
The degree of synergism was determined using the interaction index (𝛾) (74, 75). If the combination ratio 
is synergistic its interaction index value will be less than one (𝜸 < 𝟏), if additive it will be equal to one (𝜸 =
𝟏), while if it is antagonistic the index will be greater than one (𝜸 > 𝟏). The combination ratio 20:1 was the 
combination of SM6Met:4-OH-Tam with the lowest interaction index, therefore, the highest degree of 
synergism. We used the interaction index plot instead of the conventional isobologram to simplify the 
graphical representation of the data in addition to showing the relation between the different effect levels.  
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In regards to anti-cancer therapies, synergism (𝜸 < 𝟏) at high effect levels is better than synergism at low 
effect levels, for example a combination therapy that is synergistic at the low effect level of 50% means 
that only 50% of the concentration range used in the dose response curve will be synergistic, whereas a 
combination therapy that is synergistic at a high effect level of 90% will be synergistic at 90% of the 
concentration range of the dose response curve.  Therefore, the combination ratio 20:1 not only has the 
lowest interaction index, but it is synergistic at all the effect levels (50%, 75% and 90%) tested. 
Other studies have also reported synergistic effects of plant-derived products in combination with 4-OH-
Tam. Examples include a study by  Yaacob et al. (42), who used the Chou-Talalay non-constant ratio drug 
combination method and showed synergistic inhibition of MCF-7 and MDA-MB-231 breast cancer cell 
growth by the combination of a bioactive subfraction of Strobilanthes crispus leaves (SCS - a shrub 
originally from Madagascar) and tamoxifen with combination index values of 0.32 – 0.40 for MCF-7 cells 
and 0.29 – 0.52 for MDA-MB-231 cells at 84 – 97% effect levels. A study by Chisholm et al. (43) where the 
synergistic cytotoxic effects of epigallocatechin gallate (the most common catechin found in green tea) in 
combination with tamoxifen on MDA-MB-231 breast cancer cells was shown  and a study by Samadi et al. 
(95) that showed synergistic inhibition of proliferation and induction of apoptosis in MDA-MB-231 and 
H1299 cells by the combination of vinblastine (isolated from the flowering Madagascan plant, Catharanthus 
roseus) with tamoxifen.  
Due to the various theories, hypotheses, approaches and models used, it is hard to compare the claimed 
synergistic results of the studies previously mentioned with the results obtained in the current study. 
Although all three studies claim synergism, the studies by Chisholm et al. (43) and Samadi et al. (95) only 
show enhanced effectiveness for the various combinations and as described by Chou et al. (69, 73) 
enhanced effectiveness does not necessarily mean that the drug combination is synergistic. The most 
recent methods to determine synergy describe synergism as a measure of the degree of enhancement or 
reduction in potency and not effectiveness (73, 76). Without a standardized method of analysis, 
unsubstantiated or faulty claims of synergism are unescapable. However, the study by Yaacob et al. (42) 
did establish combination index (CI) values, which is comparable to the interaction index calculated in the 
current study, but for effect levels (84-97%), which differ from those of the current study (50%,75% and 
90%). Nonetheless, the best interaction index (0.04) achieved in the current study by the 20:1 ratio of 
SM6Met:4-OH-Tam at the 90% effect level is substantially greater than the best combination index (0.32) 
achieved by Yaacob et al. (42) in the MCF-7 cell line.  
In summary, the presence of multiple compounds in natural agents such as SM6Met may provide the 
advantage of acting on multiple pathways that control the process of cancer development and progression 
and highlight the importance of natural agents in the research, understanding and development of 
combinatorial therapies for cancer prevention and treatment. 
3.4.5 In conclusion  
The results of this study may be assessed in terms of the potential of SM6Met, a SERSM, as an alternative 
treatment for breast cancer, either as monotherapy or in combination with current SOCs like 4-OH-Tam.  
With regard to SM6Met as monotherapy, it is clear that SM6Met could not, in terms of efficacy or potency, 
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compete with the SOC treatments like 4-OH-Tam and fulvestrant and future work should concentrate on 
enhancing the effects of SM6Met or recreating its ER subtype selective characteristics synthetically.  
 
However, the most exciting outcome of this study is the two novel findings with regard to combination 
therapies. Firstly, the most effective combination of the ERα antagonist, MPP, with the ERβ agonist, 
liquiritigenin, displayed 24.5%, 33.5% and 17.5% higher inhibition of E2-induced breast cancer cell 
proliferation than MPP and the SOC therapies, 4-OH-Tam and fulvestrant, respectively, thereby validating 
the concept that a mixture displaying both ERα antagonist and ERβ agonist properties is not only more 
effective than ER subtype selective compounds on their own at reducing E2-induced breast cancer cell 
proliferation, but also more effective than some SERMs and SERDs on their own. These results therefore 
show that extracts like SM6Met that contain compounds that selectively modulate the ER subtypes show 
promise for the development of anti-cancer agents.  
Secondly, the observation that SM6Met synergized the anti-proliferative effects of 4-OH-Tam on E2-
induced breast cancer proliferation with the combination ratio of 20:1 displaying the highest degree of 
synergism. Subsequently in combination with SM6Met about 20 times lower concentrations of 4-OH-Tam 
are needed to elicit the same effect as 4-OH-Tam alone and therefore such combined treatments could not 
only potentially prevent or delay the onset of resistance, but also potentially lower or delay the onset of 
adverse side effects associated with tamoxifen use (42, 43, 75). Further work should be done to clarify the 
mechanism with which SM6Met synergizes the effects of 4-OH-Tam as well as on the potential synergistic 
effects of SM6Met in combination with other SOC therapies like other SERMs, SERDs or chemotherapies. 
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Figure S1: Evaluation of the proliferative potential of the solvents used to prepare stock solutions of the test 
panel, which was used for induction in all experimental work. The MCF-7BUS cell were withdrawn from steroids 
for a week before plating, by changing the growth medium to treatment medium. Thereafter, MCF-7BUS cells were 
induced with the three negative solvent controls including (1) treatment medium, (2) 0.1(v/v) EtOH in treatment medium 
and (3) 0.025% (v/v) DMSO in treatment medium together with the positive control, 10-11M E2, for a period of seven 
days, wherein there were two retreatments. Thereafter, MTT solution was added to the cells and after a 4hr incubation 
the medium was removed and the formazan crystals that formed through metabolism was dissolved in isopropanol. 
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparisons test as post-test, where 
different letters indicate statistical significance (P<0.05).  Average ± SEM is of two to three independent biological 





















































Figure S2: Evaluation of subtype selective agonism of all the test panel by ERE-containing promoter reporter 
activity induced in ERα and ERβ transfected HEK 293 cells by the different compounds and extract. HEK 293 
cells were transiently transfected with 150ng of pSG5-hERα (A-F) or pSG5-hERβ (G-L) together with an ERE-
containing promoter reporter constructs (ng) and left for 24hrs. After transfection, the cells were re-plated into sterile 
24 well plates and treated 24hrs later with E2 (A, G), 4-OH-Tam (B, H), fulvestrant (C, I), MPP (D, J), liquiritigenin (E, 
K) and SM6Met (F, L) in a dose dependant manner for 24hrs. Subsequent to the 24hr induction with the test panel, the 
cells were lysed using passive lysis buffer. Luciferase activity was measured and normalised to protein content which 
was determined using a Bradford assay. One-way ANOVA with Tukey’s multiple comparisons test as post-test, 
showing statistical difference to the solvent control ( , P<0.05;  , P<0.01,   , P<0.001) was performed for statistical 
analysis. The average ±SEM is of two to three independent biological experiments done in triplicate. 




























































































































































































































































































































































































Figure S3: Evaluation of subtype selective antagonism of the test panel by ERE-containing promoter reporter 
activity induced in ERα and ERβ transfected HEK 293 cells by the different compounds and extract. HEK 293 
cells were transiently transfected with either pSG5-hERα (A-E) or pSG5-hERβ (F-J) together with an ERE-containing 
promoter reporter constructs (ng) and left for 24hrs. After transfection, the cells were re-plated into sterile 24 well plates 
and treated 24hrs later with 4-OH-Tam (A, F), fulvestrant (B, G), MPP (C, H), liquiritigenin (D, I) and SM6Met (E, J), all 
in the presence of 10-11M E2, in a dose dependant manner for 24hrs. Subsequent to the 24hr induction with the test 
panel, the cells were lysed using passive lysis buffer. Luciferase activity was measured and normalised to protein 
content which was determined using a Bradford assay. One-way ANOVA with Tukey’s multiple comparisons test as 
post-test, showing statistical difference to 10-11M E2 (*, P<0.05; * *, P<0.01, * * *, P<0.001) was performed for statistical 
analysis. The average ±SEM is of two to three independent biological experiments done in triplicate. 
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Figure S4: Evaluation of subtype selective agonism of the test panel by ERE-containing promoter reporter 
activity induced in ERα and ERβ transfected COS-1 cells by the different compounds and extract. COS-1 cells 
were transiently transfected with 150ng of pSG5-hERα (A-F) and pSG5-hERβ (G-L) together with an ERE-containing 
promoter reporter constructs (ng) and left for 24hrs. After transfection, the cells were re-plated into sterile 24 well plates 
and treated 24hrs later with E2 (A, G), 4-OH-Tam (B, H), fulvestrant (C, I), MPP (D, J), liquiritigenin (E, K) and SM6Met 
(F, L) in a dose dependant manner for 24hrs. Subsequent to the 24hr induction with the test panel, the cells were lysed 
using passive lysis buffer. Luciferase activity was measured and normalised to protein content which was determined 
using a Bradford assay. One-way ANOVA with Tukey’s multiple comparisons test as post-test, showing statistical 
difference to solvent control ( , P<0.05;  , P<0.01,   , P<0.001) was performed for statistical analysis. The average 
±SEM is of two to three independent biological experiments done in triplicate. 
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Figure S5: Evaluation of subtype selective antagonism of the test panel by ERE-containing promoter reporter 
activity induced in ERα and ERβ transfected COS-1 cells by the different compounds and extract. COS-1 cells 
were transiently transfected with either pSG5-hERα (A-E) or pSG5-hERβ (F-J) together with an ERE-containing 
promoter reporter constructs (ng) and left for 24hrs. After transfection, the cells were re-plated into sterile 24 well plates 
and treated 24hrs later with 4-OH-Tam (A, F), fulvestrant (B, G), MPP (C, H), liquiritigenin (D, I) and SM6Met (E, J), all 
in the presence of 10-11M E2, in a dose dependant manner for 24hrs. Subsequent to the 24hr induction with the test 
panel, the cells were lysed using passive lysis buffer. Luciferase activity was measured and normalised to protein 
content which was determined using a Bradford assay. One-way ANOVA with Tukey’s multiple comparisons test as 
post-test, showing statistical difference to 10-11M E2 (*, P<0.05; * *, P<0.01, * * *, P<0.001) was performed for statistical 
analysis. The average ±SEM is of two to three independent biological experiments done in triplicate. 
 



























































































Figure S6: Comparison between the efficacies of the ERα antagonists in the HEK293 and COS-1 cells. HEK293 
and COS-1 cells were plated into sterile 10cm2 tissue culture dishes at a density of 2 x 106 cells/dish and transiently 
transfected with pSG5-hERα together with an ERE-containing promoter reporter construct, 24hrs after plating. 
Antagonism was tested by treating the cells with 4-OH-Tam, fulvestrant, MPP, liquiritigenin and SM6Met in a dose 
dependant manner (Figureb & f) in the presence of 10-11M E2. Subsequent to the 24hr induction with the test panel, 
the cells were lysed using passive lysis buffer. Luciferase activity was measured and normalised to protein content 
which was determined using a Bradford assay. Efficacies are expressed as fold values, where the antagonist were 
normalised to solvent control (E2 =1). Statistical analysis was performed using One-way ANOVA with Tukey’s multiple 
comparisons test as post-test, where different letters indicate statistical significance (P<0.05). The average ± SEM is 
of two independent biological experiments done in triplicate.


















































































































































Figure S7: Comparison between the efficacies of the ERβ agonists and antagonists in the HEK293 and COS-1 
cells. HEK293 and COS-1 cells were plated into sterile 10cm2 tissue culture dishes at a density of 2 x 106 cells/dish 
and transiently transfected with pSG5-hERβ together with an ERE-containing promoter reporter construct, 24hrs after 
plating. To test agonism (a & b) the cells were treated for with E2, 4-OH-Tam, fulvestrant, MPP, liquiritigenin and 
SM6Met in a dose dependant manner (Figurea & e) 24hrs after transfection, whereas antagonism (c & d) was tested 
by treating the cells with 4-OH-Tam, fulvestrant, MPP, liquiritigenin and SM6Met in a dose dependant manner (Figureb 
& f) in the presence of 10-11M E2 (set as 1 for antagonism). Subsequent to the 24hr induction with the test panel, the 
cells were lysed using passive lysis buffer. Luciferase activity was measured and normalised to protein content which 
was determined using a Bradford assay. Statistical analysis was performed using One-way ANOVA with Tukey’s 
multiple comparisons test as post-test, where different letters indicate statistical significance (P<0.05). The average ± 
SEM is of two independent biological experiments done in triplicate.



























































































































































































































Figure S8: Evaluation of the effects of the test panel on breast cancer cell proliferation in the absence (alone) 
and presence (+ 10-11M E2) of E2, by means of dose response curves. MCF-7BUS cells were treated with a 4-OH-
Tam (B), fulvestrant (C), MPP (D), liquiritigenin (E) and SM6Met (F) in the absence and in the presence of 10-11M E2 
(A), in a dose dependent manner for a period of seven days, wherein there were two retreatments on day 3 and 6. 
Thereafter, MTT solution was added to the cells in order to determine the amount of formazan formed, which indicates 
the number of viable cells, through metabolism and dissolved in isopropanol. One-way ANOVA with Tukey’s multiple 
comparisons test as post-test, showing statistical difference to solvent control (, P<0.05;  , P<0.01,   , P<0.001) 
and E2 (*, P<0.05; * *, P<0.01, * * *, P<0.001)  was used for statistical analysis. The average ±SEM is of three 
independent biological experiments done in triplicate. The compounds and extract tested in the presence of E2 was 
normalized to E2, while the compounds and extract tested in the absence of E2 was normalised to solvent and both are 









The synergistic combination of SM6Met with 4-OH-Tam (20:1) 
displays the highest anti-metastatic potential 
4.1 Introduction 
Breast cancer is a worldwide problem, accounting for 13,7% of cancer deaths and 22,9% of all cancer  
cases (1), with metastasis to distant organs the main reason for most of these deaths (2). Disrupting 
metastatic progression is for that reason crucial in reducing breast cancer deaths. It has been argued that 
all cancers share six distinct hallmarks (Fig. 4.1) that not only direct the transformation of a normal cell into 
a cancer cell, but also assist in cancer progression and metastasis. These six hallmarks of cancer cells 
include 1) self-sufficient proliferative signalling (sustaining proliferative signalling); 2) insensitivity to anti-
growth signals (evading growth suppressors); 3) ability to evade programed cell death (resisting cell death); 
4) infinite replication (enabling replicative immortality); 5) stimulation of blood vessel growth for increased 
nutrient delivery (inducing angiogenesis) and 6) ability to invade local tissue and disperse to distant tissues 
(activating invasion and metastasis) (3, 4). 
 
Figure 4.1: The six hallmarks of cancer. Figure taken from Hanahan and Weinberg (4) 
 
It has been argued that the capability of a tumour cell to maintain continuous proliferation is the most 
fundamental characteristic of tumour cells. Tumour cells sustain continuous proliferation by deregulating 
the carefully controlled process of cell growth through interfering with the signals involved in regulatory  
entry into and progression through the cell cycle (3). The cell cycle (Fig. 4.2), of mammalian cells, consists 
of the G0/G1 phase, the S phase and the G2/M phase (5, 6). Each phase depends on the accurate 
completion of the phase before it. The cell cycle starts with the G1 phase where the mother cell is checked 
for DNA damage, which can lead to one out of three possible outcomes. The cell can temporarily enter into 
the G0 phase (quiescent), the cell can permanently enter into the G0 phase (senescent) or the cell can 
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continue to synthesize mRNA and proteins in preparation for continuing into the S phase. In the S phase, 
DNA is replicated and since accurate replication is essential for the survival of the cell, the G1/S transition 
is an important regulatory checkpoint in the cell cycle. After completion of the S phase the cell enters into 
the G2 phase, which directly precedes mitosis. In this phase the G2 checkpoint arrests cells with DNA 
damage and prepares non-damaged cells for mitosis through rapid growth and protein synthesis. Finally 
the cell enters the M phase (mitosis), where the cell stops growing and undergoes division to generate two 
identical daughter cells. External and/or intracellular stimuli may lead to a pause in cell cycle progression, 
often referred to as checkpoints. These checkpoints control cell cycle progression and allow the cell time 
to repair damaged DNA or to acquire sufficient levels of growth factors required for transition to the next 
phase. In the event that the DNA damage is too severe at any checkpoint and cannot be repaired, the cell 










Figure 4.2: Cell cycle phases and regulation by checkpoints. Cell cycle checkpoints regulate the cell cycle and act 
as barriers to prevent carcinogenesis through maintaining genomic stability. To maintain continuous proliferation 
tumour cells may deregulate the cell cycle check points (designated by yellow arrows) including: the restriction point 
(G0), the G1 checkpoint, the intra-S checkpoint, the G2 checkpoint and the mitosis-associated spindle assembly 
checkpoint.  Figure adapted from Bower et al. (7).  
 
Once the tumour cell has achieved continuous proliferation, it will produce daughter cells with the same 
ability to sustain high proliferation. As these daughter cells rapidly proliferate and divide, they acquire more 
hallmark capabilities that allow these cells to invade and metastasize to other organs (8). Metastasis to 
distant organs is the leading cause of death amongst breast cancer patients, accounting for about 90% of 
breast cancer fatalities (9–11). Metastasis is a complex multistep process involving the detachment from 
the primary tumour, invasion of the basement membrane and entry into the vascular system, survival in 
circulation, migration to a secondary site and formation of a new colony of tumour cells (secondary tumour) 











G0 (Restriction Point) 
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Previously (chapter 3) I showed that SM6Met weakly antagonises breast cancer cell proliferation in 
comparison to SOC therapies like tamoxifen. However, I also showed that the effects of SM6Met on breast 
cancer cell proliferation could be replicated by combining MPP (ERα antagonist) with liquiritigenin (ERβ 
agonist) and that SM6Met in combination with 4-OH-Tam synergistically reduced breast cancer cell 
proliferation. As proliferation is dependent on the cell cycle, I wanted to evaluate the effects of SM6Met on 
the cell cycle phase distribution of human MCF7-BUS breast cancer cells, in comparison to the rest of the 
test compounds as well as the previously studied MPP and liquiritigenin combination and SM6Met and 4-
OH-Tam combination. In addition, I investigated the effects of the test compounds as well as the two drug 
combinations (MPP with liquiritigenin and SM6Met with 4-OH-Tam) on the migration, invasion and colony 
formation (anchorage independent growth) capabilities of the MCF-7BUS cell line, thereby evaluating the 
effects of the test panel and two drug combinations on the metastatic potential of MCF-7BUS cells. 
4.2 Material and Methods 
4.2.1 Test compounds used  
17β-Estradiol (E2), a proven agonist of both ER subtypes (13–16); (2)-4-hydroxytamoxifen (the active 
metabolite of tamoxifen, which will be referred to as 4-OH-Tam in this study), a proven antagonist of both 
ER subtypes in breast tissue (17–19) and fulvestrant (Ful), a pure antagonist of both ER subtypes in all 
estrogen target tissues (20–22) were all obtained from Sigma-Aldrich®, South Africa (Sigma). Methyl-
piperidino-pyrazole (MPP), a proven ERα selective antagonist (23, 24) and liquiritigenin (Liq), a proven 
ERβ selective agonist (25) are products of Tocris bioscience, which were obtained from Whitehead 
Scientific Pty (Ltd), South Africa. The C. subternata extract, SM6Met, was previously prepared by a former 
laboratory member, J.A.K. Visser (16, 26). E2, 4-OH-Tam, fulvestrant, MPP and Liq stock solutions were 
prepared in absolute ethanol (EtOH), while SM6Met, stock solutions were prepared in dimethylsulfoxide 
(DMSO), which was diluted with absolute ethanol to a final concentration of 25%. 
4.2.2 Cell culture 
The MCF-7BUS human breast cancer cell line (27) (a generous gift from A. Soto, Tufts University, Boston, 
Massachusetts, United States of America) was maintained in 175cm2 filter cap culture flasks (SPL Life 
Sciences) containing, high glucose (4.5g/L) Dulbecco’s modified eagle’s medium (DMEM) from Sigma, 
supplemented with heat inactivated 5% (v/v) fetal calf serum (FCS) from Merck, South Africa, 100IU/ml 
penicillin and 100μl/ml streptomycin (1% Penstrep), 44mM sodium-bicarbonate and 1mM sodium-pyruvate 
(Sigma). The cells were maintained at 37°C, 97% relative humidity and 5% CO2 in a humidified cell 
incubator. 
4.2.3 Cell cycle analysis 
The human MCF-7BUS breast cancer cells were plated into sterile 10cm2 tissue culture dishes (Nest 
Biotechnology Co., Ltd.) at a density of 1 x 106 cells/dish and allowed to settle for 24hrs. After settling, the 
cells were serum starved for four hours by washing the cells once with 10ml sterile, pre-warmed PBS per 
plate and replacing the medium with unsupplemented DMEM without phenol red (Sigma). Thereafter, the 
medium was changed to the treatment medium consisting of DMEM without phenol red supplemented with 
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5% fetal calf serum (Merck), double stripped with dextran coated charcoal and heat inactivated (DS-HI-
FCS), and 1% Penstrep and treated with 10-11M E2, 10-9M 4-OH-Tam, 10-9M fulvestrant, 10-6M MPP, 10-
9M liquiritigenin and 0.098µg/ml SM6Met for 48 hours, respectively. After the treatment period the nuclei 
were isolated and stained using propidium iodide (PI) according to the instructions of the manufacturer of 
the CycleTEST™ PLUS DNA reagent kit (Bectib Dickinson, South Africa). A 448nm solid state sapphire 
laser was used to excite the PI stained nuclei and emittance was measured in the PE Texas Red channel 
on a linear scale using a 616/23 bandpass filter. Histograms were generated of the fluorescent light emitted 
from the nuclei between 580 and 650nm using the BD FACS Aria Cell sorter from Becton Dickinson 
manufactured in San Jose, California, USA, and the FACS Diva 6.1.3. software. ModFit LTTM 3.0 software 
(Verity Software House, Topsham, Maine, USA) was used to analyse the fluorescence histograms to 
determine cell cycle phase distribution. Final results were presented as fold relative to the average results 
of the three negative solvent controls including (1) treatment medium, (2) 0.1% (v/v) EtOH in treatment 
medium and (3) 0.025% (v/v) DMSO in treatment medium. 
4.2.4 Scratch-wound healing assay (migration) 
MCF-7BUS cells were seeded into 12 well tissue culture plates (Lasec SA [Pty] Ltd) at a density of 1 x 106 
cells/well and left to incubate until 100% confluency was reached (24-48 hours in general). Once the cells 
had reached 100% confluency, the medium was changed to phenol red free DMEM supplemented with 5% 
DS-HI-FCS and 1% Penstrep. Mytomycin C (5µg/ml) was added to each well to inhibit cell proliferation and 
incubated for two hours. After the incubation, the mixture was aspirated and a “scratch” was made by 
scraping a vertical wound through the cell monolayer using a sterile 200µl pipette tip after which the cells 
were washed twice with 400µl sterile, pre-warmed PBS per well to remove any debris. Phenol red free 
DMEM supplemented with 5% DS-HI-FCS and 1% Penstrep containing the test panel (concentrations 
indicated in figure legends) was carefully added to each well to avoid detachment of additional cells. The 
images representing time point zero (T0) were immediately taken using the Olympus IX81 widefield inverted 
microscope at the Central Analytical Facility of Stellenbosch University, and thereafter, images where taken 
at intervals of 24hrs up to time point 72hrs (T72). The images were analysed by measuring the distance 
between the edges of the wound using ImageJ software (Version 1.49). The distance migrated (moved) 
was calculated by taking the distance migrated at T72 and subtracting it from the distance of the initial 








Figure 4.3: Diagram depicting the principle behind the determination of the distance that the cells migrated in 
the scratch-wound healing assay. 
T0 T72 
Initial scratch (time point zero) 
(T0) 
Scratch after 72 hours of induction 
(T72) 
 
Distance migrated over 72 hours 
(T0 – T72) 
 
Stellenbosch University  https://scholar.sun.ac.za
105 
 
4.2.5. Cell invasion assay  
The MCF-7BUS cells were seeded (1x106 cells/dish) into 10cm tissue culture dishes and after 24hrs the 
cells in each plate was washed with 10ml sterile, pre-warmed PBS before the medium was changed to 
phenol red free DMEM supplemented with 5% DS-HI-FCS and 1% Penstrep and allowed 24hrs to settle. 
The CytoSelect™ 96-well invasion assay kit (Basement membrane, fluorometric format) from Cell Biolabs, 
Inc., BIOCOM biotech, South Africa was used to determine the number of invasive cells as described by 
the manufacturer (Fig. 4.4). In short, the invasion plate consisting of a plate cover (top), membrane chamber 
insert plate (middle) and feeder tray (bottom), was allowed to warm up to room temperature for 10 minutes 
after which the basement membrane layers of the membrane chamber insert plate were rehydrated by 
incubation for 1hr with 100µl of unsupplemented phenol free DMEM in each inner compartment of the 96 
well membrane chamber plate. During rehydration the cell suspensions were prepared in treatment 
medium consisting of unsupplemented phenol free DMEM containing the test compounds or extract 
(concentrations indicated in figure legends). After rehydration, the medium was removed without disturbing 
the basement layer and the already prepared cell suspensions were seeded at a density of 5x105 
cells/chamber into the 96 well membrane chamber plate. The membrane chamber plate was then placed 
into the feeder tray containing the chemoattractant (DMEM supplemented with 10% DCS-FCS) and left for 
24hrs to incubate at 37ºC. After incubation, the membrane chamber plate was removed from the feeder 
tray containing the chemoattractant and placed into another feeder tray known as the harvesting tray 
containing the Cell Detachment Solution were the cells that invaded through the membrane were dislodged 
from the bottom of the membrane. The cells were then lysed and stained with 4x Lysis Buffer/ CyQuant® 
GR dye (Invitrogen) for 20 minutes at room temperature after which the invasive cells were quantified by 
measuring fluorescence with a Thermo Scientific™ Varioskan plate reader at 480nm/ 520nm. Final results 
are presented as fold relative to the average results from the three negative solvent controls including (1) 














Figure 4.4: Schematic overview of the CytoSelect™ 96-well invasion assay principle 
Cell suspension added into 
membrane chambers (5x105 
cells/chamber) and placed 
on feeder tray  
Invasive cells pass through 
basement membrane and 
cling to bottom of 
membrane chamber insert, 
while non-invasive cells stay 
in upper chamber 
Membrane camber insert 
placed in harvesting tray 
containing cell detachment 
buffer which is used to 
dissociate invasive cells 
from membrane 
Invasive cells are lysed and 
quantified using CYQuant® 
GR Flourescent Dye 
/ 
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4.2.6 Soft agar colony formation 
Soft agar assays were conducted as previously described by Perkins et al. (28). In short, MCF-7BUS cells 
were mixed with phenol red free DMEM supplemented with 5% DS-HI-FCS, 1% Penstrep and 0,6% 
agarose (Sigma) and plated into a 24 well plate at a density of 1.5 x 104 cells/well on top of a solidified layer 
of phenol red free DMEM supplemented with 5% DS-HI-FCS, 1% Penstrep and 1% agarose. The top cell 
containing layer was allowed an hour to set at room temperature after which 1ml of treatment medium 
consisting of phenol red free DMEM supplemented with 5% DS-HI-FCS and 1% Penstrep, containing the 
test compounds or extract (concentrations indicated in figure legends) was added to the wells (Fig. 4.5). 
Cells were re-induced and fed weekly for 4 weeks by carefully removing and adding new treatment medium 
containing the test compounds or extract, without disturbing the cell containing layer. On day 28, the cells 
were stained overnight with 0.005% crystal violet made up in 10% EtOH (diluted with distilled water, dH2O). 
Plates were placed on an illuminated background and photographs were taken, which were analysed using 
ImageJ software (Version 1.49) to determine the number of colonies formed. Final results are presented 
as fold relative to the average results from the three negative solvent controls including (1) treatment 








Figure 4.5: Schematic overview of the plating procedure for the soft agar colony formation assay  
4.2.7 Statistical analysis of data 
GraphPad Prism® version 5.03 for Windows was used for graphical presentation and statistical analysis. 
One-way ANOVA with Tukey’s multiple comparisons test as post-test was used as statistical analysis 
method (as described in all figure legends). Statistical significance between groups are indicated with 
different letters and was calculated as a p-value with levels of significance indicated for each experiment. 
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4.3.1 Evaluation of the effects of the test compounds and extract on breast cancer cell cycle 
distribution, in the presence of E2 
The cell cycle is a multifaceted process consisting of four distinct phases i.e. G1 phase, S phase, G2 phase 
and M phase. The accurate progression and completion of each phase is responsible for the activation of 
every following phase. The cells can also exit the cell cycle and enter a state of temporary quiescence also 
known as the G0 phase. The progress of the cell cycle is regulated through checkpoints, which involve a 
network of regulatory proteins (29). As excessive estrogen signalling is associated with the acquired cancer 
promoting characteristics described by Hanahan and Weinberg (4), I were interested in investigating the 
effects of SM6Met in the presence of E2 on the cell cycle phase distribution. 
4.3.1.1 SM6Met induced apoptosis and the accumulation of MCF-7BUS cells in the S phase of the cell 
cycle. 
The effects of the test panel, in the presence of 10-11M E2, on the distribution of MCF7-BUS breast cancer 
cells in each phase of the cell cycle as well as the number of apoptotic cells was determined. 
The EC50 concentration of E2 as determined from the proliferation studies (Fig. 3.4, Ch. 3) was used for the 
cell cycle assay, however E2 showed no significant effect on the cell cycle in comparison to the solvent 
treated cells (represented by the dashed line, Fig. 4.6B), thereby suggesting, that the EC50 concentration 
of a compound determined by one test system is not always the optimum testing concentration for another 
test system, as some test systems may be more sensitive. Because E2 alone at 10-11M E2 had no significant 
effect on cell cycle distribution it is difficult to establish whether the effects of the test compounds or extract 
on the distribution of cells through the cell cycle is a result of the test compounds or extracts on their own 
or if E2 contributed to the effects observed (Fig. 4.6, Fig. 4.7 and Fig. 4.8). However, due to time and 
financial limitations I were not able to redo the cell cycle assay at higher concentrations of E2. 
Nonetheless, with regard to the SOC therapies, relative to solvent 4-OH-Tam showed a slight decrease of 
cells in the G2/M phase (Fig. 4.6E) with a slight increase of cells in the S phase (Fig. 4.6D) and an 11-fold, 
although not significant, increase in apoptotic cells (Fig. 4.6F), whereas treatment with fulvestrant 
significantly (P<0.05) increased the number of cells in the G0/G1 phase (Fig. 4.6C), while significantly 
(p<0.05) decreasing cells in the S phase and G2/M phase (Fig. 4.6D & E) relative to solvent and/or E2. 
Interestingly, fulvestrant, like E2, did not cause any cells to go into apoptosis (Fig. 4.6F). 
With regard to the two commercially available ER selective ligands, MPP (ERα antagonist) and liquiritigenin 
(ERβ agonist), significantly (P<0.05) decreased the number of cells in the G0/G1 phase (Fig. 4.6C) and 
significantly (P<0.01) increased the number of cells in the S phase (Fig. 4.6D) relative to solvent treated 
cells. Although MPP and liquiritigenin, increased the number of cells in the apoptotic phase, this was not 
significant for MPP (Fig. 4.6F). 
SM6Met significantly (P<0.001) decreased the number of cells in the G0/G1 phase (Fig. 4.6C), while 
significantly (P<0.01) increasing the number of cells in the S phase (Fig. 4.6D) and apoptotic phase (Fig. 
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4.6F), relative to solvent treated cells. Relative to the other compounds, SM6Met showed the greatest 
reduction of cells in the G0/G1 phase and the highest accumulation of cells in the S phase. 
4.3.1.2 The effects of SM6Met on the cell cycle phases was replicated by combining an ERα selective 
antagonist (MPP) with an ERβ selective agonist (liquiritigenin) 
In the previous chapter, I showed that SM6Met acts as an ERα antagonist and ERβ agonist and not only 
could I recreate the effects of SM6Met on E2 induced breast cancer cell proliferation by combining an ERα 
selective antagonist (MPP) with an ERβ selective agonist (liquiritigenin) (Ch. 3; Fig. 3.2 & 3.3 ), but this 
combination also proved to be better at inhibiting E2 induced breast cancer cell proliferation than the ER 
subtype selective ligands, MPP and liquiritigenin, alone and the SOC therapies, 4-OH-Tam and fulvestrant. 
Therefore, I wanted to investigate the combinatorial effects of an ERα selective antagonist (MPP) with an 
ERβ selective agonist (liquiritigenin) on cell cycle distribution, in the presence of E2, to determine whether 
the same trend could be seen for cell cycle distribution. 
Combining the IC50 concentration of MPP with the IC50 concentration of liquiritigenin in a 1:1 ratio resulted 
in the redistribution of the cells to a cell cycle distribution profile that was not significantly different from that 
obtained with SM6Met (Fig. 4.7), specifically the 1:1 ratio, like SM6Met alone, decreased the number of 
cells in the G0/G1 phase (Fig.4.7A), while significantly (P<0.01) increasing the number of cells in the S 
phase (Fig.4.7B) and apoptotic phase (Fig. 4.7D), relative to solvent treated cells. 
4.3.1.3 The addition of SM6Met to 4-OH-Tam not only increased the accumulation of cells in the S-phase, 
but also the number of cells in the apoptotic phase 
In Chapter 3, I showed that combining SM6Met with 4-OH-Tam not only resulted in a greater reduction of 
E2 induced breast cancer cell proliferation (Ch. 3; Fig. 3.7), but also that SM6Met synergistically enhanced 
the potency of 4-OH-Tam to reduce breast cancer cell proliferation (Ch. 3; Fig. 3.9 and Fig. 3.10). 
Therefore, I wanted to evaluate the effect of combining SM6Met with 4-OH-Tam, in ratios (10:1 and 20:1) 
obtained from Chapter 3, on cell cycle distribution, in the presence of E2.  
The addition of SM6Met to 4-OH-Tam, in the presence of 10-11M E2, resulted in a dose dependant increase 
(1.6 fold for the 10:1 ratio and 2.4 fold for the 20:1 ratio) in the number of cells in the S phase and a dose 
dependant, although not significant, decrease in the number of cells in the G2/M phase (Fig. 4.8B & C). 
Furthermore, the addition of SM6Met to 4-OH-Tam showed a significant (P<0.001) increase (6.9 fold for 
10:1 ratio and 7.1 fold for 20:1) in the number of cells in the apoptotic phase in relation to cells treated only 
with 4-OH-Tam (Fig. 4.8D). 































































































































































































































































































































































































Figure 4.6: Cell cycle analysis of MCF-7BUS cells show that treatment with SM6Met in the presence of 10-11M 
E2 induces the accumulation of cells in the S phase. (A), represents the histogram generated by the FACS Diva 
6.1.3 software used to analyse the treated cells with solvent. (B), represents the effects of 10-11M E2 on cell cycle 
distribution, presented as fold relative solvent. The effects of the IC50 concentrations (as determined from Fig. 3.4 in 
Ch. 3) of 4-OH-Tam, fulvestrant, MPP, liquiritigenin and SM6Met, in the presence of 10-11M E2 after treatment for 48hrs, 
on cells in the G0/G1 phase (C), S phase (D), G2/M phase (E) and apoptotic phase (F) is presented as fold relative to 
solvent. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparisons test as post-test, 
where different letters indicate statistical significance (P<0.05). The dotted line through the bars represents the fold 
induction of the solvent group, which was set to one. Average ± SEM is of two independent biological experiments 
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4.3.2 Evaluation of the effects of the test panel on breast cancer metastatic potential 
Metastasis is of great importance to cancer research as metastasis is the leading cause of mortality 
associated all types of cancer (estimated cause of about 90% of all cancer deaths) (30, 31). The process 
of tumour metastasis, collectively known as the metastatic cascade, involves a chain of events including 
detachment of cells from the primary tumour, invasion into local tissue, intravasation (migration into the 
blood stream), survival in circulation, extravasation (exit of tumour cells from circulation) and colonization 


















































































































































































































































































































































Figure 4.7: Cell cycle analysis of MCF-7BUS cells show that the effect of SM6Met on cell cycle phase 
distribution can be replicated by combining an ERα selective antagonist with an ERβ selective agonist, in the 
presence of 10-11M E2. The effects of the IC50 concentrations (as determined from Fig. 3.4 in Ch. 3) of SM6Met, MPP, 
liquiritigenin and a 1:1 combination of the IC50 concentrations of MPP and liquiritigenin after 48hr treatment on cells in 
the G0/G1 phase (A), S phase (B), G2/M phase (C) and apoptotic phase (D) is presented as fold relative to solvent.. 
Statistical analysis was performed using One-way ANOVA with Tukey’s multiple comparisons test as post-test, where 
different letters indicate statistical significance (P<0.05). The dotted line through the bars represents the fold induction 
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Figure 4.8: Cell cycle analysis of MCF-7BUS cells shows increased accumulation of cells in the S phase and 
apoptotic phase in response to increasing amounts of SM6Met in the presence of 4-OH-Tam. The effects of the 
IC50 concentrations (as determined from Fig. 3.4 in Ch. 3) of 4-OH-Tam and combinations of SM6Met and 4-OH-Tam 
in ratios of 10:1 and 20:1 (10 times and 20 times the IC50 concentration of SM6Met), in the presence of 10-11M E2 after 
48hr treatment, on cells in the G0/G1 phase (A), S phase (B), G2/M phase (C) and apoptotic phase (D) is presented by 
fold relative to solvent. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparisons 
test as post-test, where different letters indicate statistical significance (P<0.05). The dotted line through the bars 
represents the solvent control, which was set to one. Average ± SEM is of two independent biological experiments 
done in triplicate. 
 
These processes like migration, invasion and colony formation could possibly provide new, more selective 
targets for cancer treatment. Some cancer types have the tendency to metastasise to certain organs, for 
example breast cancer has a tendency to metastasise to bone (32), lung (33), liver (34) and brain tissue 
(35). The tendency of certain tumours to metastasise to specific organs was first described by Stephen 
Paget in 1889 and according to his “seed and soil” theory, cancer cells metastasise to locations with similar 
microenvironments and characteristics as the tissue they originate from (36–38). 
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4.3.2.1 Evaluation of the effects of the test panel on breast cancer cell migration 
Metastasis can only occur if a cell has the ability to move actively or passively from one location to another. 
This ability is defined as migration, a process that is dependent on numerous cell activities like the 
organization of cytoskeletal constituents, extracellular proteolysis and interference with or establishment of 
the cell matrix and/or cell-cell adhesion (39). The aforementioned cell activities associated with migration, 
could provide new targets for the development of anti-metastatic therapeutic agents (39). As motility is a 
prerequisite for invasion and metastasis, I used the in vitro scratch assay to evaluate the effects of the test 
panel on E2 induced breast cancer cell motility.  
 
4.3.2.1.1 Estradiol reduced breast cancer cell migration, while SM6Met and fulvestrant increased 
migration to a lesser extent than MPP, the known ERα selective antagonist 
The effects of the test panel on migration was evaluated, which involved an incubation period with 
Mytomycin C to block mitosis (proliferation), thereby, allowing us to differentiate between migration and 
proliferation to subsequently minimize false results (40, 41). In section 4.3.1, the EC50 concentration of E2 
(10-11M, also representative of post-menopausal E2 levels (42)), was determined from the dose response 
studies on breast cancer cell proliferation (Fig. 3.4; Ch. 3), but did not have a significant effect on breast 
cancer cell cycle distribution (Fig. 4.6), thereby suggesting that not all in vitro assays are equally sensitive. 
Therefore, I evaluated breast cancer cell migration not only in the presence of 10-11M E2, but also at 10-9M 
E2, another physiologically relevant concentration as it reflects the pre-menopausal levels of E2 in the 
human body (42).  
Although 10-11M E2 decreased the migration of the human MCF-7BUS cells slightly, it did not reach a level 
of significance, while induction with 10-9M E2 significantly (P<0.01) decreased the migration of these cells 
(Fig. 4.9). In addition, none of the test compounds or the extract, in the presence of 10-11M E2, had a 
significant effect on breast cancer cell migration (Fig. 4.9B). However, in the presence of 10-9M E2, all the 
test compounds and the extract counteracted the effects of 10-9M E2, by significantly increasing cell motility 
in comparison to cells treated with 10-9M E2.  
Specifically, the two SOC therapies, 4-OH-Tam and fulvestrant induced similar levels of migration, in the 
presence of 10-9M E2. Interestingly, although liquiritigenin (ERβ selective agonist) displayed slightly higher 
induction of breast cancer cell migration in relation to 4-OH-Tam and fulvestrant, the difference was not 
statistically significant. MPP, the ERα selective antagonist, displayed the highest induction of breast cancer 
cell migration, whereas SM6Met displayed the lowest induction of breast cancer cell migration among the 
compounds tested. Collectively, the results illustrate that all the test compounds as well as the extract, 
SM6Met, counteracted (to varying degrees) the protective effects of E2 on the migration of the human MCF-































































































































































































































Figure 4.9: Estradiol reduced breast cancer cell migration, while SM6Met and fulvestrant increased migration 
to a lesser extent than the ERα selective antagonist, MPP. Immediately after induction with the test  panel (4-OH-
Tam, fulvestrant, MPP, liquiritigenin and SM6Met, all in the presence of either 10-11M or 10-9M E2) an image was 
captured using an Olympus IX81 widefield microscope at 10x magnification and will be referred to as time point zero 
(T0). (A), represents the wound at 24hr intervals, starting at time point zero and ending at 72hrs. The distance migrated 
was calculated using the formula T72-T0/T0 for each compound or extract and normalised to solvent (B and C). Statistical 
analysis was performed using One-way ANOVA with Tukey’s multiple comparisons test as post-test, where different 
letters indicate statistical significance (P<0.05). The dotted line through the bars represents the solvent, which was set 
to one. Average ± SEM is of two independent biological experiments done in triplicate. 
 
4.3.2.1.2 The increased migratory effect of MPP (ERα selective antagonist) was reduced to the 
same level as the solvent control when combined with liquiritigenin (ERβ selective agonist) 
Liquiritigenin was combined with MPP to mimic the ER subtype characteristics of SM6Met and to evaluate 
whether this combination would deliver the same effects as SM6Met on breast cancer cell migration. For 
this reason, the IC50 concentrations (as determined from proliferation studies, Fig. 3.4 of Ch. 3) of 
liquiritigenin (ERβ selective agonist) and MPP (ERα selective antagonist) were used in combination ratios 
of 1:1, 10:1, 100:1 and 1000:1. Increasing the concentration of liquiritigenin in the combination resulted in 
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the reduction of the high migratory effect of MPP, in a dose dependant manner, to the same level as the 












































































































Figure 4.10: Combining increasing concentrations of liquiritigenin with MPP reduced the migratory effect of 
MPP on human MCF-7BUS breast cancer cells to the same level as the solvent control. Immediately after 
induction with the test  panel (SM6Met, MPP, liquiritigenin and MPP in combination with increasing concentrations of 
liquiritigenin, all in the presence of 10-9M E2) an image was captured using an Olympus IX81 widefield microscope at 
10x magnification and will be referred to as time point zero (T0). (A), represents the wound at 24hr intervals, starting at 
time point zero and ending at 72hrs. The distance migrated was calculated using the formula T72-T0/T0 for each 
compound or extract and normalised to solvent (B). Statistical analysis was performed using One-way ANOVA with 
Tukey’s multiple comparisons test as post-test, where different letters indicate statistical significance (P<0.05). The 
dotted line through the bars represents the solvent, which was set to one. Average ± SEM is of two independent 
biological experiments done in triplicate. 
 
The results suggest that a lower concentration of the ERα antagonist and a higher concentration of the 
ERβ agonist could be more advantageous for the reduction of breast cancer cell migration. In summary, I 
showed that the effects of SM6Met on cell migration could be replicated by the addition of an ERβ agonist 
(liquiritigenin) to an ERα antagonist (MPP) (Fig. 4.10B) and that increasing concentrations of the ERβ 
agonist in the combination could potentially reduce breast cancer cell migration even further. 
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4.3.2.1.3 Combining SM6Met with tamoxifen in a ratio of 20:1 completely reversed the migratory 
potential, leading to an overall reduction in migration  
In support of the role ERβ plays in the regulation and inhibition of breast cancer cell migration (43, 44), 
increasing the concentration of SM6Met (increasing ERβ activity) in combination with 4-OH-Tam resulted 
in dose dependant significant breast cancer cell migration inhibition (Fig. 4.11). At a ratio of 20:1 this 





































































































Figure 4.11: Increasing the concentration of SM6Met in the ratio to which it is combined with 4-OH-Tam 
reduced breast cancer cell migration up to the same extent as E2. Immediately after induction with the test  panel 
(SM6Met, 4-OH-Tam, SM6Met and 4-OH-Tam in combination with increasing concentrations of SM6Met, all in the 
presence of 10-9M E2) an image was captured using an Olympus IX81 widefield microscope at 10x magnification and 
will be referred to as time point zero (T0). (A), represents the wound at 24hr intervals, starting at time point zero and 
ending at 72hrs. The distance migrated was calculated using the formula T72-T0/T0 for each compound or extract and 
normalised to solvent (B). Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparisons 
test as post-test, where different letters indicate statistical significance (P<0.05). The dotted line through the bars 
represents the solvent, which was set to one. Average ± SEM is of two independent biological experiments done in 
triplicate. 
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4.3.2.2 Evaluation of the effects of the test panel on breast cancer cell invasion 
Cell invasion is closely related to cell migration and is defined as the ability to penetrate neighbouring 
tissues via the lymphatic and blood vessels by navigating through the extracellular matrix (ECM) to enter 
into the circulation and invade tissue elsewhere in the body to form secondary tumours (4, 45). As cell 
penetration through the basal membrane is a prerequisite for cell invasion and metastasis, the effects of 
the test panel on breast cancer cell invasion was investigated. 
4.3.2.2.1 SM6Met, decreased the number of invasive MCF-7BUS cells in the absence and presence 
of E2 
All the test compounds and the extract, on their own, significantly (P<0.001) decreased the number of 
invasive MCF-7BUS cells (Fig. 4.12A). In addition, SM6Met displayed significantly higher reduction of 
invasive MCF-7BUS cells than the SOC therapies on their own (4-OH-Tam and fulvestrant) or the ERα 
selective antagonist (MPP) on its own. No significant change in the number of invasive cells was observed 
after treatment with 10-11M E2 on its own, while treatment with 10-9M E2 resulted in a significant (P<0.001) 














































































































































Figure 4.12: SM6Met, decreased the number of invasive MCF-7BUS cells in the absence and presence of E2. 
The number of invasive MCF-7BUS cells was determined using the CytoSelect™ 96-Well cell invasion assay kit as 
described in the material and methods section. (A) displays the effects of the test panel (4-OH-Tam, fulvestrant, MPP, 
liquiritigenin and SM6Met) on the number of invasive cells in the absence of E2, while (B) demonstrate the effect of the 
test panel on the number of invasive cells in the presence of 10-9M E2. Statistical analysis was performed using One-
way ANOVA with Tukey’s multiple comparisons test as post-test, where different letters indicate statistical significance 
(P<0.05). The dotted line through the bars represents the solvent, which was set to one. Average ± SEM is of two 
independent biological experiments done in triplicate. 
 
In the presence of 10-9M E2, the test panel no longer significantly reduced MCF-7BUS cell invasion in 
relation to solvent treated cells, however the whole test panel, with the exception of 4-OH-Tam, significantly 
decreased E2 induced invasion (Fig. 4.12B). Despite slight differences between the levels of inhibition 
elicited by the test compounds and extract, no statistical difference was found between the effects. In 
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summary, it appears that in the presence of 10-9M E2 the test panel is less effective at inhibiting cell invasion 
relative to solvent, but is still able to antagonise, with the exception of 4-OH-Tam, the effects of E2 alone. 
 
4.3.2.2.2 Combining MPP with liquiritigenin slightly reduced the number of invasive cells  
In Fig. 4.13A, liquiritigenin and MPP significantly (P<0.001) inhibited MCF-7BUS cell invasion on their own. 
However, treatment with SM6Met on its own resulted in an inhibition of MCF-7BUS cell invasion which was 
significantly higher than the effect of liquiritigenin (P<0.05) or MPP (P<0.01). By combining MPP and 
liquiritigenin in a 1:1 ratio (10-6M MPP + 10-9M Liq) the inhibitory effect of the two compounds, although not 
significantly different to the compounds alone, was slightly enhanced. Furthermore, the 1:1 ratio was not 
significantly different from SM6Met alone, suggesting that the effects of SM6Met on breast cancer cell 
invasion could be replicated by combining two compounds that represent the subtype specific 
characteristics of SM6Met i.e. MPP (ERα antagonist) and liquiritigenin (ERβ agonist). 
Once again, with the addition of 10-9M E2 the test panel (SM6Met, MPP, liquiritigenin and the 1:1 
combination of MPP with liquiritigenin) became less effective at inhibiting cell invasion relative to solvent, 
but was still able to significantly antagonise the effect of 10-9M E2 (Fig. 4.13B). In the presence of 10-9M E2, 
no significant difference was found between MPP, liquiritigenin, the 1:1 ratio (10-6M MPP + 10-9M Liq) and 
SM6Met. However, the inhibitory effects of the MPP and liquiritigenin alone, although not significantly so, 





































































































































Figure 4.13: Combining MPP with liquiritigenin resulted in a slight decrease in the number of invasive MCF7-
BUS cells, almost to the same extent as SM6Met. The number of invasive MCF-7BUS cells was determined using 
the CytoSelect™ 96-Well cell invasion assay kit as described in the material and methods section. (A) displays the 
effects of the test panel (SM6Met, MPP, liquiritigenin and a 1:1 combination of the IC50 concentrations of MPP with 
liquiritigenin) on the number of invasive MCF-7BUS cells in the absence of E2, while (B) shows the effects of the test 
panel on the number of invasive MCF-7BUS cells in the presence of 10-9M E2. Statistical analysis was performed using 
one-way ANOVA with Tukey’s multiple comparisons test as post-test, where different letters indicate statistical 
significance (P<0.05). The dotted line through the bars represents the solvent, which was set to one. Average ± SEM 
is of two independent biological experiments done in triplicate. 
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4.3.2.2.3 SM6Met in combination with 4-OH-Tam, in the presence of 10-9M E2, reduced the number 
of invasive cells even more than 4-OH-Tam on its own 
In Fig. 4.14A, SM6Met on its own could reduce MCF-7BUS cell invasion to a significantly (P<0.01) greater 
extent than 4-OH-Tam alone. However, the results suggest that in combination 4-OH-Tam initially 
outcompetes the effect of SM6Met. Nonetheless, increasing the concentration of SM6Met in the 
combination ratio with 4-OH-Tam resulted in a slight increase of the inhibitory effects relative to 4-OH-Tam 
alone. 
In the presence of 10-9M E2 (Fig. 4.14B), 4-OH-Tam was able to significantly reduce E2 induced cell 
invasion. SM6Met alone, also, significantly (P<0.001) reduced E2 induced cell invasion. The addition of 
SM6Met to 4-OH-Tam resulted in significant (P<0.05) reduction of cell invasion relative 10-9M E2 as well as 
to solvent, with the highest inhibition elicited by the 20:1 combination ratio of SM6Met with 4-OH-Tam. 
Furthermore, the combination of SM6Met with 4-OH-Tam shows significantly (P<0.05) higher inhibition of 















































































































Figure 4.14: SM6Met in combination with 4-OH-Tam, in the presence of 10-9M E2, is more effective than 4-OH-
Tam alone at reducing the number of invasive MCF-7BUS cells. The number of invasive MCF-7BUS cells was 
determined using the CytoSelect™ 96-Well cell invasion assay kit as described in the material and methods section. 
(A) displays the effects of the test panel (4-OH-Tam, SM6Met and the IC50 ratio combinations 1:1, 10:1 and 20:1 of 4-
OH-Tam with SM6Met) on the number of invasive cells in the absence of E2, while (B) shows the effects of the test 
panel on the number of invasive cells in the presence of 10-9M E2. Statistical analysis was performed using One-way 
ANOVA with Tukey’s multiple comparisons test as post-test, where different letters indicate statistical significance 
(P<0.05). The dotted line through the bars represents the solvent, which was set to one. Average ± SEM is of two 
independent biological experiments done in triplicate. 
 
4.3.2.3 Evaluation of the effects of the test panel on breast cancer colony formation 
In the event that a cell detaches from the ECM, the cell will undergo apoptosis also known as detachment-
apoptosis or anoikis (45). Anoikis is an important physiological defence system that prevents cell re-
attachment at incorrect locations. The ability of tumour cells to evade anoikis, grow independently and form 
a new colony is known as anchorage-independent growth (4, 45). Anchorage independent growth is not 
only a hallmark of cancer, but is also a characteristic needed for cancer metastasis. Therefore, I evaluated 
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the effects of the test panel on anchorage-independent growth of the MCF-7BUS cell line using the soft-
agar colony formation assay (28, 46). 
4.3.2.3.1 SM6Met reduced MCF-7BUS cell colony formation to the same extent as 4-OH-Tam and 
liquiritigenin in the presence of E2 
E2 was able to inhibit the formation of colonies in a dose-dependent manner from 10-9M E2 (Fig. 4.15), and 
consequently at high concentrations of E2 the effects of the test panel was over shadowed by the effect of 
E2. Thus, discrimination between the effects of test panel was evaluated at lower concentrations of E2.  
In the presence of 10-11M E2 (Fig. 4.15A & B), 4-OH-Tam, liquiritigenin and SM6Met displayed similar 
inhibition levels. Fulvestrant and MPP were both able to inhibit colony formation more effectively (P<0.01) 
than SM6Met, with MPP displaying the highest level of inhibition.  
In the presence of 10-9M E2 (Fig. 4.15C), 4-OH-Tam and MPP were the only compounds to significantly 
(P<0.05) reduce colony formation relative to 10-9M E2 on its own. The overpowering effect of E2, made 
comparing the test compounds to SM6Met increasingly difficult as no statistical difference was observed 
between the inhibition levels of the test compounds and the extract in the presence of 10-7M and 10-5M E2 
(Fig. 4.13D & E). 
4.3.2.3.2 MPP displayed a strong inhibiting effect on colony formation, in the presence of E2, thereby 
in combination overshadowing the effects of liquiritigenin. 
In the presence of 10-11M E2 (Fig. 4.16), SM6Met, MPP, liquiritigenin and the 1:1 combination of liquiritigenin 
with MPP were all able to significantly reduce colony formation relative to solvent and 10-11M E2. However, 
MPP displayed a significantly (P<0.001) 8.5-fold greater inhibition than SM6Met and a 10-fold greater 
inhibition than liquiritigenin. Although the addition of liquiritigenin to MPP resulted in a slight 2.96-fold 
increase in the inhibitory effect of MPP, it was not statistically different to that of MPP on its own in the 
presence of 10-11M E2. The combination of liquiritigenin and MPP, like MPP alone, showed significantly 
higher inhibition of colony formation than SM6Met alone. The over shadowing effects of 10-6M MPP 
suggests that ERα plays a pivotal role in colony formation. 
4.3.2.3.3 All the combinations of SM6Met with 4-OH-Tam showed greater reduction in colony 
formation in comparison to SM6Met and 4-OH-Tam on their own 
In the presence of 10-11M E2 (Fig. 4.17), SM6Met displayed a similar level of inhibition of colony formation 
as 4-OH-Tam, however, when SM6Met was combined with 4-OH-Tam in a 1:1 ratio it resulted in 
significantly (P<0.001) 10-fold further reduction of colony formation. The level of inhibition, however, did 
not significantly change when the concentration of SM6Met was increased in the combination ratio with 4-
OH-Tam suggesting that the 1:1 combination ratio is efficient in reducing colony formation and that higher 
concentrations of SM6Met are not required. 




















































































































































































































































































































































































SM6Met  Solvent 10-11M E2 4-OH-Tam Ful Liq MPP 
+ 10-11M E2
Figure 4.15: SM6Met reduced MCF-7BUS cell colony formation to the same extent as 4-OH-Tam and 
liquiritigenin in the presence of E2. MCF7-BUS cells were suspended in 0.6% agarose and added onto the bottom 
1% agarose layer. The cells were treated weekly with the test panel including 4-OH-Tam, fulvestrant, MPP, liquiritigenin 
and SM6Met, all in the presence of (B) 10-11M E2, (C) 10-9M E2, (D) 10-7M E2 and (E) 10-5M E2 for the duration of 21 
days. At day 21, images were taken and the number of colonies formed were counted using ImageJ software. 
Representative images of the test panel in the presence of 10-11M E2 is shown (A). Statistical analysis was performed 
using one-way ANOVA with Tukey’s multiple comparisons test as post-test, where different letters indicate statistical 
significance (P<0.05). The dotted line through the bars represents the solvent, which was set to one. Average ± SEM 
is of two independent biological experiments done in triplicate. 
 
 




































































































Solvent 10-11M E2 SM6Met MPP Liq MPP + Liq
+ 10-11M E2
 
Figure 4.16: MPP displayed a strong inhibiting effect on colony formation, in the presence of E2, thereby, in 
combination, overshadowing the effects of liquiritigenin. MCF7-BUS cells were suspended in 0.6% agarose and 
added onto the bottom 1% agarose layer. The cells were treated weekly with the test panel including SM6Met, MPP, 
liquiritigenin and the IC50 concentrations of MPP and liquiritigenin in a 1:1 ratio, all in the presence of 10-11M E2 for the 
duration of 21 days (B). At day 21, images were taken and the number of colonies formed were counted using ImageJ 
software. Representative images of compound or extract in the presence of 10-11M E2 is shown (A). Statistical analysis 
was performed using One-way ANOVA with Tukey’s multiple comparisons test as post-test, where different letters 
indicate statistical significance (P<0.05). The dotted line through the bars represents the solvent, which was set to one. 






































































































Figure 4.17: All the combinations of SM6Met with 4-OH-Tam showed greater inhibition of colony formation in 
comparison to SM6Met and 4-OH-Tam on their own. MCF7-BUS cells were suspended in 0.6% agarose and added 
onto the bottom 1% agarose layer. The cells were treated weekly with the test panel including 4-OH-Tam, SM6Met, 
and 4-OH-Tam in combinations with SM6Met at 1:1, 10:1 and 20:1 ratios, all in the presence of 10-11M E2 for the 
duration of 21 days (B). At day 21, images were taken and the number of colonies formed were counted using ImageJ 
software. Representative images of compound or extract in the presence of 10-11M E2 is shown (A). Statistical analysis 
was performed using One-way ANOVA with Tukey’s multiple comparisons test as post-test, where different letters 
indicate statistical significance (P<0.05). The dotted line through the bars represents the solvent, which was set to one. 
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Table 7: Summary of the effects of the test panel on the metastatic potential of the human MCF-7BUS breast cancer cells 
(nd) = not done; (↑) = Increased; (↓) = Decreased; (-) = No significant effect 
aTested in the presence of 10-11 M E2. 
bTested in the presence of 10-9 M E2. 
cStatistically different from solvent (● represents P < 0.05, ● ● represents P < 0.01 and ● ● ● represents P < 0.001).  
dStatistically different from E2 (* represents P < 0.05, * * represents P < 0.01 and * * * represents P < 0.001). 
eStatistically different from 4-OH-Tam alone ($ represents P < 0.05, $ $ represents P < 0.01 and $ $ $ represents P < 0.001). 
fStatistically different from SM6Met (# represents P < 0.05, # # represents P < 0.01 and # # # represents P < 0.001).





assaya  G0/G1 phase S phase G2/M phase Apoptosis 
10-11 M E2 - - - - - - ↑● ● ● 
10-9 M E2 nd nd nd nd ↓● ● ↑● ● ● ↓● ● ● 
Ful ↑* ↓** ↓* - ↑*** ↓*** ↓*** 
4-OH-Tam - - - - ↑*** - ↓*** 
SM6Met ↓** ↑*** - ↑** ↑** ↓*** ↓*** 
SM6Met:4-
OH-Tamc/d,e 
1:1 nd nd nd nd ↑***,ns  ↓***, $ $ ↓***, $ $ $ 
10:1 - - - ↑***, $ $ $ ↑**,ns ↓***, $ $ ↓***, $ $ $ 
20:1 - ↑*, $ - ↑***, $ $ $ ↓●, $ $ $ ↓***, $ $ ↓***, $ $ $ 
Liq ↓* ↑** - ↑*** ↑*** ↓** ↓*** 
MPP ↓* ↑** - - ↑*** ↓*** ↓*** 
 
Liq:MPPd,f 
1:1 ↓*, ns ↑***, ns - ↑**, ns ↑***, ns ↓***, ns ↓***, # # # 
10:1 nd nd nd nd ↑*, ns nd nd 
100:1 nd nd nd nd - ns nd nd 
1000:1 nd nd nd nd - ns nd nd 
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In the process of cancer initiation a cancer cell acquires certain capabilities, which involves the ability to 
sustain cell growth signalling, evade inhibitory growth signals, avoid apoptosis, induce limitless replication, 
stimulate angiogenesis and activate the metastatic cascade (migration, invasion and colony formation) (4).  
In chapter 3, the results from the MCF-7BUS proliferation assay showed that SM6Met was able to 
significantly inhibit E2 induced breast cancer cell proliferation, albeit with a lower potency and efficacy than 
the SOC therapies. Furthermore, I demonstrated that the effects of SM6Met could be replicated by 
combining an ERα antagonist (MPP) with an ERβ agonist (liquiritigenin) and that in combination with 4-OH-
Tam, SM6Met synergistically enhanced the effects of 4-OH-Tam to inhibit E2 induced breast cancer cell 
proliferation.  
Chapter 4 focused on: (1) how SM6Met compares to SOC therapies, like 4-OH-Tam and fulvestrant, (2) if 
the properties of SM6Met could be replicated by combining an ERα antagonist (MPP) with an ERβ agonist 
(liquiritigenin), and (3) how the synergistic combination of 4-OH-Tam with SM6Met compares to 4-OH-Tam 
alone, with regard to their effects on human breast cancer cell cycle regulation as well as metastatic 
potential. Results are summarized in Table 7. 
4.4.1 Effects on breast cancer cell cycle 
Cell proliferation relies on the controlled progression of cells through the cell cycle, a process dysregulated 
in cancer cells to gain infinite replicative potential, a hallmark characteristic of cancer (3, 4). Cell cycle 
analysis, a test system regarded as more accurate than proliferation studies, provides information on how 
a drug elicits its effects on cell proliferation with regard to cell cycle arrest and apoptosis (47, 48). 
4.4.1.1 SM6Met, like liquiritigenin, induced apoptosis and the accumulation of MCF-7BUS cells in the S 
phase of the cell cycle  
Various studies have shown that E2 decreases the number of cells in the G0/G1 phase and increases the 
number of cells in the S phase and G2/M phase (49–51). However, in the current study E2 (at the 
concentration 10-11M) only slightly, but not significantly, increased the number of cells in the S phase (DNA 
synthesis).  
In the presence of 10-11M E2, treatment with fulvestrant displayed similar cell cycle distribution patterns to 
previous studies where MCF7-BUS cells were treated with fulvestrant alone (51). Specifically fulvestrant 
caused an accumulation of cells in the G0/G1 phase (Fig. 4.6C), with no activation of apoptosis (Fig. 4.6F), 
thereby, suggesting that cell cycle progression was “paused” at the G0/G1 restriction checkpoint with cells 
entering a state of quiescence (rest) after treatment with fulvestrant. This restriction point is largely 
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controlled by the Rb/E2F signalling pathway, therefore, mechanistically fulvestrant could be eliciting its 
effects through upstream regulators of Rb, for example Cyclin D1, CDK4 or CDK6 (7). Previous studies 
showed that treatment with 4-OH-Tam alone induced a significant G0/G1 phase arrest (52–55), whereas 
in the current study, 4-OH-Tam, in the presence of 10-11M E2, induced a slight (not significant) increase in 
the number of cells in the S phase and in the number of apoptotic cells, while slightly decreasing the number 
of cells in the G2/M phase. However, taking into consideration the much higher concentrations of 4-OH-
Tam used in previous studies (10-3M – 10-6M), 4-OH-Tam in the current study at the concentration of 10-
9M, most probably, had little to no effect on the cell cycle distribution. 
In this study, SM6Met, in the presence of 10-11M E2, also displayed similar cell cycle distribution patterns to 
previous studies where MCF7-BUS cells were treated SM6Met alone (26). Specifically, SM6Met induced 
significant accumulation of cells in the S phase (Fig. 4.6D) as well as significantly increasing the number of 
apoptotic cells (Fig. 4.6F). It has previously been postulated that SM6Met may elicit its effects on the S 
phase by down-regulating cyclin-dependent kinase 2 (CDK2), thereby inhibiting DNA replication or by up-
regulating inhibitors of CDK 2, like ataxia telangiectasia mutated (ATM) (56). MPP and liquiritigenin, like 
SM6Met, induced significant accumulation of cells in the S phase (Fig. 4.6D), while only liquiritigenin, like 
SM6Met, induced a significant number of apoptotic cells (Fig. 4.6F), suggesting that MPP and liquiritigenin 
alone, like SM6Met, inhibits cell proliferation via S phase arrest. No literature was found on the effects of 
MPP and liquiritigenin on breast cancer cell cycle distribution and thus comparison with literature is not 
possible. 
In summary, SM6Met alone disrupts cell cycle progression via arresting cells in the S phase, while the SOC 
therapies, 4-OH-Tam and fulvestrant, arrests cells in the G0/G1 phase. This implies that SM6Met elicits its 
effects on the regulation of cell cycle machinery via a different mechanism than that of the SOC therapies, 
which is preferred for combination therapies as studies suggest breast cancer is more responsive to 
combinations that inhibit multiple molecular targets associated with the development and progression of 
breast cancer (57, 58). Therefore, SM6Met has great potential to be used in combination with current SOC 
therapies to provide a multi-targeted approach. 
4.4.1.2 The effects of SM6Met on cell cycle progression could be replicated by combining an ERα selective 
antagonist (MPP) with an ERβ selective agonist (liquiritigenin) 
The addition of 10-9M liquiritigenin to 10-6M MPP at a combination ratio of 1:1 resulted in a cell cycle 
distribution similar to that of SM6Met (Fig. 4.7). Specifically, although MPP and liquiritigenin on their own 
induced S phase accumulation, combining the two compounds resulted in a further significant increase in 
the number of cells in this phase to a level similar to that of SM6Met (Fig. 4.7D). Conversely, the effects of 
MPP and liquiritigenin on apoptosis seem to counteract each other as the combination significantly reduced 
the number of apoptotic cells relative to liquiritigenin, while increasing the number of apoptotic cells relative 
to MPP, however, the net result of the combination of liquiritigenin with MPP was similar to that of SM6Met. 
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Therefore I may postulate that the combination of MPP and liquiritigenin, like SM6Met, disrupts cell cycle 
progression via arresting cells in the S phase and inducing apoptosis.  
To our knowledge, the combination of an ERβ selective agonist and an ERα selective antagonist and its 
effects on cell cycle regulation have not previously been investigated. However, these results support the 
notion that a compound with similar characteristics to the Cyclopia extract, SM6Met, could be synthesized 
to possibly avoid some of the limitations associated with natural compounds or extracts like low potency 
and effectiveness compared to synthetic drugs. 
4.4.1.3 The addition of SM6Met to 4-OH-Tam not only increased the accumulation of cells in the S-phase, 
but also the number of cells in the apoptotic phase 
The addition of SM6Met to 4-OH-Tam in the combination ratios 10:1 and 20:1 increased the number of cells 
in the S phase and the number of apoptotic cells, while decreasing the number of cells in the G2/M phase. 
This suggest that in combination SM6Met and 4-OH-Tam mechanistically enhanced S phase arrest, which 
conceivably lead to morphological changes and a subsequent increase in apoptosis. These findings show 
for the first time that in combination SM6Met enhances the pro-apoptotic effects of 4-OH-Tam. This implies 
that women taking tamoxifen as adjuvant therapy, may benefit further from co-treatment with SM6Met as a 
treatment strategy.  
Similar to our study, a previous study by Charalambus et al. (59), showed that the combination of equol, 
the metabolite of the soy phytoestrogen, diazen, with 4-OH-Tam also significantly enhanced the number of 
apoptotic cells in comparison to equol and 4-OH-Tam alone through activation of caspase-mediated 
apoptotic pathways. To our knowledge there are no further studies on the effects of combinations of 
compounds or extracts with 4-OH-Tam on cell cycle progression. Thus, the mechanisms by which SM6Met 
and other compounds enhance the anti-breast cancer activity of tamoxifen are still largely unknown.  
4.4.2 Effects on metastatic potential of breast cancer cells 
Despite the advances in treatment targeting primary tumours, treatment strategies for metastasis have 
been less effective and development of secondary tumours play a major role in the high mortality still 
associated with cancer (60–62). Therefore, I looked at the effects of the test panel on hallmark capabilities 
of cancer cells that are involved in metastasis i.e. cell motility, cell invasion and anchorage independent 
growth. 
4.4.2.1 SM6Met reduced E2 induced breast cancer cell invasion and colony formation to a level comparable 
to that of the SOC therapies, but also like all the other test compounds induced breast cancer cell migration 
Previous studies have shown that in ER-positive breast cancer cells E2 stimulates migration through 
activation of mitogen-activated protein kinase (MAPK) phosphorylation of cSRC which in turn interacts with 
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focal adhesion kinases and the delta 5 truncated form of SRC3. This process stimulates the development 
of filopodia and pseudopodia at the leading edges of the breast cancer cells (63–65). However, in contrast 
to previous studies, I showed that 10-9M E2 inhibited breast cancer cell migration (66, 67), which may be 
attributed to differences in methodology like different cell lines, induction periods, culture conditions and the 
use of mytomycin C, an inhibitor of cell proliferation used to truly identify the migratory potential. As the use 
of mitomycin C has only recently been introduced to migratory studies (wound healing assays) to distinguish 
between actual migration and proliferation, no literature was found to corroborate the effects of the test 
panel on breast cancer cell migration. Nevertheless, all the test compounds and extract reversed the 
protective effect of E2 on cell migration with MPP displaying the highest induction of migration, thus, 
suggesting a protective role for ERα against breast cancer cell migration and shows promise for therapeutic 
strategies that do not primarily target ERα for the treatment and prevention of breast cancer. 
There is contradicting evidence as to the effects of E2 on breast cancer cell invasion as some studies have 
shown that E2 reduces breast cancer cell invasion (66), some show no effect of E2 on breast cancer cell 
invasion (26, 68) and others, like our study, indicate an increase in breast cancer cell invasion (40, 68). To 
our knowledge this is the first time that the effects of 4-OH-Tam alone on breast cancer cell invasion were 
analysed and showed significant inhibition of invasion. Although 4-OH-Tam, in the presence of E2, had no 
significant effect on breast cancer cell invasion in the current study, it has previously been shown that 4-
OH-Tam increases breast cancer cell invasion in relation to E2 (66, 68). In contrast to a study by Foty et al. 
(69), fulvestrant on its own in the current study reduced breast cancer cell invasion, whereas similar to 
previous studies, fulvestrant reduced E2 induced breast cancer cell invasion in the current study (69). I 
show for the first time that SM6Met, in the presence and absence of E2, was able to inhibit breast cancer 
cell invasion. SM6Met alone reduced invasion to a greater extent than the SOC therapies, 4-OH-Tam and 
fulvestrant, while in the presence of E2, SM6Met displayed a similar level of inhibition as fulvestrant.  
In relation to previous studies E2 (at the concentration 10-11M in the current study) displayed an increase in 
colony formation (70, 71). However, to our knowledge this is the first time that it has been shown that 
increasing the concentration of E2 reduces colony formation in a dose dependent manner, suggesting a 
possible biphasic effect of E2 on breast cancer colony formation. All the test compounds as well as the 
extract were able to inhibit E2 induced colony formation, with the ERα selective ligand, MPP, displaying the 
highest level of inhibition and SM6Met showing similar inhibition levels to 4-OH-Tam and liquiritigenin. 
Except for 4-OH-Tam that has previously been shown to decrease E2 induced colony formation (70), no 
previous studies were found to corroborate the findings of the current study. Nevertheless, these findings 
suggest that ERα plays a positive role in the induction of colony formation.  
In summary, these results show that SM6Met is just as effective as the SOC therapies at targeting 
processes involved in breast cancer metastasis, like invasion and colony formation, and supports the 
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concept that by targeting and inhibiting one of the pro-metastatic processes like cell invasion through 
therapeutic interventions metastasis may be inhibited or delayed (72, 73). 
4.4.2.2 The addition of liquiritigenin (ERβ selective agonist) to MPP (ERα selective antagonist) reduced 
migration and colony formation to levels exceeding that of SM6Met and the SOC therapies, 4-OH-Tam and 
fulvestrant  
To our knowledge, the combination of an ERβ selective agonist and an ERα selective antagonist and its 
effects on the biological processes implicated in breast cancer metastases including cell migration, invasion 
and colony formation have not previously been investigated. Therefore, the results pertaining to the effects 
of this combination on breast cancer cell migration, invasion and colony formation are novel. 
In the presence of E2, the addition of liquiritigenin to MPP, reduced the high migratory effects of MPP, to a 
level lower than that of SM6Met alone and similar to the solvent treated cells, whereas the combination of 
MPP and liquiritigenin, in the presence and absence of E2, inhibited breast cancer cell invasion to a degree 
comparable to that of SM6Met alone. Moreover, E2 induced colony formation was inhibited to a greater 
extent than with SM6Met, liquiritigenin and MPP alone, when liquiritigenin was combined with MPP. 
However, the slight 2.96-fold increase in the inhibitory effect of MPP in the presence of liquiritigenin was 
not statistically different to that of MPP on its own. Taken together, in contrast to the proliferation studies 
(Ch. 3) were the combination of MPP with liquiritigenin mimicked the effects of SM6Met, the combination 
exerted effects greater than that of SM6Met on migration and colony formation, suggesting that a compound 
with the ability to strongly agonize ERβ, while antagonizing ERα, may regulate genes and proteins 
associated with these processes in such a way that it inhibits the development of migratory and anchorage 
independent characteristics of the cell. This also implies that a compound that may elicit the same beneficial 
characteristics of SM6Met with greater efficacy could be synthesized.   
4.4.2.3 Combining SM6Met with tamoxifen in a ratio of 20:1 inhibited all three processes implicated in 
breast cancer metastasis to a degree greater than that of the rest of the test panel 
The results of this study show, for the first time, that SM6Met in combination with 4-OH-Tam in a ratio of 
20:1 could inhibit breast cancer cell migration to a level greater than that of SM6Met or 4-OH-Tam alone 
and similar to that of 10-9M E2, the compound with the highest inhibitory effect on migration in the current 
study. Furthermore, in the presence of E2, SM6Met alone inhibited breast cancer cell invasion to a similar 
extent as fulvestrant and to a greater extent than 4-OH-Tam. However, the addition of SM6Met to 4-OH-
Tam, decreased the number of invasive breast cancer cells further than SM6Met or 4-OH-Tam alone, in a 
dose dependant manner. The ERα selective antagonist, MPP, displayed the highest level of inhibition of 
colony formation, while SM6Met displayed similar inhibition levels as 4-OH-Tam and liquiritigenin, but less 
than fulvestrant alone. However, when adding SM6Met in combination with 4-OH-Tam, enhanced inhibition 
of colony formation to a level similar to that of MPP was observed. Hence, the combination of SM6Met with 
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4-OH-Tam was more effective at targeting breast cancer cell migration, invasion and colony formation than 
the SOC therapies, 4-OH-Tam and fulvestrant, alone. As the combination of SM6Met and 4-OH-Tam was 
the only treatment to substantially inhibit all three processes implicated in breast cancer metastasis (Table 
1), it shows great potential to not only be developed as treatment for primary or early stage breast cancer, 
but also metastatic breast cancer.  
4.4.3  Role of ER signalling in breast cancer progression and metastasis 
Although this study focuses purely on the physiological effects of the test panel on processes involved in 
breast cancer progression and metastasis i.e. proliferation, migration, invasion and colony formation, the 
results from this study provide some insight into the role of the ER subtypes, ERα and ERβ, on breast 
cancer progression and metastasis.  
With regard to cell cycle regulation in the presence of  E2, ERα has been implicated in various cell cycle 
regulatory events that promote cell proliferation, including positive regulation of cyclin D1 and A and 
inhibition of p27 nuclear accumulation (74, 75). Although ERβ has not been as extensively studied as ERα, 
it has been shown to counteract the proliferative effects of ERα, by negatively regulating cyclin D1 and 
activating p21 and p27 expression (76, 77). Unfortunately, due to time and financial constraints I were 
unable to validate the effects of the test panel on cell cycle distribution in the presence of E2. However, this 
study supports previous findings on the physiological role of the ERs, characterizing ERα as mediator and 
driving component of breast cancer cell proliferation and supports the anti-proliferative effects of ERβ. 
Furthermore, early studies on cancer, including breast cancer, suggested that ERα signalling inhibits 
migration and invasion (78). However, more recent studies have contradicted these findings and found that 
ERα signalling promotes motility and invasiveness (79–83) and thereby drives metastasis. In contrast, ERβ 
expression has been associated with less invasive and migratory cells (84–87). With regard to breast 
cancer cell migration, the results of the current study showing that E2 inhibits breast cancer cell migration, 
while MPP, an ERα antagonist, counteracts the effects of E2, support earlier studies suggesting that ERα 
signalling plays a protective role in breast cancer cell migration. Conversely, similar to other recent studies 
(79–83), the results of the current study implicate ERα activity in the promotion of breast cancer 
invasiveness. Moreover, our study supports the anti-migratory role of ERβ, as the results of the current 
study show that by increasing the concentration of liquiritigenin, an ERβ selective agonist, in combination 
with MPP, the high migratory effect of MPP is reduced to the same effect level as that of the solvent treated 
cells.  
No previous literature was found on the possible role of the ER subtypes, ERα and ERβ, in breast cancer 
colony formation. Moreover, except for 4-OH-Tam that has been shown to decrease E2 induced colony 
formation (70), no previous studies were found to support our findings of the effects of the other test 
compounds and the SM6Met extract in the presence of E2 on breast cancer colony formation. Despite this 
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the overwhelming inhibitory effect of MPP on colony formation in the current study would suggest a role for 
ERα. Collectively, the results of the current study implicate ERα in the promotion of breast cancer cell 
proliferation, invasion and colony formation, while suggesting an anti-migratory role for ERα, and implicating 
ERβ in the inhibition of breast cancer cell proliferation, migration, invasion and colony formation.  
4.4.4  Conclusion 
The results of this study present insights into the potential of SM6Met as a treatment for metastatic breast 
cancer, either as monotherapy or in combination with current SOC therapies, like 4-OH-Tam. It is important 
to remember that this study only investigated the combinations of the IC50 ratios and that other 
concentration combinations could yield more beneficial results in terms of reducing breast cancer 
metastasis. As monotherapy, SM6Met was able to inhibit two out of the three pro-metastatic processes 
evaluated in this study (Table 1).  Specifically, SM6Met was just as effective or more effective at inhibiting 
E2 induced breast cancer cell invasion and colony formation as fulvestrant and 4-OH-Tam. Thus, SM6Met 
shows promise as an inhibitor of metastasis by targeting pro-metastatic processes.  
However, the most exciting outcomes of this study are the results pertaining to the combination therapies. 
Firstly, although the 1:1 combination ratio of liquiritigenin with MPP, like SM6Met, induced breast cancer 
cell migration, by increasing the concentration of liquiritigenin in the combination ratio with MPP to 1000:1, 
the high migratory effect of MPP was reduced to the same level as that of the solvent treated cells. This 
suggests that combining an ERβ selective agonist with an ERα selective antagonist may provide a novel 
means of targeting breast cancer metastasis and highlighting the therapeutic potential of ER subtype 
selective modulators, otherwise known as selective estrogen receptor subtype modulators (SERSMs). 
Furthermore, the in terms of invasion and colony formation the 1:1 ratio of liquiritigenin and MPP was 
generally more effective than the compounds alone. 
Secondly, the combination of SM6Met with 4-OH-Tam at a ratio of 20:1 was the only treatment able to 
substantially inhibit all three pro-metastatic processes evaluated in this study i.e. migration, invasion and 
colony formation in the presence of E2. Thus, combined therapies with a compound or extract with 
ERβ agonist and ERα antagonist properties such as SM6Met may provide a novel approach for the 
treatment and or prevention of metastatic breast cancer. These promising effects warrant further 
investigation into the mechanisms through which SM6Met enhances the effects of 4-OH-Tam. Furthermore, 
once the mechanism of action is established, one may predict and study the possible synergistic effects of 
SM6Met in combination with other SOC therapies. 
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Final discussion and conclusions 
Breast cancer is globally the most commonly diagnosed cancer amongst women (23% of all cancer cases) 
and is responsible for 14% of all cancer deaths (1). Estrogen overexposure has been shown to play a major 
role in breast cancer development and progression through induction of hyper-proliferation and generation 
of genotoxic metabolites, which inflict DNA damage (2–4). Therefore, current hormone treatments focus on 
blocking the estrogen signalling pathway. For example, AIs or ovarian function suppressors target estrogen 
synthesis (5–10), while SERMs and SERDs target estrogen receptors (ERs) (11–15). However, blocking 
estrogen signalling can induce menopause-like side-effects (11–19) as well as increase the risk of 
inflammatory diseases (20, 21) and osteoporosis (10, 19, 22). Furthermore, despite the overall 
effectiveness of these endocrine therapies, some breast cancer cases develop resistance (23–25), 
resulting in the need for the development of an alternative approach to breast cancer treatment with lower 
side-effect profiles and a reduced risk of resistance development. 
Previous studies have characterized ERα, especially in breast cancer cells, as mediator and driving 
component of cell proliferation in the presence of estradiol (26), while ERβ has shown anti-proliferative 
effects on breast cancer cells by opposing the actions of ERα (27, 28). The physiological function of the 
two ER subtypes suggest that an agent with the dual effect of antagonising ERα, while activating ERβ may 
provide a safer, more effective alternative to prevent breast cancer initiation and/or inhibit breast cancer 
progression, which can either be used as monotherapy or in combination with existing therapies. 
SM6Met, an extract from the fynbos plant Cyclopia subternata most commonly known as honeybush, has 
previously been shown to act as an ERα antagonist and ERβ agonist (29), to have anti-inflammatory effects 
and to inhibit E2 induced breast cancer cell proliferation, uterine- and mammary tumour growth (30, 31). 
Therefore, the main aim of this study was to explore the physiological implications of the dual activity (multi-
targeting) of the SERSM, SM6Met, on the processes required for the development and progression of 
breast cancer such as proliferation, migration, invasion and colony formation, either as monotherapy or in 
combination with current SOC therapies, like tamoxifen. The results of the current study will be discussed 
in terms of three research questions. 
5.1  How does SM6Met, as monotherapy, compare to SOC therapies, like 4-OH-
Tam and fulvestrant, with regard to their effects on breast cancer cell proliferation, 
migration, invasion and colony formation? 
To answer the first research question (Fig. 5.1), the MCF7-BUS cell line was used to analyse the effects of 
the test panel as it represents an integrated model where both ER subtypes are co-expressed and 
contribute to the final phenotype (20, 21, 32). From this test system it was found that although SM6Met, like 
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4-OH-Tam and fulvestrant, was able to significantly inhibit E2 induced breast cancer cell proliferation, it 
could not attain the same potency nor efficacy as the SOC therapies, 4-OH-Tam and fulvestrant. Similarly, 
SM6Met was able to significantly inhibit breast cancer cell invasion and colony formation. However, with 
regard to efficacy, SM6Met, in the presence of E2, displayed a similar efficacy as fulvestrant at inhibiting 
cell invasion, while 4-OH-Tam had no effect. Furthermore, although fulvestrant showed greater inhibition of 
colony formation, in the presence of E2, than SM6Met, SM6Met displayed similar efficacy to that of 4-OH-
Tam. Interestingly, the whole test panel induced breast cancer cell migration, with SM6Met displaying 
similar induction levels as the SOC therapies, 4-OH-Tam and fulvestrant. Together these results suggest 
that SM6Met as monotherapy cannot compete with current SOC therapies at targeting breast cancer cell 
proliferation, however, SM6Met may prove just as effective as the SOC therapies at targeting pro-metastatic 
processes including breast cancer cell invasion and colony formation. Therefore, SM6Met shows great 












Figure 5.1: Schematic representation of the effects of SM6Met in comparison to the SOC therapies, 4-OH-Tam 
and fulvestrant, on the processes involved in breast cancer development and progression. Breast cancer 
carcinogenesis encompasses various steps, each of which present an opportunity for new therapies. Carcinogenesis 
is characterized by uncontrolled cell proliferation (1), which leads to the acquisition of specific properties which allow 
the tumour cell to detach, migrate (2) and invade (3) local tissue to ultimately enter into circulation, travel to distant 
organs and form colonies (4) at the secondary tumour site. Here the red solid line indicates the inhibiting effects of 
SM6Met, fulvestrant and 4-OH-Tam in order of efficacy, while the green solid line represents induction. Figure adapted 
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5.2 Can the SERSM properties of SM6Met be replicated by the combination of an 
ERα antagonist (MPP) and an ERβ agonist (liquiritigenin)? 
Natural extracts are commonly associated with lower potency and efficacy in comparison to synthetic 
compounds. Therefore, the active constituent is usually characterized, isolated, chemically replicated and 
synthesized. However, a recent study showed that the desirable estrogenic effects of SM6Met could not be 
retained or significantly enhanced by fractionation (34). This raised our second research question (Fig. 5.2):  
that if the active constituent in SM6Met could not be identified or isolated, could the SERSM effects of 
SM6Met be replicated by combining an ERα antagonist (MPP) with an ERβ agonist (liquiritigenin). Despite 
several studies and reviews advocating the approach (35–40), to our knowledge the combination of a 
selective ERα antagonist, like MPP, with a selective ERβ agonist, like liquiritigenin, has not previously been 
investigated for breast cancer treatment or prevention and all results pertaining to the effects of this 
combination are novel. The most effective combination (10-7M liquiritigenin together with 10-6M MPP also 
referred to as 100:1) of these compounds was not only more effective at inhibiting E2 induced breast cancer 
cell proliferation than 10-6M MPP alone and 10-7M liquiritigenin alone, but was also more effective than 
SM6Met and the SOC therapies, 4-OH-Tam and fulvestrant. Furthermore, although the combination of MPP 
with liquiritigenin at ratio 1:1 (10-9M liquiritigenin together with 10-6M MPP) induced breast cancer cell 
migration, in the presence of E2, to a slightly greater, yet not significant extent than SM6Met, by increasing 
the concentration of liquiritigenin up to a ratio of 20:1 and 30:1 in combination with MPP, the high migratory 
effects of MPP and liquiritigenin were reduced to a level similar to solvent treated cells and substantially 
below that of SM6Met. The 1:1 combination of liquiritigenin with MPP inhibited breast cancer cell invasion 
to a similar extent as SM6Met and to a greater extent than the compounds alone, while this combination 
displayed greater inhibition of colony formation, in the presence of E2, than SM6Met or than the compounds 
alone. Together these results suggest that combining an ERα antagonist (MPP) with an ERβ agonist 
(liquiritigenin) improves the anti-proliferative and anti-metastatic potential of the individual compounds; that 
the ideal ER subtype selective properties of SM6Met can be replicated or enhanced; and that a purer, highly 
concentrated synthetic drug or nutraceutical combination with the same SERSM characteristics could 























Figure 5.2: Schematic representation of the effects of the combination of liquiritigenin with MPP compared to 
SM6Met on the processes involved in breast cancer development and progression. Breast cancer carcinogenesis 
encompasses various steps, each of which present an opportunity for new therapies. Carcinogenesis is characterized 
by uncontrolled cell proliferation (1), which leads to the acquisition of specific properties which allow the tumour cell to 
detach, migrate (2) and invade (3) local tissue to ultimately enter into circulation, travel to distant organs and form 
colonies (4) at the secondary tumour site. Here the red solid line indicates the inhibiting effects of the combinations of 
liquiritigenin with MPP and SM6Met in order of efficacy, while the green solid line represents induction and the blue line 
represents no effect. Figure adapted from Saxena and Christofori (33). 
 
5.3 Does SM6Met act synergistically in combination with 4-OH-Tam? 
The recent development of combined therapies, many of which notably include the use 
of more natural products, such as tea leaf extracts, in combination with conventional chemotherapeutic 
agents have been driven by the drawbacks associated with current SOC therapies, like severe side-effect 
profiles and the occurrence of endocrine resistance (41–43). As many of these combinations have been 
shown to produce synergistic activity or enhancement of the anti-cancer effects of tamoxifen (42, 43), our  
third and final research question (Fig. 5.3) entailed the investigation of the potential synergistic effects of 
SM6Met in combination with 4-OH-Tam and how the potential synergistic combination of 4-OH-Tam with 
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SM6Met compares to 4-OH-Tam alone. For the first time the current study demonstrated that the 
combination of 4-OH-Tam (the active metabolite of tamoxifen) and SM6Met (a honeybush extract) produces 
a strong synergistic effect in terms of antagonising E2 induced breast cancer cell proliferation. In 
combination with SM6Met, 20 times lower concentrations of 4-OH-Tam are required to produce the same 














Figure 5.3: Schematic representation of the effects of the combinations of SM6Met with 4-OH-Tam compared 
to SM6Met alone and 4-OH-Tam alone on the processes involved in breast cancer development and 
progression. Breast cancer carcinogenesis encompasses various steps, each of which present an opportunity for new 
therapies. Carcinogenesis is characterized by uncontrolled cell proliferation (1), which leads to the acquisition of specific 
properties which allow the tumour cell to detach, migrate (2) and invade (3) local tissue to ultimately enter into 
circulation, travel to distant organs and form colonies (4) at the secondary tumour site. Here the red solid line indicates 
the inhibiting effects of the combinations of SM6Met with 4-OH-Tam, SM6Met alone and 4-OH-Tam alone in order of 
efficacy, while the green solid line represents induction and the blue represents no effect. Figure adapted from Saxena 
and Christofori (33). 
 
Furthermore, increasing the concentration of SM6Met in combination with 4-OH-Tam to a ratio of 20:1 
resulted in an overall inhibition of breast cancer cell migration not seen with either 4-OH-Tam or SM6Met 
alone. The combination of SM6Met with 4-OH-Tam was the only treatment strategy, apart from E2, to inhibit 
breast cancer cell migration. Although 4-OH-Tam, in the presence of E2, had no significant effect on breast 
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cancer cell invasion, when added in combination with SM6Met it displayed significant inhibition to a level 
greater than that of SM6Met. Specifically, the 20:1 combination ratio of SM6Met with 4-OH-Tam displayed 
the highest inhibition of breast cancer cell invasion compared to the rest of the test panel and other 
combination mixtures, including that of MPP and liquiritigenin. Moreover this combination of SM6Met with 
4-OH-Tam was able to significantly inhibit breast cancer colony formation to the same extent as MPP, which 
displayed the highest level of inhibition and to a significantly greater extent than either 4-OH-Tam or 
SM6Met alone. Therefore, these results suggest that SM6Met with 4-OH-Tam could be a viable drug 
combination, which may potentially delay resistance and ameliorate the negative side effects associated 
with tamoxifen monotherapy on breast cancer patients and may suppress the migratory, invasive and 
anchorage independent nature of MCF-7 cells and may ultimately inhibit or prevent metastatic progression 
of breast cancer. In addition the lower dose of tamoxifen and incorporation of a honeybush extract do 
suggest that this would also be a more affordable alternative to conventional chemotherapy and highlights 
the potential of honeybush tea to be used as a dietary intervention for the prevention of breast cancer. 
5.4 Conclusion 
To conclude, the well-characterized phytoestrogenic extract, SM6Met, has previously been shown to have 
an estrogenic potency comparable to commercially available phytoestrogenic nutraceuticals (29, 44), to 
display subtype selective activity by acting as an ERα antagonist and ERβ agonist (29), to inhibit E2 induced 
breast cancer cell proliferation through G0/G1 arrest like tamoxifen, to induce S phase arrest in the absence 
of E2 (45), to antagonize E2 induced uterine growth and delay vaginal opening in an immature rat 
uterotrophic model (29) as well as inhibit rat mammary tumour growth (30, 31). However, none of these 
studies investigated the metastatic potential of SM6Met nor the combination of SM6Met with a conventional 
chemotherapeutic or endocrine therapy agent.  
The key findings of the current work lie in the following. Firstly, with regard to SM6Met as monotherapy, 
although SM6Met could not compete with the efficacy or potency of SOC treatments, like 4-OH-Tam and 
fulvestrant, at targeting breast cancer cell proliferation, SM6Met showed promising anti-metastatic potential 
equal if not better than the SOC therapies by targeting two components of the metastatic pathway, invasion 
and colony formation. Secondly, for the first time the combination of an ERβ selective agonist (liquiritigenin) 
and an ERα selective antagonist (MPP) was evaluated and found to not only inhibit breast cancer 
proliferation to a degree greater than the rest of the test panel, but also to display promising anti-metastatic 
potential greater than that of current SOC therapies by not inducing breast cancer cell migration and by 
targeting invasion and colony formation, thereby validating the concept that an ideal SERSM would 
antagonize ERα, while activating ERβ and may be more beneficial for the treatment and prevention of 
breast cancer. Thirdly, for the first time the combination of SM6Met with 4-OH-Tam was proven to be 
synergistic in inhibiting breast cancer cell proliferation, while the best combination ratio (20:1) showed the 
highest degree of anti-metastatic potential as it was the only treatment to inhibit all three components of the 
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metastatic pathway that was evaluated in this study i.e. migration, invasion and colony formation, 
suggesting that combination therapy is not only a viable strategy for delaying resistance and ameliorating 
the negative side effects associated with current SOC endocrine therapies, like tamoxifen, but could also 
provide a new therapeutic strategy for preventing breast cancer metastasis. In addition the lower dose of 
tamoxifen required when combined with SM6Met, a plant extract, suggests that this would also be a more 
affordable alternative to conventional chemotherapy.   
It is clear that plants extracts have great potential in combination therapies, as strategy to overcome the 
drawbacks of resistance and severe side-effects associated with current SOC endocrine therapies. 
However, future work is needed to not only elucidate the molecular mechanism of SM6Met, but to also 
validate the current findings and establish the optimal combination ratios of the mixtures evaluated in this 
study, especially as pertaining to metastatic potential.  
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